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Abstract 
 
Clostridium difficile is a leading cause of nosocomial, antibiotic-associated, 
diarrhoea in industrialised countries.  C. difficile spores are dormant and resistant 
structures responsible for the colonisation and persistence of C. difficile infection 
(CDI) within patients as well as the transmission between them. This thesis 
examines firstly, the role of a C. difficile spore coat protein, CotE, in the 
establishment of CDI, and secondly, the role of allochthonous Bacillus within the 
GI tract in suppressing CDI. CotE is a protein displayed on the C. difficile spore 
surface which carries two functional elements, an N-terminal peroxiredoxin and a 
C-terminal chitinase domain. Using isogenic mutants, it was demonstrated in vitro 
and ex vivo that CotE enables binding of spores to mucus by direct interaction with 
mucin and contributes to its degradation. In animal models of CDI, it was shown 
that when CotE was absent, both colonisation and virulence were markedly 
reduced. It is demonstrated here that the attachment of spores to the intestine is 
essential in the development of CDI. The developments of infection within the host 
GI tract requires germination of the spore, followed by outgrowth of the vegetative 
cell; a process which requires a multitude of factors to favour C. difficile 
proliferation. In a series of experiments, it was shown that environmentally 
acquired Bacillus help to suppress CDI by the production of lipopeptides in vivo 
with activity against C. difficile and that the use of antibiotics abrogates this 
phenomenon. Using hamster and mouse models, it was demonstrated that the 
administration of these Bacillus provides complete colonisation resistance against 
CDI in clindamycin treated animals. Reversed-phase high-performance liquid 
chromatography, dynamic light scattering and MALDI-TOF analysis identified the 
active molecules to be a micellar complex of lipopeptides comprised of 
chlorotetaine, iturins, fengycins and surfactins. Through this work, it is 
demonstrated that the attachment of spores to the intestine is essential in the 
development of CDI and suggests a direct role for the spore in the establishment 
and promotion of disease.       
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CHAPTER 1 
 
Introduction 
 
1.1 Identification of C. difficile as a pathogen 
The Clostridia are believed to have emerged as a taxonomic Class approximately 
2.9 billion years ago, prior to the ‘Great Oxygenation Event’ which resulted in the 
induction of free oxygen into the atmosphere (Battistuzzi et al., 2004). Clostridia, 
of the phylum Firmicutes, are a Gram positive, polyphyletic Class with the ability 
to form highly resistant endospores. Consistent with an origin prior to the Great 
Oxygenation Event, the Clostridia Class are obligate anaerobes. Most Clostridia are 
saprophytic organisms and can be found throughout the environment, most 
commonly in soil. There appear several human pathogens within Clostridia; the 
toxins produced by some being amongst the deadliest known to mankind. 
Clostridium tetani and Clostridium botulinum both produce potent neurotoxins 
which can lead to severe autonomic nervous system dysfunction and death 
(Thwaites, 2017). Clostridium perfringens, Clostridium septicum, Clostridium 
sordellii, Clostridium histolyticum, and Clostridium novyi can all cause gangrenous 
soft tissue infections (Stevens et al., 2012). C. perfingens is associated with 
necrotising soft tissue infections, foodborne gastroenteritis and endometritis. 
Several species of Clostridia, including Clostridium saccharaobutylicum, 
Clostridium acetobutylicum and Clostridium beijerinckii are capable of converting 
carbohydrates into solvents and are therefore of interest in the potential 
development of biofuels (Galadima et al., 2015). Non-toxigenic or attenuated 
strains of Clostridia are currently being investigated as drug delivery vehicles for 
potential use in the treatment of cancer; Clostridium novyi has been shown to confer 
a survival advantage in canine soft tissue carcinoma via induction of anti-tumour 
responses following local spore administration of an attenuated strain (Heap et al., 
2014; Roberts et al., 2014; Theys and Lambin, 2015). Clostridial spores are being 
assessed as selective delivery vehicles of high therapeutic doses of anti-cancer 
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agents to tumours (Minton, 2003). This design system relies on the ability of 
intravenously injected spores to infiltrate, germinate and survive within the hypoxic 
environment of solid tumours. It has been demonstrated that engineered 
Clostridium sporogenes strains expressing a prodrug-converting enzyme can 
convert a non-toxic prodrug to a cytotoxic drug specifically at tumour sites (Heap 
et al., 2014). 
 
Clostridium difficile was first isolated from the stool of new-born infants by Hall 
and O’Toole in 1935 and was initially named Bacillus difficile, due to the difficulty 
in culturing the bacteria (Hall and O’Toole, 1935). In 2016 Clostridium difficile 
was reclassified and assigned to a new genus following restiction of the genus to 
Clostridium butyricum and other related species in 2015 (Lawson et al., 2016). C. 
difficile was originally assigned to the Clostridium genus due to its broad 
phenotypical similarties with other members. Recently performed phenotypic, 
chemotaxonomic and phylogenetic analyses found C. difficile to share the most 
similarities with species within the Peptostreptococcaceae family. Commercial and 
medical concerns regarding the change in name prompted the creation of the genus 
Clostridioides and the species Clostridioides difficile.  
 
Initial investigators found C. difficile to be toxic in guinea pigs and rabbits, but its 
presence in neonates led them to believe that the pathogen was a normal species of 
a healthy human intestinal flora. The asymptomatic carriage of C. difficile by 
neonates, and their clearance after approximately 12 months is now widely 
acknowledged by researchers (Al-Jumaili et al., 1984; Lees et al., 2016; Kuiper et 
al., 2017). However, the explanation for the lack of C. difficile toxicity in infants 
remains unknown (Jangi and Lamont, 2010).  
 
Although cases of pseudomembranous colitis (PMC) symptoms began to rise in the 
1950’s due to the increased use of antibiotics (with rates as high as 27% in 
postoperative patients), C. difficile was believed to not be associated with the 
condition and rather Staphylococcus aureus was presumed to be the causative agent  
(Bartlett, 2008). This hypothesis was undermined in a study by Tedesco et al. 
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(1974), who reported high levels of PMC in patients being treated with 
clindamycin. Of the 200 patients receiving clindamycin, 42 (21%) developed PMC 
and despite the ease of isolating S. aureus, stool samples were found to be negative 
for the bacteria. This article spawned interest in discovering the cause, the 
pathophysiology and modes of treatment for “clindamycin colitis”.  
 
Following this, a succession of studies started to illuminate a clear link between 
these cases and C. difficile. Most important among these studies included work by 
Bartlett et al. (1977) and Chang et al. (1978) who demonstrated that C. difficile 
causes PMC in hamsters. This work was supported by controlled analyses in 
hospitals such as University Hospital in Ann Arbor, Michigan (Keighley et al., 
1978) and The General Hospital in Birmingham (Lusk et al., 1977).  
 
Although C. difficile had been recognised as the causative agent of C. difficile 
infection (CDI), funding was limited and remained so throughout the 80’s and 90’s 
despite the public outcry following an outbreak in 1991/2 of CDI in three hospitals 
in Manchester, UK causing the deaths of 17 patients (Cartmill et al., 1994). It was 
not until the 21st Century that C. difficile was recognised as a ‘hospital superbug’ 
following a number of high-profile outbreaks coupled with extensive media 
coverage. An outbreak at Stoke Mandeville hospital in Buckinghamshire, UK, in 
2005 led to a public enquiry following complaints made by staff of poor senior 
management, contributing to the conditions which facilitated the outbreak 
(Katikireddi, 2005). This outbreak was proceeded by another, at a hospital in 
Maidstone, UK, leading to 90 fatalities between 2004 and 2006. The subsequent 
increase in research funding has helped bring us to the present day, where our basic 
understanding of C. difficile and its implications on gastrointestinal health has risen 
exponentially, albeit with many questions remaining un-answered.  
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1.2 C. difficile infection 
1.2.1 The disease 
C. difficile is now considered to be one of the foremost nosocomial pathogens in 
humans. It has been responsible for numerous hospital outbreaks with symptoms 
ranging from diarrhoea to pseudomembranous colitis and death (Rodriguez et al., 
2016). CDI is acquired following antibiotic treatment which leads to perturbation 
of the gut microbiota (which is protective against C. difficile colonisation and 
growth) allowing outgrowth and infection by antibiotic resistant strains of C. 
difficile. Although those most at risk of CDI often have a history of antibiotic 
treatment, prolonged periods of hospitalisation, and are over 65 years of age, recent 
studies have described increased incidences of the infection spreading further into 
the community as well as increases in severity and occurrences of nosocomial CDI 
within North America and Europe (Kuijper et al., 2006; Rodriguez et al., 2014; 
Borali et al., 2015). This increase has been principally attributed to the emergence 
of ‘hypervirulent’ ribotypes, notably ribotype 027 and 078 (Cookson, 2007). Strains 
within these ribotypes, when compared to endemic strains, typically demonstrate 
increased microbial resistance, particularly to quinolone antibiotics, increased 
infectiousness and an increased symptomatic disease rate. Since the identification 
of these strains in 2005, ribotype 027 has been reported in most European countries, 
forty US states and every province in Canada (Pepin et al., 2004; Loo et al., 2005; 
Hubert et al., 2007; Kuijper et al., 2008; Rupnik et al., 2009). Meanwhile, C. 
difficile ribotype 078 has increased in prevalence from 3 to 13% in several European 
countries (Goorhuis et al., 2008; Rupnik et al., 2008). However, it should be noted 
that although the increasing rates of CDI can largely be attributed to hypervirulent 
strains, other endemic strains have continued to be associated with outbreaks 
(Borgmann et al., 2008).  
 
Every antibiotic has the potential to place a patient at risk of CDI, however several 
antibiotics pose a significantly higher risk than others. The use of penicillins, 
clindamycin and cephalosporins can place a patient at significant risk for acquiring 
CDI whilst the emergence of hypervirulent strains with resistance against 
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fluoroquinolones means that this antibiotic is also high risk (Owens et al., 2008). It 
has been demonstrated that 25 to 30% of hospital patients are asymptomatic carriers 
of C. difficile (Shim et al., 1998). Asymptomatic carriage is thought to be a 
consequence of the host’s high anti-toxin IgG response against C. difficile Toxin A 
(following exposure to C. difficile) resulting in decreased morbidity (Kyne et al., 
2001). Asymptomatic carriage then is thought to play a role in transmission of C. 
difficile  in many unexplained cases (Eyre et al., 2013).  
 
Non-toxigenic strains of C. difficile have also been observed colonising patients at 
a prevalence of between 0.4 and 6.9% (Boone et al., 2012). Studies in hamsters 
have demonstrated that non-toxigenic C. difficile can have a protective effect 
against toxigenic infection and trials are underway to find evidence for a therapeutic 
or preventative role (Natarajan et al., 2013). A definitive mechanism for this 
protective effect is yet to be found, but it has been suggested that non-toxigenic 
strains compete with toxigenic strains for colonisation thereby attenuating the 
severity of infection (Nagaro et al., 2013; Gerding et al., 2018). This is because 
binding of C. difficile vegetative cells to colonic mucus producing cells is thought 
to play a role in colonisation, and it is possible that prior exposure of host cells to 
non-toxigenic C. difficile S-layer protein increases colonisation resistance by 
significantly reducing attachment of the subsequent toxigenic strain (Merrigan et 
al., 2013). Nutrient acquisition and competition for a niche in the gastrointestinal 
tract has also been suggested (Natarajan et al., 2013). Studies involving infecting 
hamsters with a non-toxigenic strain of C. difficile (CD1342) have perhaps provided 
evidence for an active role played by the spore itself during the infection process, 
where cell damage in the caecum and an inflammatory response were observed 
(Buckley et al., 2013). 
 
Interestingly, among community acquired infections there has been a recent 
increase in the number of individuals who acquire CDI without any prior antibiotic 
use (Khanna et al., 2012). It has also been observed that new-borns (humans and 
piglets) and infants can be colonised by C. difficile without any prior antibiotic use 
(Jangi and Lamont, 2010; Rousseau et al., 2012; Moono et al., 2016). These studies 
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would suggest that antibiotics are not necessarily a prerequisite to C. difficile 
germination and outgrowth.   
 
In the previous two decades C. difficile has had a substantial economic and clinical 
worldwide impact (Hung et al., 2015; Nanwa et al., 2015). A recent review 
analysing 45 independent cost-of-illness studies described that the cost of 
hospitalised CDI patients ranges from $8,911 to $30,049 per patient in the USA 
(Nanwa et al., 2015). CDI is the most frequently reported healthcare associated 
infection in the USA with the number of incidences ranging from 2.8 to 9.3 per 
10,000 patient days (Evans and Safdar, 2015). In 2011, it was estimated that there 
were 453,000 cases of CDI in US hospitals and long-term care facilities resulting 
in 29,000 deaths (Lessa et al., 2015). Although CDI is considered to be primarily 
a healthcare related disease, incidences of community acquired infections have 
increased and are now estimated to be in the range of 1.3 to 2.7 per 10,000 patient 
days (Evans and Safdar, 2015).  
 
In Europe, the annual economic cost of CDI is approximately €3 billion, a figure 
expected to rise due to the increasing proportion of elderly people in European 
countries (Kuijper et al., 2006). In Saxony, Germany, the incidence rate of CDI 
has risen from between 1.7  and 3.8 cases per 100,000 people in 2002 to 14.8 
cases per 100,000 people in 2006 (Burckhardt et al., 2008). While in Spain, the 
number of hospital discharges over the age of 65 years diagnosed with CDI 
tripled between 1997 and 2005 (Soler et al., 2008). 
 
CDI is most frequently associated with nosocomial diarrhoea in Europe and 
Northern America; however, this is partly due to the scarcity of data available in 
developing countries. In a study describing the rates of CDI in travellers, the 
highest number of cases were reported in low- and middle-income countries 
(Neuberger et al., 2013). CDI was reported to often be acquired in the community 
by younger patients and was associated with antimicrobial use, particularly 
fluoroquinolones (Neuberger et al., 2013).  
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An epidemiological review of CDI in Asia suggests that the prevalence of 
infection is similar to Europe and the US but with a predominance of toxin A-
negative/toxin B-positive strains (Collins et al., 2013).  In stark contrast to 
Europe, ribotypes 027 and 078 have rarely been reported in Asia (Collins et al., 
2013). As is the case in Asia, there is little data of CDI prevalence in South 
America. In a study assessing the epidemiology of C. difficile-associated 
diarrhoea in a Peruvian hospital, 12.9 incidences per 1000 patients were reported. 
The high prevalence (for comparison, in a six-month prospective surveillance 
study covering nine Canadian provinces an overall CDI rate of 4.6 cases per 
1,000 patients was reported) was attributed by the author to in-hospital 
transmission and the need for implementing more stringent hygiene programmes 
in low-resource settings was emphasised (Garcia et al., 2007; Gravel et al., 
2009).  
 
Of additional concern in developing countries is the comorbidity of HIV and CDI. 
A study in India discovered that C. difficile was the most commonly identified 
bacterial pathogen in adults with HIV, with a prevalence of 18% (Jha et al., 2012). 
A similar trend was observed in Nigeria where HIV positive inpatients and 
outpatients were found to be positive for C. difficile in 43% and 14% of cases 
respectively (Onwueme et al., 2011). These studies demonstrate the necessity in 
controlling and regulating access to antibiotics in low- and middle-income countries 
in addition to improving early diagnosis of intestinal pathogens, particularly among 
those infected with HIV. 
 
1.2.2 Presentation of the disease  
Once CDI has developed it can present in several ways (Rupnik et al., 2009). The 
classical presentation of mild, symptomatic CDI presents with diarrhoea, which can 
range in severity from mild to moderate and often resolves itself after the 
discontinuation of antibiotic treatment (Rao and Higgins, 2016). The most common 
clinical manifestation is non-pseudomembranous colitis, with symptoms being 
inflammation of the colon, fever, abdominal pain and severe diarrhoea. PMC is 
diagnosed if upon endoscopical examination pseudomembranous-like structures 
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are observed (appearing as raised yellow plaques) on the colorectal mucosa (Cohen 
et al., 2010). Severe CDI often shows systemic signs of infection including 
leucocytosis, fever and acute kidney injury (Cohen et al., 2010). Complicated CDI 
presents with hypotension, shock, ileus and/or toxic megacolon (Cohen et al., 
2010). Approximately 3% of CDI cases are diagnosed as complicated 
(Kachrimanidou and Malisiovas, 2011). Toxic megacolon can result in 
complication; fever, colonic perforations, systemic inflammatory response and 
occasionally death (Kachrimanidou and Malisiovas, 2011). Cases of severe and 
complicated CDI cause significant morbidity and treatment may require a 
colectomy. Even with treatment, a median of 19% of patients will die within 30 
days of initial diagnosis (Abou Chakra et al., 2014). 
 
Following recovery from CDI, recurrence within two months is common and occurs 
in approximately 25% of individuals (Abou Chakra et al., 2014). Ordinarily, a 
second CDI episode occurring 8 weeks or more after resolution of a previous 
infection are considered to be a new infection but a study utilising molecular typing 
demonstrated that of these 65% were in fact recurrences (Kamboj et al., 2011). The 
incidence of recurrent CDI is significantly higher in older adults and in those with 
irritable bowel syndrome (IBS) (Goodhand et al., 2011; Abou Chakra et al., 2014). 
In those who experience a first recurrence, 30-45% will have a second recurrence, 
and of those 45-60% will experience a third with ≤5% of those suffering from 
chronic, seemingly endless cycles of recurrence (Gough et al., 2011; Rao and 
Higgins, 2016). Among those who do not recur, up to 35% may experience 
functional bowel disorder in the first two weeks following resolution of CDI (Piche 
et al., 2007). Although a transient disorder, approximately 4% of patients will go 
on to develop IBS lasting more than three months from initial CDI diagnosis (Piche 
et al., 2007).  
 
1.2.3 Establishment of infection  
CDI occurs following antibiotic perturbation of the microbiota residing within the 
gut. Recent studies are beginning to demonstrate, using 16S ribosomal RNA 
sequencing, that the perturbation inflicted upon the natural gut flora by antibiotic 
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treatment is more extensive than was previously realised, and contributes to the 
markedly disrupted and decreased diversity thought to play an integral role in 
recurrent CDI (Chang et al., 2008; Dethlefsen et al., 2008). 
 
The antibiotic resistance of C. difficile enables the bacterium to colonize and 
outgrow within the host during antibiotic treatment (Figure 1.1). Studies using 
hamster models have shown that different antibiotics cause susceptibility to CDI 
for varying lengths of time after cessation of treatment. Colonisation resistance is 
restored rapidly after treatment with cephalosporins while clindamycin has a 
prolonged period of susceptibility (Merrigan et al., 2003; Rupnik, Wilcox and 
Gerding, 2009). The recovery of the gut microbiota and consequently host 
colonisation resistance, is therefore necessary to prevent CDI.  
 
As an obligate anaerobe, C. difficile relies on its spore form as the chosen method 
of transmission and dissemination. After ingestion by a host, the process by which 
C. difficile spores germinate, outgrow and cause disease involves complex 
interactions with a number of bile salts (Karen and John, 2011; Shen, 2015). In 
early experiments performed in hamsters, C. difficile spores were shown to 
germinate rapidly (~1 hour) within the small intestine in response to the bile salt 
sodium taurocholate (Wilson et al., 1985). 
 
This finding was supported by the later work of Sorg and Sonenshein (2008), where 
it was demonstrated that spores germinate in response to cholate derivatives in 
combination with amino acid co-germinants. Meanwhile, chenodeoxycholate, 
another primary bile salt, was found to competitively inhibit cholate-induced 
germination by process of having greater affinity for C. difficile spores (Sorg and 
Sonenshein, 2010). In accordance with these findings, small intestinal extracts have 
been shown to induce the germination of C. difficile spores  (Giel et al., 2010). Pre-
treatment of intestinal extracts with cholesterylamine, a bile salt sequestrant, 
negated this effect indicating that interaction of spores with bile salts is a pivotal 
moment in C. difficile's intestinal life residency (Giel et al., 2010). C. difficile most 
likely interacts with bile acid germinants using the germinant receptor, CspC, a 
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subtilisin-like pseudoprotease that is in control of a unique signalling pathway 
(discussed in more detail in Section 1.3.3) (Paredes-Sabja et al., 2014). 
 
 
 
Figure 1.1. The link between antibiotic disruption of the intestinal flora and CDI risk. In the 
absence of antibiotic therapy, the gut microbiota is unperturbed, and the host is resistant to CDI (a). 
Antibiotic therapy disrupts the intestinal flora and CDI risk increases as resistant C. difficile has an 
opportunity to outgrow (b). The antibiotic level rapidly decreases with cessation of therapy, but the 
intestinal flora remains perturbed for a variable period of time depending on the antibiotic used (c). 
During this period susceptibility to resistant or susceptible C. difficile is greatest. Once the intestinal 
flora recovers host colonisation resistance to C. difficile is restored (d). (Modified from Rupnik, 
Wilcox and Gerding, 2009). 
 
Although germination has been demonstrated in both antibiotic and non-antibiotic 
treated animals, small intestinal extracts from antibiotic treated mice are 3 to 10 
fold more effective at germinating C. difficile spores (Giel et al., 2010; 
Koenigsknecht et al., 2015). These findings imply a role for the microbiota, as a 
protector of gastrointestinal health via regulation of bile salt levels, and therefore 
providing resistance against CDI. Antibiotic treatment of mice increases the ratio 
of cholate (germinant) to muricholic acids (germination inhibitor) within the small 
intestine (Francis, Allen and Sorg, 2013; Koenigsknecht et al., 2015). Antibiotic 
treatment has also been shown to increase the quantity of taurocholate in the caecum 
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and decrease the levels of muricholic acids and deoxycholate (Theriot et al., 2014; 
Buffie et al., 2015; Koenigsknecht et al., 2015). Deoxycholate, a derivative of 
cholate, like its precursor acts as a germinant for C. difficile spores but is toxic to 
the vegetative form thereby preventing outgrowth (Sorg and Sonenshein, 2008). 
Muricholic acids have also been shown to inhibit the growth of vegetative C. 
difficile (Francis, Allen and Sorg, 2013). This antibiotic induced change in the 
caecal bile acid profile results in a 30-fold increase in spore germination when 
compared to untreated mice (Giel et al., 2010). This is supported by ex vivo viability 
assays, where caecal extracts from untreated mice display decreased C. difficile 
viability while extracts from antibiotic treated animals support growth (Buffie et 
al., 2015). This ability to support growth is restored in extracts from non-antibiotic 
treated mice by pre-treating with cholestyramine, signifying that secondary bile 
acids play an integral role in preventing both germination and outgrowth of C. 
difficile.  
 
The spatio-temporal dynamics of CDI establishment and progression in a mouse 
model has been eloquently described by Koenigsknecht et al. (2015). After the 
ingestion of C. difficile spores by mice, vegetative cells were first detected in the 
colon after 6 hours signifying that spore germination and outgrowth had occurred 
within this time. At approximately 15 hours post-ingestion sporulation occurs 
concomitantly with toxin production. 24 hours post-ingestion of spores the C. 
difficile CFU count had increased by ~5 logs and the highest numbers were found 
in the large intestine and the caecum. Spores were first detected in the large intestine 
24 hours post-ingestion and at 30-36 hours ~20% of viable CFU were in the form 
of spores. Toxin levels were highest at 24 hours and symptoms of disease presented 
within 6 hours after detection of toxin. A diagrammatic representation of this cycle 
is displayed in Figure 1.2. 
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Figure 1.2. The development of CDI. Spore germination occurs within the small intestine in 
response to cholate derivatives (Wilson et al., 1985; Koenigsknecht et al., 2015). The degradation 
of the cortex layer in germinating spores is shown followed by rapid outgrowth of vegetative cells 
at 6-hours post infection. The precise time at which sporulation is induced is unclear, as are the 
mechanisms behind its co-occurrence with toxin production (Koenigsknecht et al., 2015). The effect 
of antibiotic treatment on bile acids in specific areas of the gut is shown (Buffie et al., 2015; 
Koenigsknecht et al., 2015). Note that muricholic acids are murine specific. Green arrows show 
increase in bile acid germinants while red arrows show decreases in C. difficile inhibitory bile acids. 
(Modified from Shen, 2015). 
 
 
1.2.4 Virulence factors 
1.2.4.1 Toxins 
The range in symptoms described in Section 1.2.2 can largely be attributed to two 
glucosyltransferase toxins: TcdA (308 kDa) and TcdB (269 kDa). C. difficile strains 
also produce a third, binary toxin known as CDT. Toxin A and B are encoded for 
by genes found on the 19.6 kb chromosomal pathogenicity locus (PaLoc) (Lyerly 
et al., 1988; Rupnik et al., 2009). The PaLoc contains the toxin genes, tcdA and 
tcdB, the putative phage holin tcdE and two regulators; tcdR which encodes a sigma 
factor involved in positive transcriptional regulation and tcdC, a negative regulator 
(Figure 1.3). In non-toxigenic C. difficile strains, the PaLoc is substituted for a 115 
bp non-coding sequence. Both TcdA and TcdB are produced during the late log and 
29 
 
stationary phases of growth (Hundsberger et al., 1997). Toxins A and B are the 
primary determinants of pathogenicity and virulence in CDI and their actions lead 
to the symptoms most commonly observed during infection (Thelestam and 
Chaves-Olarte, 2000; Jank et al., 2007). In a hamster model of CDI, via genetic 
inactivation of tcdA and tcdB, it has been demonstrated that the absence of toxins 
leads to an absence of symptoms (Kuehne et al., 2010).  
 
TcdA and TcdB belong to a family of single-chained proteins named large 
clostridial toxins (LCTs). LCTs are glucosyltransferases and have between 30 and 
90% amino acid sequence similarity, while TcdA and TcdB share 63% homology 
in their sequences (von Eichel-Streiber et al., 1996; Chaves-Olarte et al., 1997). 
LCTs contain four functional domains; an amino-terminal catalytic domain, a 
carboxy-terminal binding domain, a cysteine protease domain and a delivery and 
receptor-binding domain (von Eichel-Streiber et al., 1996; Rupnik et al., 2009; 
Chen et al., 2019).  
 
The amino-terminal catalytic domain functions by transferring a glucose from 
UDP-glucose to the threonine residues on GTPases of the Rho and Ras families in 
the epithelial cells of the GI tract within the host (Riegler et al., 1995; Thelestam 
and Chaves-Olarte, 2000). Glycosylation of the Rho and Ras proteins is thought to 
prevent the exchange of GDP for GTP and/or prevent their interaction with 
downstream inhibitors and thereby results in their inactivation. These hypotheses 
have been supported by structural studies demonstrating that the threonine which is 
to be glucosylated (Thr37) is more accessible in the GDP rather than the GTP state 
(Ihara et al., 1998). In another study, Rho-GDP was shown to be a preferred target 
over Rho-GTP (Just et al., 1995). These small GTPases function as messengers 
between external signals and actin signalling within the eukaryotic cell, either by 
direct interaction or by means of downstream effectors (Spiering and Hodgson, 
2011). The inactivation of these proteins by toxins results in disintegration of the 
actin cytoskeleton and tight junctions leading to decreased transepithelial resistance 
and consequently loss of cell shape (Riegler et al., 1995; Thelestam and Chaves-
Olarte, 2000). Consequences of this damage to cellular structure is fluid 
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accumulation, destruction of the intestinal epithelium and the eventual symptoms 
of CDI. A further consequence of the damage inflicted upon host cells is the release 
of inflammatory cytokines from epithelial cells, macrophages and mast cells. The 
disruption of the tight junction permits an influx of neutrophils; this is believed to 
be directly influenced by TcdA and indirectly by inflammatory cytokines such as 
IL-8 (Kelly, Pothoulakis and LaMont, 1994; Voth and Ballard, 2005). These factors 
amplify the inflammatory response observed during CDI.  
 
The receptor binding domains contain multiple “amino acid short repeats” and 
“amino acid long repeats”, collectively named combined repetitive oligopeptides 
(CROPs). Within this C-terminal repetitive domain, CROPs can consist of 21, 30 
or 50 amino acid residues (Sun et al., 2010). Various approaches in CROP sequence 
analysis has revealed that TcdA has between 30 and 38 contiguous repeats in this 
region, whereas TcdB appears to contain between 19 and 24 residues (Ho et al., 
2005; Greco et al., 2006). The similarity of these sequences with several cell wall 
binding bacterial proteins has led to speculation that the multiple repeats may 
increase the affinity and avidity of receptor binding on host epithelial cells (von 
Eichel-Streiber et al., 1992; Fernández-Tornero et al., 2001).      
 
Due to the homology of the CROP region of the binding domains to the 
carbohydrate binding region of streptococcal glucosyltransferases, it was 
hypothesised that toxins may bind to host cell receptors via carbohydrate 
recognition (von Eichel-Streiber and Sauerborn, 1990). In concordance with this 
theory, seven potential carbohydrate binding sites have been identified as putative 
receptors for TcdA (Ho et al., 2005; Greco et al., 2006). In mice, the trisaccharide 
Gal1(α1–3)Gal(β1–4) GlcNAc comprises part of the TcdA receptor but in humans 
this receptor is not present (Krivan et al., 1986). In humans, gp96, a glycoprotein 
found within the heat shock family of proteins, has been shown to act as a receptor 
for TcdA in human colonocytes (Na et al., 2008). However, whether this acts as the 
principal TcdA receptor in vivo remains to be determined. Until recently the 
receptor for TcdB remained elusive, however a recent study using CRISPR-Cas9-
mediated genome-wide screens identified members of the Wnt receptor frizzled 
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family (FZDs) as TcdB receptors (Tao et al., 2016). In a mouse model, Tao et al. 
(2016) were able to show that TcdB binds to the Wnt binding site, named the 
cysteine rich domain, with preferential binding to FZD1, 2 and 7. TcdB blocks Wnt 
signalling by competing for binding to FZDs, and in FZD7-knockout mice, the 
colonic epithelium was shown to be less susceptible to TcdB-induced tissue damage 
in vivo (Tao et al., 2016). The size of the role that the CROP region plays in toxin 
uptake and cytotoxicity has recently been questioned, with the observation that 
TcdA lacking CROPs is still able to enter the host cell and facilitate cytotoxicity 
(Olling et al., 2011; Gerhard et al., 2013).  
 
Following binding to the host cell receptor, toxins are internalised after 
encapsulation by an endosome. The uptake of toxin by host cells seems to be a 
clathrin-dependent mechanism (Papatheodorou et al., 2010). While the endosome 
acidifies, the toxin alters in structure thereby exposing the hydrophobic pore 
domain which subsequently inserts itself within the endosomal membrane leading 
to the translocation of the protease and glucosyltransferase domains into the cytosol 
(Reineke et al., 2007). The binding of inositol, a eukaryotic signalling molecule 
activates the protease domain resulting in proteolytic release of the amino-terminal 
glucosyltransferase domain into the host cell cytosol, with the rest of the toxin 
polypeptide remaining attached to the membrane (Reineke et al., 2007; Pruitt and 
Lacy, 2012). The glucosyltransferase is eventually able, after a cascade of reactions, 
to inhibit the small GTPases ultimately leading to increased membrane 
permeability, loss of barrier function and cellular death.  
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Figure 1.3. C. difficile toxins.  
a. TcdA (308 kDa) and TcdB (269 kDa) are encoded on the pathogenicity locus. In non-toxigenic 
strains, this region is replaced by a short 115 bp sequence. Both toxins are single chain polypeptides 
with different functional domains. 
b. The binary toxin CDT is encoded on the CdtLoc pathogenicity locus, comprised of the proteins, 
CdtA and CdtB. CdtA has enzymatic activity while CdtB has a binding function. (Modified from 
Rupnik, 2009 and Chen et al., 2019). 
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The binary toxin is the least studied of the three C. difficile toxins (Gerding et al., 
2014). CDT is frequently observed in strains of C. difficile linked to increased 
severity of CDI. CDT has also been shown to be cytotoxic to Vero cells in vitro 
(Perelle et al., 1997). Nevertheless, studies have demonstrated that tcda- tcdb- cdt+ 
C. difficile strains cause no symptoms in hamsters leading many to the conclusion 
that CDT plays no role in virulence (Perelle et al., 1997; Geric et al., 2006). A more 
recent finding has cast some doubt on CDT’s lack of effect in animals, where 3 of 
9 animals infected by an A-B-C+ isogenic 027 strain succumbed to disease. 
Although the deceased hamsters did not display the typical symptoms of CDI, 
haemorrhaging and inflammation was observed in the small intestine implicating a 
role for CDT in C. difficile virulence. The binary toxin comprises two separate toxin 
components; CdtA, an ADP-ribosylating enzyme able to modify actin and CdtB 
which is able to bind to host cells and translocate CdtA into the cytosol (Gerding et 
al., 2014). CDT is encoded on the binary toxin locus, CdtLoc, alongside the 
regulatory cdtR gene (Perelle et al., 1997).   
 
1.2.4.2 S-layer proteins 
C. difficile vegetative cells are encapsulated by an external proteinaceous layer 
called the S-layer (Calabi et al., 2001). S-layers form a regularly arranged lattice 
above the peptidoglycan cell wall of many Gram-positive bacteria. C. difficile is 
unusual in that it expresses two S-layer proteins (SLPs) which vary in size among 
different strains, and arise due to post-translational cleavage of a single precursor, 
SlpA (Eidhin et al., 2006). The two SLPs exist as high and low molecular weight 
species which self-assemble on the cell exterior. Although the exact role of the C. 
difficile S-layer in virulence is yet to be fully understood, several experiments have 
provided evidence as to how it may affect CDI pathogenicity. SLPs have been 
shown to play a role in adhesion to enteric cells (Calabi et al., 2001). This 
observation was complemented by a study demonstrating the capability of isolated 
SLPs to inhibit binding of C. difficile to Caco-2 cells (Merrigan et al., 2013). 
Purified SLPs from C. difficile have been shown to elicit the release of pro-
inflammatory and regulatory cytokines from human monocytes, increase T-cell 
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proliferation and cause the maturation of dendritic cells (Ausiello et al., 2006). In 
C. fetus the S-layer is able to avoid the immune system and phagocytic digestion, 
providing a possible function for the C. difficile S-layer (Sára and Sleytr, 2000). A 
recent study using a mouse model has demonstrated that SLPs cause maturation of 
bone marrow derived dendritic cells, which play a key role in cytokine production 
and helper T-cell induction (Ryan et al., 2011). The study went on to show that 
SLPs activate innate and adaptive immunity via Toll-like receptor 4 (TLR4) 
mediation, and in TLR4-defient mice CDI is more severe thereby providing 
evidence that SLPs play a key role in the immune system’s recognition of C. 
difficile (Ryan et al., 2011). It has recently been suggested that S-layers from 
different ribotypes, in addition to having different sequences also elicit different 
immune responses (Lynch et al., 2017). S-layers from ribotype 027 and 078 were 
shown to be able to induce a more potent macrophage and cytokine response when 
compared to ribotypes 001 and 014 (Lynch et al., 2017). The authors posit that the 
differing S-layer proteins may play a role in driving the emergence of hypervirulent 
strains.  
 
1.2.5 Rise of community acquired infections  
The Infectious Disease Society of America define CDI as community acquired if it 
satisfies the following requirements; if symptoms occur in the community or within 
48 hours of hospital admission, or after 12 weeks following hospital discharge 
(McDonald et al., 2007). Incidences of community-acquired C. difficile infections 
(CA-CDI) have almost doubled in the past decade and severity is closely linked to 
hypervirulent ribotypes 027 and 078, with poor outcomes (Chitnis et al., 2013; 
Lewis et al., 2016). Data from Europe and North America estimate that CA-CDI 
comprise 20-27% of diagnosed CDI cases (Centers for Disease Control and 
Prevention (CDC), 2005; Wilcox et al., 2008). The rise in incidences of CA-CDI is 
of particular concern to healthcare professionals, especially as it often coincides 
with increased infection rates among those previously viewed as low risk, such as 
the young (McDonald et al., 2007). CA-CDI is not associated as strongly with 
antibiotic treatment as is nosocomial CDI, and as a consequence it appears to 
present in patients as less severe (Gupta et al., 2014). Although infection is often 
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less acute, CA-CDI can nevertheless prove fatal (Taori et al., 2014). A 2012 study 
focussing on community acquired infections found that 40% of patients needed 
hospitalisation, 20% suffered from severe infection, 20% experienced treatment 
failure and 28% relapsed (Khanna and Pardi, 2012). Whole genome sequencing 
performed in Oxfordshire, UK from 2007 until 2011 showed that less than 25% of 
diagnosed CDI cases had originated from another patient, implicating transmission 
from a community source (Eyre et al., 2013). So, although CDI is rightfully 
considered primarily a nosocomial infection, it cannot be considered primarily a 
nosocomial transmitted infection.   
 
1.3 The spore  
1.3.1 Spore structure and function  
Bacterial endospores (spores) are dormant, highly resistant, non-reproductive 
structures produced by bacteria within the Firmicutes phylum (de Hoon et al., 
2010). Spore-forming bacteria are able to initiate sporulation in response to adverse 
environmental conditions, such as nutrient limitation, and are then able to germinate 
into vegetative cells once conditions become favourable (de Hoon et al., 2010). 
Sporulation can therefore be considered as a long-term survival mechanism, 
allowing the bacterium to endure conditions the vegetative cells would otherwise 
not be able to. When vegetative C. difficile cells start replicating in the GI tract, a 
subset of the population will initiate sporulation. This developmental process 
generates the metabolically dormant, highly resistant spores that are essential for 
C. difficile to survive excretion from the host. Infected hosts shed large amounts of 
infectious spores that provide an environmental reservoir for C. difficile (Lawley et 
al., 2009). 
 
The formation of spores by C. difficile is therefore integral to the pathogenesis of 
CDI. With C. difficile being an obligate anaerobe, it is the role of the spore to 
transmit and disseminate CDI between hosts (Jump et al., 2007). C. difficile strains 
which are unable to form spores have been shown to be incapable of persisting 
within the GI tract and of being horizontally transmitted (Deakin et al., 2012). This 
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implies that C. difficile spores are the sole agent of CDI transmission. Persistence 
of spores within the GI tract also plays a role in recurrent CDI where a small 
population of spores that do not germinate during infection are able to survive 
antibiotic treatment. This residual and persistent population of spores can 
subsequently germinate and cause disease following the cessation of treatment 
(McFarland et al., 2002).  
 
Spores are dehydrated and metabolically dormant, and the chromosome is encased 
in a thick proteinaceous shell (the spore coat). These features make the spore robust, 
enabling it to be resistant to antibiotics (Baines et al., 2009), disinfectants (Vohra 
and Poxton, 2011), the host’s immune system (Paredes-Sabja and Sarker, 2012b), 
alcohol (Jabbar et al., 2010), heat and ionizing radiation (Setlow, 2006). Thus, 
spores are able to survive in the environment for long periods of time prior to 
infecting a host, germinating into vegetative cells, outgrowing and producing more 
spores. High numbers of spores are then shed into the environment from the host’s 
faecal matter and the cycle continues.  
 
Transmission electron microscopy (TEM) has revealed that C. difficile spores are 
encapsulated by an exosporium (Panessa-Warren et al., 1997). The exosporium is 
a loose-fitting structure enveloping the spore and is comprised of various proteins 
and glycoproteins (Lawley, Croucher, et al., 2009). Of particular interest are the 
glycoproteins BclA1, BclA2 and BclA3 (Lawley, Croucher, et al., 2009) and the 
cysteine rich proteins CdeC and CdeM (Calderón-Romero et al., 2018). A C. 
difficile mutant lacking BclA1 has been shown to be less effective at colonising and 
causing infection within a host implicating this glycoprotein in the initial, pre-spore 
germination stages of infection (Phetcharaburanin et al., 2014). bclA1 mutants 
demonstrate increased germination rates, suggesting that germinants can access the 
spore more freely due to destabilisation of the exosporium, potentially decreasing 
spore hydrophobicity and therefore its adhesive properties. CdeC is one of the most 
abundant proteins found on C. difficile spores (Lawley, Croucher, et al., 2009; 
Díaz-González et al., 2015). CdeC is believed to form a protective layer around the 
spore, and the absence of the protein leads to increased spore coat permeability, 
37 
 
alongside increased susceptibility to heat, ethanol and phagocytic cells (Barra-
Carrasco et al., 2013; Calderón-Romero et al., 2018). CdeM is highly abundant on 
the spore exosporium and has no known homology to any other protein (Janoir et 
al., 2013; Díaz-González et al., 2015).  The exclusivity of CdeM to C. difficile, in 
addition to its high accessibility on the spore surface makes it a potential candidate 
as an antibody target for a vaccine, and a mouse infection model using the C. 
difficile UK1 strain has confirmed this hypothesis (Ghose et al., 2016). CdeM is 
upregulated principally during sporulation and has been shown to be highly 
expressed throughout infection in experiments using axenic mice (Janoir et al., 
2013). A study comparing the fitness of an isogenic cdeM mutant to a wild-type 
strain suggested that CdeM may have a role to play in colonisation and persistence 
of C. difficile spores in a CDI mouse model (Janoir et al., 2013).      
 
The exact function of the exosporium remains unclear however, but it has been 
suggested that it may play a role in spore persistence and in the adhesion of spores 
to surfaces (Setlow, 2006). Removal of the exosporium layer by sonication or 
proteases has been shown to reduce spore hydrophobicity (Escobar-Cortés et al., 
2013). Interestingly, a C. difficile cdeC::erm mutant, unable to assemble an 
exosporial layer, demonstrated increased levels of adhesion to epithelial cells, 
mucin, fibronectin and vitronectin (Mora-Uribe et al., 2016). This translated to an 
increase in fitness of the cdeC mutant compared to wild-type in a mouse infection 
model (Calderón-Romero et al., 2018). A possible explanation may be gleaned 
from somewhat contradictory observations; cdeC mutants show lower levels of 
adhesion to a healthy colonic mucosa, yet higher levels to a damaged mucosa. 
During CDI, toxins and inflammation inflict damage upon the mucosa, including 
tight junction disruption and epithelial erosion, thereby remodelling it and exposing 
an increased number of alternative binding sites such as vitronectin and fibronectin. 
So although CdeC may contribute to higher adhesion to healthy colonic tissue, it 
seems that in the case of tissue damage mediated by infection an absence of CdeC 
leads to greater persistence within the host (Calderón-Romero et al., 2018). A 
possible caveat to studies performed with cdeC mutants are the global changes 
enacted upon the surface of the spore thereby leading to experimentally unforeseen 
38 
 
and uncontrolled for consequences. As an example, in cdeC mutant spores 
increased levels of low molecular weight BclA1, 2 and 3 are detected and as 
described earlier BclA1 is strongly implicated in the pathogenesis and severity of 
CDI (Phetcharaburanin et al., 2014).  
Beneath the exosporium lies the spore coat. The C. difficile spore coat possesses 
lamaellae similar to those found in spores of B. subtilis, but despite this structural 
resemblance only 25% of the genes encoding spore coat proteins in B. subtilis have 
homologues in C. difficile (Henriques and Moran, 2007). Several spore coat 
proteins have been identified and characterised, including CotA, CotB, CotCB, 
CotD, CotE, SodA (Permpoonpattana et al., 2011) and most recently CotL (Alves 
Feliciano et al., 2018). CotA is believed to play a role in spore coat stabilisation 
and a cotA mutant exhibits major structural defects in spore assembly, while 
displaying increased sensitivity to ethanol and lysozyme (Permpoonpattana et al., 
2011). CotB and CotE contain orthologues in other members of the Bacilli and 
Clostridia (Permpoonpattana et al., 2011). CotCB and CotD are putative manganese 
catalases and share 70% homology with each other, and with the B. subtilis spore 
coat protein CotJC (Permpoonpattana et al., 2011). While cotD mutants show a 
significantly greater reduction in catalase activity when compared with cotCB 
mutants, activity is not completely abolished suggesting functional redundancy 
(Permpoonpattana et al., 2013). CotE is a novel, bifunctional protein with 
peroxiredoxin activity at the amino-terminus, and chitinase activity at the carboxy-
terminus (Permpoonpattana et al., 2011). SodA carries superoxide dismutase 
(SOD) activity and may be involved in polymerising spore coat monomers via 
oxidative cross-linking, which in turn may provide a role for CotE’s peroxiredoxin 
as a reducer of the SOD by-product, hydrogen peroxide (Permpoonpattana et al., 
2013). The chitinase activity carried by CotE has been hypothesised to be involved 
in macromolecular turnover and the production of nutrients for use by vegetative 
cells after germination of the spore (Permpoonpattana et al., 2011). CotL is the most 
recently discovered of the C. difficile spore coat proteins. CotL is essential for coat 
assembly with mutant spores carrying major morphological defects, resulting in the 
reduction and incorrect localisation of several spore coat proteins (Alves Feliciano 
et al., 2018). In addition to this, cotL mutant spores displayed higher sensitivity to 
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lysozyme and showed germination impairment, providing further evidence in 
support of CotL being a C. difficile morphogenetic spore coat protein (Alves 
Feliciano et al., 2018). 
 
An outer membrane exists directly below the spore coat. This membrane forms after 
spore engulfment by the mother cell during sporulation (as described in Section 
1.3.2). Although the outer membrane contains a number of lipids and proteins the 
precise role of the outer membrane for the dormant spore has not yet been 
elucidated (Setlow, 2006; Setlow and Johnson, 2013; Loison et al., 2016). Beneath 
the outer membrane is the cortex, made of peptidoglycan (PG). Precursors made by 
the mother cell are transported into the intermembrane space and used to synthesise 
the cortex peptidoglycan (Meador-Parton and Popham, 2000). Interestingly, the 
spore cortex peptidoglycan is structurally different to that of the vegetative cell, for 
example, it contains fewer peptide linkages (Popham et al., 1996; Popham, 2002). 
The cortex plays a role in the heat resistance of spores and it has been proposed to 
play an active role in the attainment and maintenance of spore dehydration, a crucial 
attribute which provides spores with their characteristically high resistance to the 
environment (Gaylarde, 2002; Popham, 2002). The cortex may also play a role in 
germination and outgrowth (Meador-Parton and Popham, 2000).  
 
Beneath the C. difficile spore cortex lies the germ cell wall (GCW). The GCW is 
comprised of peptidoglycan, but unlike the cortex, this PG is similar to that of the 
vegetative cell. The GCW is not degraded during germination and serves as the cell 
wall of the germinating C. difficile spore (Atrih et al., 1998). Beneath the GCW lies 
a second membrane, the spore’s inner membrane. The inner membrane contains 
germination receptors and therefore plays an integral role in spore germination 
(Cowan et al., 2004; Zheng et al., 2016). The most extensively studied are the 
highly conserved GerA family of germination receptors, however C. difficile has 
no orthologue and instead responds to germinants via the unique pseudoprotease 
CspC (Moir, 2006; Francis, Allen, Shrestha, et al., 2013; Setlow, 2014). It has been 
suggested that interactions between germinants and their receptors alters the 
permeability of the inner membrane, resulting in an efflux of ions (Setlow, 2014). 
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The inner membrane also serves as a permeability barrier to damaging chemicals 
(Setlow and Setlow, 1980; Swerdlow et al., 1981). The inner most layer of the C. 
difficile spore is the core. The core contains all the genetic material, but due to spore 
dormancy no damage can be repaired, and so protection of DNA is of utmost 
importance. The most important contributing factors to spore resistance is the low 
water content, saturation of DNA with small acid soluble spore proteins (SASPs), 
and the high concentration of dipicolonic acid (DPA). SASPs alter the 
photochemistry of spore DNA in response to UV, minimising the risks of DNA 
damage. The high levels of DPA (25% of core dry weight) is chelated with Ca2+ 
and is released upon germination and so is often used as a direct correlate of 
germination. DPA plays a key role in core dehydration, contributing to the heat and 
desiccation resistance exhibited by spores (Setlow, 2006).  
 
1.3.2 Sporulation pathway 
The process of sporulation, of a vegetative cell entering a metabolically dormant 
state requires extensive morphological alterations and unsurprisingly is highly 
regulated, with an estimated 500 genes being involved in the process (Galperin et 
al., 2012). It remains unclear what signals are required for C. difficile vegetative 
cells to initiate the sporulation process, however in Bacillus low nutrient availability 
and high cell density are essential for initiation of unicellular development (Rao 
and Higgins, 2016). Recently, RstA was reported as a novel positive regulator 
involved in the sporulation of C. difficile (Edwards et al., 2016). RstA encourages 
initiation of sporulation through its peptide-interacting domain, while negatively 
regulating motility and toxin production (Zhu et al., 2018). The authors suggest that 
RstA may be a global transcriptional regulator, but a detailed pathway has not yet 
been fully elucidated (Edwards et al., 2016). In some Bacillus and Clostridium 
species it has been demonstrated that initiation of sporulation is regulated by several 
histidine kinases in response to environmental cues resulting in phosphorylation of 
the master transcriptional regulator Spo0A (Hoch, 1993). Phosphorylated Spo0A 
acts as both a transcriptional repressor (for other sporulation repressor genes such 
as arbB (Strauch, 1993)) and activator (for other sporulation promoter genes such 
as spoIIG (Satola et al., 1992)). Once phosphorylated Spo0A reaches a threshold 
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level within the cell, the equilibrium between genes repressed or activated by 
Spo0A shifts, thereby committing the cell to sporulation (Chung et al., 1994). 
Spo0A and the histidine kinases are conserved in the C. difficile genome, however 
sporulation regulation is different to that of B. subtilis (Underwood et al., 2009). 
Absence of Spo0A in C. difficile mutants prevents the formation of spores, while a 
mutant devoid of the histidine kinase CD2492 was shown to have a decreased 
sporulation capacity suggesting that other kinases may be phosphorylating Spo0A. 
The absence of the B. subtilis proteins responsible for the transfer of a phosphoryl 
group from the histidine kinases to Spo0A (Spo0F and Spo0B) seems to suggest 
that in C. difficile the kinases phosphorylate Spo0A directly, and recent in vitro 
evidence supports this hypothesis (Underwood et al., 2009). Currently, only one C. 
difficile histidine kinase has been shown to autophosphorylate and transfer a 
phosphoryl group directly to Spo0A; CD1579 (Underwood et al., 2009). It is yet to 
be determined whether the remaining histidine kinases can directly phosphorylate 
Spo0A. 
 
Spo0A functions due to its regulation of sporulation-specific RNA polymerase 
sigma factors, specifically SigE, SigF, SigG and SigK (Fimlaid and Shen, 2015). 
The sporulation regulatory pathway of C. difficile is as follows; (1) Immediately 
after polar septation, SigF is activated in the forespore when anti-sigma factor 
SpoIIAB binds to unphosphorylated anti-anti-sigma factor SpoIIAA; (2) SigF 
activity results in SpoIIR expression, which interacts with the protease SpoIIGA 
resulting in cleavage of pro-SigE yielding active SigE; (3) Active SigF and SigE, 
within the forespore and mother cell respectively, cause mother cell engulfment of 
the forespore; (4) SigE activity results in SpoIIIA-H expression, which via 
interaction with SigF regulated SpoIIQ forms a channel within the inner and outer 
forespore membranes. SpoIIIAH and SpoIIQ interact within the intermembrane 
space after localisation to the asymmetric septum and engulfing membranes; (5) 
SigE regulated SpoIIID activates SigK in the mother cell (Haraldsen and 
Sonenshein, 2003; Pereira et al., 2013; Paredes-Sabja et al., 2014; Fimlaid and 
Shen, 2015; Zhu et al., 2018). Although many factors that control spore formation 
are shared between B. subtilis and C. difficile, there are differences. C. difficile 
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produces mature SigK rather than pro-SigK, SigK is responsible for germinant 
receptor transcription while SigG is in B. subtilis, SigE and SigG are dispensable 
in their activation of SigG and SigK respectively, while SigG can also be activated 
prior to SigE and SigK (Pereira et al., 2013; Fimlaid and Shen, 2015). These 
differences indicate that C. difficile sigma factor activation is less tightly controlled 
in comparison to B. subtilis. 
 
At the beginning of sporulation, the vegetative cell divides asymmetrically to form 
a smaller forespore within the larger mother cell separated from each other by a 
septum. Following this, prespore chromosome segregation takes place ensuring that 
the prespore carries a full chromosome. Mother cell engulfment swiftly follows, in 
which the cell wall of the septum between the mother cell and forespore is degraded 
and the mother cell engulfs the forespore resulting in a prespore within the mother 
cell cytoplasm encapsulated within two membranes. The spore structures (as 
described in Section 1.3.1) assemble onto the prespore, followed by the subsequent 
lysis of the mother cell leading to the release of the mature spore (Errington, 2003). 
In B. subtilis, this entire process takes approximately eight hours (Driks, 2002). In 
C. difficile, sporulation is estimated to take approximately 120 hours to complete 
(Burns and Minton, 2011). 
 
1.3.3 Germination pathway 
Induction of bacterial spore germination is triggered when receptors detect specific 
germinants and the subsequent outgrowth returns the spore to its vegetative state. 
In B. subtilis the known germinant receptors include GerA, GerB and GerK but 
these do not appear in the C. difficile genome suggesting that a different set of 
environmental cues are required (Sorg and Sonenshein, 2008). It has been 
recognised that bile acids are required for C. difficile spore germination since the 
early 1980’s (Wilson, 1983). Bile acids are steroid acids synthesised in the liver, 
stored in the gall bladder and secreted into the small intestine where they facilitate 
the digestion and absorption of fats. The liver synthesises cholic acid and 
chenodeoxycholic acid, which can be modified in the GI tract by conjugation to 
taurine or glycine resulting in a more diverse range of bile salts such as glycocholate 
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and taurocholate (Sorg and Sonenshein, 2008). Work by Sorg and Sonenshein 
(2008) has demonstrated that C. difficile spores germinate in response to cholate 
and its derivatives (taurocholate, glycocholate and deoxycholate) with L-glycine 
acting as a co-germinant. Histidine has also been found to act as a co-germinant in 
combination with taurocholate and glycine (Wheeldon et al., 2011). It has however 
been shown that some C. difficile strains are able to germinate in rich media without 
the presence of bile acids, implying that the mechanism of germination receptors is 
complex (Heeg et al., 2012). Chenodeoxycholate acts as an inhibitor of germination 
by acting as a competitor of taurocholate and other cholic acid derivatives (Sorg 
and Sonenshein, 2009).    
 
A recent study by Francis et al. (2013) identified CspC as the germinant receptor 
that recognises bile acids in C. difficile. CspC is one of three serine-like proteases 
packaged into the spore, along with CspA and CspB. Both CspA and CspC encode 
an incomplete catalytic triad, but despite this loss of activity both are essential for 
spore germination (Adams et al., 2013). Disruption of CspC using Targetron (Heap 
et al., 2007) (a system for insertional mutagenesis) prevents spore germination, 
while a specific SNP mutation (G457R) alters germination specificity allowing 
germination in the presence of chenodeoxycholate, demonstrating the importance 
of CspC as a germinant receptor in C. difficile spores (Francis, Allen, Shrestha, et 
al., 2013). CspC is required for Ca-DPA release from spores in response to the 
presence of glycine and taurocholate, but whether this is due to direct activation of 
DPA channels or activation of cortex hydrolysis, the mechanism remains unclear 
(Francis, Allen, Shrestha, et al., 2013). CspA plays a functionally essential role for 
spore germination, by regulating the levels of CspC in the developing spore 
(Francis, Allen, Shrestha, et al., 2013; Kevorkian et al., 2016). The only receptor 
with an intact catalytic triad is CspB, and it has been suggested that it converts pro-
SleC into its active, cortex-degrading form (Kevorkian et al., 2016). CspA and 
CspB are encoded together as a cspBA operon in C. difficile (Adams et al., 2013). 
 
As is also the case in C. perfingens, degradation of the C. difficile spore cortex 
during germination requires the presence of Csps and SleC (Paredes-Sabja et al., 
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2009b, 2009a; Burns et al., 2010; Adams et al., 2013; Francis, Allen, Shrestha, et 
al., 2013). However, the signalling pathway resulting in SleC activation differs 
greatly between these species. In C. difficile, during spore formation the CspBA 
fusion protein undergoes interdomain cleavage resulting in the SleC dependent 
release and incorporation of CspB into the spore (Adams et al., 2013). CspB then 
converts pro-SleC into mature SleC. It is hypothesised that CspC activates CspB 
upon interaction with bile salt germinants. Subsequently, CspB activates SleC by 
cleaving the N-terminal pro-sequence which then proceeds to hydrolyse the cortex. 
Cortex degradation leads to the detection of osmotic swelling by the 
mechanosensing protein SpoVAC within the inner membrane, which next triggers 
the release of Ca-DPA from the core (Velásquez et al., 2014; Donnelly et al., 2016; 
Francis and Sorg, 2016). Inactivation of CspC or SleC prevents cortex degradation 
and Ca-DPA release. The CspC dependent cortex degradation and subsequent Ca-
DPA release is the reverse of what happens in B. subtilis, where germination occurs 
from inside-to-out as opposed to outside-to-in as is the case with C. difficile (Francis 
and Sorg, 2016). Once DPA is released from the spore cortex, water replaces it and 
the hydration of the spore core increases. Following hydrolysis further core 
hydration results in swelling and germ cell wall expansion. After the water content 
reaches a threshold level metabolic activity initiates and the spore continues its 
outgrowth culminating in the vegetative state. The whole process takes 
approximately 180 min. in vitro (Dembek et al., 2013). A depiction of the 
germination-sporulation cycle is shown in Figure 1.4. 
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Figure 1.4. The sporulation and germination cycle. Under unfavourable conditions, a vegetative 
cell may initiate sporulation in order to enter a metabolically dormant, resilient state. Sporulation 
begins with asymmetric division into a forespore and a mother cell, followed by forespore 
engulfment by the mother cell resulting in a free prespore within the mother cell cytoplasm. 
Assemblage of spore structures, and finally mother cell lysis resulting in release of the mature spore 
completes the process. The spore may then germinate into a vegetative cell and restart the cycle. 
(Modified from McKenney, Driks and Eichenberger, 2013). 
   
1.4 Control and prevention of CDI 
1.4.1 Diagnosis 
Due to the methodological issues in diagnosing CDI, the European Society of 
Clinical Microbiology and Infectious Diseases (ESCMID) recommends a two-step 
algorithm beginning with either a NAAT or GDH-EIA (Crobach et al., 2016). If 
the tests come back negative, the patient is deemed CDI negative, but if positive the 
result is confirmed with a toxin ELISA to yield a positive diagnosis for CDI 
(Crobach et al., 2016). This two-step algorithm reduces the shortcomings inherent 
to any individual test. 
 
The primary method used for the diagnosis of CDI is either the isolation of C. 
difficile spores (toxigenic culture-TC) or the detection of toxins from faeces  
(Kuipers and Surawicz, 2008; Williams and Spencer, 2009). Other methods include 
glutamate dehydrogenase (GDH) enzyme immunoassays (GDH-EIA) and nucleic 
acid amplification tests (NAAT). An effective diagnosis combines the presence of 
46 
 
symptoms (e.g. diarrhoea, abdominal pain, fever) with a positive laboratory test 
(Debast et al., 2014). As the symptoms of CDI also present in many other common 
illnesses, an accurate case history of the patient is important; symptoms presenting 
in patients considered high risk such as the young, the elderly and those undergoing 
antibiotic therapy are considered to more likely be CDI related (Debast et al., 2014; 
Crobach et al., 2016). Toxins are detected and quantified either using cell 
cytotoxicity neutralisation assays (CCNA) or with the use of immunodiagnostics, 
by which ELISA is the primary method (Debast et al., 2014; Peng et al., 2018). 
Although TC and CCNA are considered to be the gold standard, both methods have 
limitations. Both methods are time consuming, labour intensive and expensive 
while TC has low specificity for clinical disease due to its inability to distinguish 
between toxigenic and non-toxigenic strains of C. difficile (Peng et al., 2018). 
CCNA is analytically sensitive for toxin B, however interpretation of the data is 
subjective leading to poor reproducibility between laboratories. They are however 
favourable compared to GDH-EIA, which are not specific due to the commonality 
of GDH in non-toxigenic Clostridial species (Surawicz et al., 2013). NAATs have 
excellent specificity and sensitivity, simplified data reporting, and are rapid. 
NAATs are therefore considered the most cost-effective method of diagnosing CDI 
(Schroeder et al., 2014). NAATs target the encoding genes of TcdA and TcdB, 
resulting in their main disadvantage; no differentiation between active toxin 
production and C. difficile colonisation without the production of toxin (Dunwoody 
et al., 2018).  
 
1.4.2 Prevention 
1.4.2.1 Hospital management and hygiene 
Since the turn of the century and the spate of CDI outbreaks, considerable effort 
has been made to improve the conditions of hospital environments as a means of 
controlling CDI. Although these simple preventative measures draw upon the 16th 
Century germ theory of disease, a theory brought into practice by Joseph Lister in 
the 1870s through the use of aseptic surgical techniques, it would not be until 2004 
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that the UK government started the “Cleanyourhands” campaign leading to a 
decrease in the CDI rate (Stone et al., 2012).  
 
Studies in mice have demonstrated the ease and rapidity of CDI transmission and 
so the implementation of standardised regimens of glove use, disinfection, hand 
washing and education within hospitals was paramount (Department of Health and 
the Health Protection Agency, 2008; Lawley et al., 2009). Due to the high number 
of spores excreted in faeces by patients during the ‘supershedding’ state of CDI the 
environment can become inundated with highly resistant spores, significantly 
increasing the probability of nearby susceptible patients developing the disease. 
Alcohol gel hand rub has been shown to be ineffective at removing C. difficile 
spores, while washing hands with soap and water has been shown to correlate with 
a decrease in CDI cases (Stone et al., 2012). In mice, disease persistence only 
requires 7 spores/cm2 and spores are able to persist on surfaces for at least five 
months, highlighting the importance of keeping equipment and surfaces clean 
(Gerding et al., 2008; Stabler et al., 2009). Due to the chemically resistant 
properties of C. difficile spores, only hydrogen peroxide and chlorine disinfectants 
have been demonstrated to destroy spores (Gerding et al., 2008). Interestingly, 
recent work provides evidence for the use of alcohol-based sanitisers containing 
taurocholic acid to induce germination thereby rendering spores susceptible to 
disinfection (Nerandzic and Donskey, 2017).  
 
1.4.2.2 Probiotics 
CDI is the result of a perturbed microbiota, so the ingestion of live bacteria 
(probiotics) as both a prophylaxis and a treatment holds promise. The number of 
bacteria inhabiting the GI tract is estimated to equal the number of human cells in 
an entire human body (~1x1013) (Sender et al., 2016). The healthy adult microbiota 
is diverse, containing as many as 1000 different species all interacting with each 
other and their host to reach an equilibrium. Antibiotic treatment decimates this gut 
population, significantly reducing diversity and total numbers potentially causing 
symptoms such as diarrhoea, nausea and stomach cramps (Phillips, 2009). There 
therefore appears to be a niche for the ingestion of probiotics to replenish lost 
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numbers and prevent opportunistic pathogens from causing illness during this 
period of a weakened microbiome. The lack of current widespread clinical use may 
be attributed to an absence of standardisation across trials and a superficial 
understanding of what makes a good probiotic (Hell et al., 2013). Additionally, it 
remains unclear as to the exact mechanism by which commensal bacteria prevent 
colonisation by C. difficile. Hypotheses include competition for binding sites, direct 
inhibition by antimicrobials/bacteriocins, bile acid modification and competition 
for food (Borriello, 1990; Dubois et al., 2019; Buffie et al., 2015; Collins et al., 
2018; Hryckowian et al., 2018) . 
 
There have been numerous studies in mice and hamsters showing the efficacy of 
probiotics in the reduction of incidences and severity of CDI. Lactobacillus 
salivarius, Lactobacillus reuteri, Lactococcus lactis and Bacillus clausii secrete 
compounds which directly inhibit C. difficile and have been shown to partially 
protect against CDI (Corr et al., 2007; Rea et al., 2007; Mills et al., 2018). L. reuteri 
produces the C. difficile toxic antimicrobial reuterin via glycerol fermentation and 
the bacterium has been shown to have a high level of resistance against 
vancomycin, metronidazole and fidaxomicin making it an attractive treatment 
option for patients receiving antibiotic therapy (Spinler et al., 2017). B. 
amyloliquefaciens has also been shown to have direct inhibitory action against C. 
difficile, and dosing vegetative cells to mice conferred protection against CDI 
(Geeraerts et al., 2015). Mice dosed with B. amyloliquefaciens lost less weight, had 
significantly lower toxin A and B, and displayed less colon damage when compared 
to naïve and S. boulardii treated mice. Human trials have been conducted with the 
yeast S. boulardii (McFarland et al., 1994; Surawicz et al., 2000), Lactobacillus 
rhamnosus GG (Pochapin, 2000), Lactobacillus acidophilus and Bifidobacterium 
bifidum (Plummer et al., 2004) and Lactobacillus plantarum 299v (Wullt et al., 
2003). These studies all demonstrate a significant effect on the incidence and 
relapse of CDAD when used in conjunction with antibiotics (Gougoulias et al., 
2007).  Mice pre-fed with S. boulardii show enhanced intestinal IgA responses to 
orally dosed Toxoid A, providing a possible mechanism of protection (Qamar et 
al., 2001). A recent double blind, randomised controlled trial study assessed the 
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effectiveness of S. boulardii at preventing primary AAD in hospitalised patients 
receiving antibiotic therapy (Ehrhardt et al., 2016). The study included 477 
participants but failed to find an effect, although this could be due to the study being 
underpowered because of fewer than anticipated patients. A phase 2, probiotic 
adjunct trial found that an oral probiotic capsule containing a cocktail of 
Lactobacillus acidophilus NCFM, Lactobacillus paracasei Lpc-37, 
Bifidobacterium lactis Bi-07 and B. lactis Bl-04 significantly improved diarrhoea 
outcomes (Barker et al., 2017). There was however no reduction in CDI recurrence 
or functional improvement over time and the authors suggest that a larger scale 
randomised controlled study is necessary.  
 
Another interesting approach was recently shown by Buffie et al. (2015), who used 
16S rRNA sequencing in mice treated with various antibiotics to identify specific 
taxa correlated with resistance to CDI. The organism providing the greatest 
protection- C. scindens, conferred resistance by synthesising secondary bile acids 
through the action of its 7α-dehydroxylase enzyme (for more details see Section 
1.5.3). The study showed that upon administration to mice, C. scindens increases 
resistance to CDI in a secondary bile salt dependent manner. This suggests that the 
synthesis of secondary bile acids may play an integral role in microbiota-conferred 
CDI resistance. This modulation of secondary bile acid levels could be 
accomplished by oral administration of bacteria with 7α-dehydroxylase activity or 
by direct administration of secondary bile acids, with the latter having been shown 
to be successful in a single case of ursodeoxycholate treatment of CDI linked 
recurrent ileal pouchitis (Weingarden et al., 2016). 
 
1.4.2.3 Developing a vaccine 
Vaccination holds great promise at severely diminishing the risk of CDI within high 
risk populations. However, as of yet a vaccine does not exist and most research 
effort have targeted toxins A and B and aim to elicit a long term, adaptive immune 
response (de Bruyn et al., 2016; Chai and Lee, 2018). Pfizer is currently in phase 3 
trials of their vaccines, but their data has not been published (NIH, 2017). Sanofi 
Pasteur developed a vaccine, “Cdiffense”, a formalin-inactivated TcdA and TcdB 
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vaccine shown to elicit a dose dependent IgG response (Anosova et al., 2013). A 
recent Phase 3 clinical trial of Cdiffense was prematurely terminated due to a low 
probability of attaining its primary outcome (McKee, 2017). A Phase 2 trial by 
Valneva, termed VLA84, showed promising results, but they are yet to continue 
with their study (Valneva, 2015). A potential problem inherent to toxoid vaccines 
is their inability to prevent colonisation (Siddiqui et al., 2012).  
 
To prevent colonisation, it is considered essential to target the surface proteins of 
either the vegetative cell or the spore. A study by Pizarro-Guajardo et al. (2018) 
analysed the spore proteome of C. difficile strain R20291 and provided a list of five 
immunoreactive proteins; CotE, CotA, CotCB, CdeC and a cytosolic 
methyltransferase. There are yet to be any studies determining the efficacy of these 
spore coat protein targets in vivo. Antibodies to the flagellar proteins FliC and FliD, 
cell wall adhesin Cwp66, cell wall cysteine protease Cwp84 have all been found in 
patient sera indicating their potential as vaccine candidates (Pechine et al., 2005). 
Cwp84 antigen showed promise, with vaccinated hamsters showing a 33% increase 
in survival (Péchiné et al., 2011). Immunisation with the surface layer protein SlpA 
led to only a low antibody response in hamsters (Ní Eidhin et al., 2008). The surface 
polysaccharides of C. difficile are also being considered as a potential vaccine 
candidate. PSII and LTA are found on the surface of all C. difficile strains as of 
now, and antibodies against both have been found in patient sera (Ganeshapillai et 
al., 2008; Oberli et al., 2011; Reid et al., 2012; Martin et al., 2013). Although 
polysaccharides are not able to elicit a T-cell response on their own, they can be 
conjugated to a carrier protein in order to do so. Both LTA and PSII Have been 
successfully conjugated to carrier proteins (Oberli et al., 2011; Cox et al., 2013). 
Work is underway to determine if these vaccine candidates can prevent colonisation 
or CDI. It is likely that an ideal vaccine would target both the surface antigens of 
C. difficile and the toxins, for maximal benefit. 
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1.4.3 Treatment 
1.4.3.1 Antibiotics 
The first line of treatment for CDI is antibiotic therapy. For primary and recurrent 
CDI, the Infectious diseases Society of America (IDSA) now recommends 
vancomycin or fidaxomicin over metronidazole (McDonald et al., 2018). 
Vancomycin is a glycopeptide antibiotic that exerts its bacteriostatic effects against 
C. difficile by inhibiting cell wall synthesis (Reynolds, 1989). Two large, 
multicentre, randomised controlled trials both found vancomycin to be superior in 
treating any severity of CDI compared to metronidazole, with even more prominent 
differences in those suffering from severe disease (Johnson et al., 2014). 
Fidaxomicin has been approved for treatment in several countries in the past few 
years. Fidaxomicin is a macrocyclic lactone antibiotic which inhibits the σ70 factor 
thereby inhibiting transcription of any gene dependent on this factor and exerting a 
bactericidal effect upon C. difficile (Tupin et al., 2010). A metanalysis comparing 
fidaxomicin to vancomycin showed both to have equal clinical cure rates, although 
fidaxomicin may possibly be more effective at reducing persistent diarrhoea and 
death (Crook et al., 2012). The relapse rates for fidaxomicin are also lower. This 
could possibly be due to its narrower spectrum of activity having less of an effect 
on the gut microbiota and/or its ability to prevent C. difficile sporulation  
(Babakhani et al., 2012; Crawford et al., 2012). A possible barrier to widespread 
fidaxomicin use is the high price; treatment with fidaxomicin costs twice as much 
as treatment with vancomycin (Simon, 2014).  
 
1.4.3.2 Faecal microbiota transplantation (FMT) 
Faecal microbiota transplantation (FMT) is a type of bacteriotherapy that focuses 
on replenishment of healthy gut microbiota from screened donors to recipients with 
a dysregulated microflora to re-establish a protective gut microbiome (Shahinas et 
al., 2012). FMT has proved to be a very efficacious treatment for recurrent CDI, 
with success rates of ~90% (Bakken et al., 2011). FMT involves the transplant of 
screened, processed faecal matter from a healthy donor to a diseased patient. A 
suggested mechanism for the beneficial effects of FMT in CDI patients rests on the 
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theory of bacterial interference; the use of probiotic bacteria to compete for the 
niche required by pathogenic bacteria to outgrow and cause disease (Khoruts and 
Sadowsky, 2016). Supporting evidence for this theory was presented in a 
publication by Hryckowian et al. (2018), where it was found that a diet high in 
microbiota-accessible carbohydrates (MACs) led to outgrowth of MAC-utilising 
taxa and an associated decrease in C. difficile fitness. Interestingly, the sterile faecal 
filtrate from a healthy donor was shown to have a similarly high efficacy compared 
to conventional FMT for CDI treatment suggesting that soluble components within 
the filtrate (such as antimicrobials, enzymes, bacteriophages) may be an integral 
part of FMT’s efficacy, rather than the presence of the vegetative cells themselves 
(Ott et al., 2017). This could provide a valuable alternative for 
immunocompromised patients, where the transfer of live bacteria may pose a risk.  
Valerate, a short-chain fatty acid with inhibitory effects on C. difficile is depleted 
during antibiotic therapy and while antibiotic cessation does not increase its level, 
FMT does elevate levels, implicating this metabolite in FMT efficacy (McDonald 
et al., 2018). Recent studies have also demonstrated rapid, but sustained changes in 
the gut bacteriophage profiles following FMT; providing another possible 
mechanism, but more work in this area is needed (Draper et al., 2018; Zuo et al., 
2018).  
 
The possibility of identifying the microorganisms within FMT which are 
responsible for the efficacy, culturing them and delivering them to patients directly 
without the need for stool donors is an enticing prospect. A study by Lawley et al., 
(2012) attempted this and identified a culturable cocktail of phylogenetically 
diverse bacteria from healthy mouse faecal samples that were capable of re-
establishing a healthy gut microbiota and clearing CDI in mice. There have been 
several clinical studies investigating the efficacy of encapsulated FMT, and these 
studies are summarised in a recent meta-analysis (Iqbal et al., 2018). The authors 
summarise that the efficacy of freeze-dried encapsulated FMT is comparable to that 
of conventional FMT in the treatment of recurrent CDI and is safe and cost 
effective. However, randomised-controlled trials are required to investigate 
possible adverse effects, and compare efficacy to current oral antimicrobial 
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treatments (Iqbal et al., 2018). Further studies to ascertain the best route for 
administration are needed to allow for commercialisation and wider encapsulated 
FMT use. 
 
The Infectious Disease Society of America (IDSA) now recommends treating with 
FMT after antibiotic failure for at least two recurrences of CDI (McDonald et al., 
2018). The only current barriers to the widespread and universal use of FMT 
include the need for trained personnel to administer treatment, the invasiveness of 
delivery and aesthetics. The incipient clinical introduction of encapsulated FMT 
would remove these barriers.   
 
1.5 The gut microbiome 
1.5.1 Role of the microbiota  
The human gastrointestinal tract is a multifaceted system starting from the oral 
cavity, and extending through the stomach and the intestines, and terminating at the 
anus. The GI tract and the organisms which inhabit it perform a wide array of 
functions, as is shown in Figure 1.5. The GI tract lumen surface is covered by a 
thick mucus layer that acts as a protective barrier against the harsh internal 
environment. Due to the abundance of mucus, and its monomer mucin within the 
GI tract, the microbiota needs to interact with this mucosal barrier in a variety of 
ways so that its normal processes can be fulfilled (Turroni et al., 2012). The 
composition, diversity and density of the microbiota varies along the GI tract, with 
major populations predominating in areas based on their performed functions and 
by their suitability for the local environment. Shortly after birth, bacteria from the 
mother and the nearby environment rapidly colonise the gut of the infant (Sommer 
and Bäckhed, 2013). The colonisation and establishment of the gut microbiota 
within the infant is vital for the health of the adult, and the normal function of the 
gastrointestinal tract (Turroni et al., 2012). It takes approximately one to two years 
from birth for the gut microbiota to establish itself to resemble that of an adult 
(Sommer and Bäckhed, 2013). Contrary to previous thought, the gut flora does not 
merely maintain a commensal relationship with the host, but a mutualistic, 
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symbiotic one (Sears, 2005). Although humans (Steinhoff, 2005) and mice are 
capable of surviving without a microbiota, so named ‘gnotobiotic mice’ 
demonstrate an underdeveloped immune system, thinner intestinal walls, smaller 
hearts, liver and lungs resulting in diminished cardiac output and blood flow to 
organs and negative impacts on reproductive performance (Nicklas et al., 2015).  
 
Fungi, archaea, viruses and bacteria can all be found within the GI tract. The roles 
of viruses and fungi are yet to be fully elucidated, however they are implicated in 
host physiology and immunity in addition to seemingly playing a role in microbiota 
dynamics (Hillman et al., 2017). The function of bacteria within the GI tract is 
better understood; with links to vitamin production, immune system enhancement 
and pathogen defence, histological development, ion absorption, the production of 
short chain fatty acids (SCFA) and metabolites via the fermentation of non-
digestible foods (Guarner and Malagelada, 2003; Flint et al., 2007; Hillman et al., 
2017; Corfield, 2018). Several members of the gut flora can produce SCFAs 
through fermentation; SCFAs stimulate the production of innate immune cells 
thereby increasing the resistance of the host to pathogens (Levy et al., 2016). 
Research has discovered that imbalances of the gut microbiome are strongly 
associated with obesity (Ley, 2010). 
 
Initial work on the microbiota hypothesised that its key function was metabolism 
of indigestible ingested compounds, development and maintenance of the intestinal 
epithelium and directly defending against pathogens. Contemporary study, has 
however focussed more on microbiota-mediated development of the immune 
system and the gut-brain axis (Wang and Kasper, 2014). Pathogens are directly 
inhibited by the microbiota through various mechanisms including competition for 
space/nutrients and the secretion of antimicrobials. When the microbiota is 
disrupted, opportunistic enteropathogens such as C. difficile, Shigella, 
Staphylococcus aureus and Escherichia can outgrow and cause disease (Yoon et 
al., 2014). As the gut flora establishes itself, the intestinal epithelium and the 
secreted mucosal barrier develop which supports the microbiota by acting as an 
anchoring point while providing a barrier against pathogenic microorganisms 
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(Sommer and Bäckhed, 2013). The establishment of the gut microbiota also 
coincides with the development of gut-associated lymphoid tissue (GALT), which 
can detect and subsequently attack pathogens (Faderl et al., 2015). Due to this 
concomitant establishment, GALT does not consider the gut flora, or their 
metabolites as threats (Sommer and Bäckhed, 2013). Specific bacterial species have 
been shown to stimulate the immune system and elicit the production of 
inflammatory and anti-inflammatory cytokines; Bacteroides fragilis and some 
Clostridia species elicit an anti-inflammatory response while segmented 
filamentous bacteria induce Th17 cell differentiation in the small intestine (Reinoso 
Webb et al., 2016). Bacteroidetes and some Clostridia can induce regulatory T cells 
(Tregs) (Reinoso Webb et al., 2016). Tregs can suppress the immune response, 
promote repair of the epithelium and enhance tolerance to microorganisms 
(Atarashi et al., 2011; Maloy and Powrie, 2011). The gut microbiota is also able to 
regulate antibody production by promoting B cells to class switch to IgA via NF-
kB signalling (Mantis et al., 2011; Sommer and Bäckhed, 2013). IgA plays an 
important maintenance and regulating role in the gut and can diversify the gut flora 
and help in the removal of unwanted pathogenic bacteria via immune exclusion 
(Mantis et al., 2011).  
 
The gut microbiota also plays an important role in the metabolism of the host. In 
humans, the gut flora is responsible for the breakdown of indigestible 
polysaccharides, such as plant cellulose, sugars, certain fibres and starches (Clarke 
et al., 2014). It has been demonstrated that gnotobiotic mice require a caloric intake 
30% higher than conventional mice to maintain the same weight, highlighting the 
important of the gut microbiota in metabolism and digestion (Bäckhed et al., 2004; 
Clarke et al., 2014). The most common SCFAs produced by bacteria are butyric 
acid, lactic acid, acetic acid and propionic acid; all of which are a source of energy 
and nutrients for host cells (Beaugerie and Petit, 2004; Gibson, 2004). The gut 
microbiota is also able to synthesise vitamins, such as folate and biotin and aides in 
the absorption of minerals such as calcium and magnesium (O’Hara and Shanahan, 
2006). The gut flora has also been shown to be able to metabolise and remove 
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xenobiotics, including carcinogens, drugs, toxins and phytochemicals (Sousa et al., 
2008). 
 
The gut-brain axis describes the biochemical interactions between the central and 
enteric nervous systems. Recent work has begun to describe the influence the gut 
microbiota has on these interactions (Carabotti et al., 2015). This interaction is 
bidirectional through means of endocrine, neural, humoral and immune links. The 
gut microbiota is implicated in CNS interactions resulting in modulation of neuro-
endocrine systems associated with anxiety, memory and stress responses (Carabotti 
et al., 2015). These effects are often strain specific, thereby providing an avenue 
for potential therapeutic use of probiotics in treating certain neurological conditions 
(Wang et al., 2016). Probiotics may also be important in resolving the detrimental 
effect the CNS can have on the microbiota (Wang et al., 2016). For example, it has 
been shown that norepinephrine release during surgery promotes the growth of 
Pseudomonas aeruginosa which can lead to sepsis (Alverdy et al., 2000). A 2016 
study systematically reviewed 38 studies to examine the effects of probiotics on 
CNS function in human and animals (Wang et al., 2016). Various species within 
the genera Bifidobacterium and Lactobacillus showed potential in the treatment of 
various psychiatric disorders, including OCD, autism spectrum disorder, depression 
and anxiety.  
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Figure 1.5. Functions of the intestinal microbiota. The gut flora exerts a multitude of protective, 
structural and metabolic functions upon the mucosal intestinal epithelium. (Modified from O’Hara 
and Shanahan, 2006). 
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The largest proportion of gut microbes are located in the large intestine. The small 
intestine only contains a very small number of microorganisms, predominantly 
Gram-positive cocci and rod-shaped bacteria (Nelson and Mata, 1970). As one 
moves down the small intestine into the distal small intestine, the more favourable 
alkaline conditions allow for support of more Gram-positive bacteria, including 
Enterobacteriaceae (Donaldson et al., 2016). Microbes present in the small 
intestine hold a wide variety of functions, such as the expression of regulatory 
signals promoting development of the gut and vitamin metabolism (Sommer and 
Bäckhed, 2013). The large intestine on the other hand, is considered to be the largest 
reservoir for bacteria in humans (Mcbain and Macfarlane, 1998). Obligate 
anaerobes such as Bifidobacterium and Bacteroides comprise 99% of the flora 
within the large intestine, and 60% of faecal dry mass (Guarner and Malagelada, 
2003). This makes faecal matter ideal for identifying the gut flora through nucleic 
acid extraction and 16S rRNA gene sequencing. 16S rRNA sequencing has revealed 
there to be up to 1000 different bacterial species living within the gut, with 
approximately 30 to 40 species comprising 99% of the population (Beaugerie and 
Petit, 2004; Sears, 2005). 
 
1.5.2 Effect of antibiotics 
The administration of broad-spectrum antibiotics can have dramatic effects upon 
the host, by way of gut microbiota alteration, both in quantity and diversity (Carman 
et al., 2004). As described in detail in Section 1.2.3, antibiotic therapy perturbation 
of the gut flora can lead to the outgrowth of antibiotic-resistant bacteria within the 
gut potentially resulting in CDI. AAD is a more common occurrence than CDI; the 
incidence rate of AAD is between 5% and 25% (Beaugerie and Petit, 2004). AAD 
can take place when the diversity and number of gut flora species is reduced, 
diminishing the host’s ability to metabolise bile acids and ferment carbohydrates 
(Theriot and Young, 2013). The increased amount of carbohydrates can absorb 
water resulting in runny stool. Other factors contributing to AAD development 
include the toxic effects of antibiotics and the overgrowth of pathogenic organisms, 
such as C. difficile.  
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An antibiotic initiated reduction in native bacterial species can lead to the 
emergence and outgrowth of pathogens such as C. difficile and Salmonella 
kedougou, which can result in AAD (Guarner and Malagelada, 2003; Beaugerie and 
Petit, 2004). The successful treatment of these infections with FMT indicate the 
maleficent effects antibiotics can have upon the microbiota, and the importance of 
restoring these bacterial species to the gut, principally Bacteroides and Firmicutes 
(Brandt et al., 2011). In addition to altering the microbiota population of the GI 
tract, antibiotics can also affect caloric intake via carbohydrates, intra-community 
metabolic interactions and homeostasis for immune, hormonal and metabolic 
systems within the host (Carman et al., 2004). Studies have demonstrated that 
combining probiotics (including Lactobacillus and Saccharomyces species) with 
antibiotic therapy may help to prevent the onset of AAD and CDI (Brandt et al., 
2011). 
  
1.5.3 Control of CDI 
The principle mechanism by which the microbiota provide host resistance to CDI 
is through bile acid modulation. Studies have shown that bile acids not only play a 
direct role in CDI, but perhaps also an indirect one by preventing the re-
establishment of the normal microflora and subsequent CDI colonisation resistance 
(Kurdi et al., 2006). Both cholate and taurocholate have been implicated as growth 
inhibitors of several groups of bacteria and increased levels during antibiotic 
treatment provides a competitive advantage to C. difficile (Tannock et al., 1997; 
Kurdi et al., 2006). The link between microbiota health and bile acid composition 
is most acutely observed when analysis is performed on recipients of faecal 
microbiota transplantation (FMT). Prior to FMT, primary bile acid levels are 
elevated, and secondary bile acids are almost undetectable in faecal samples 
(Weingarden et al., 2014). In, contrast post-FMT samples contained mainly 
secondary bile acids, as is the case with samples from non-CDI donors (Weingarden 
et al., 2014). 
 
Secondary bile acids are formed by two bacterial enzymatic reactions; 
deconjugation within the small intestine and dihydroxylation/epimerisation within 
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the large intestine (Winston and Theriot, 2016). Conjugated bile acids are 
deconjugated by extracellular bile salt hydrolases (BSH), which are produced by a 
large variety of bacteria (Ridlon et al., 2006; Jones et al., 2008; Winston and 
Theriot, 2016). There have been 3 major phyla implicated in BSH production 
according to metagenomic screening: Firmicutes (30%), Bacteroidetes (14.4%) and 
Actinobacteria (8.9%) (Jones et al., 2008). BSHs have been shown to protect 
against colonisation by C. difficile by increasing competition within the lower GI 
tract through detoxifying bile acids deleterious to microflora (Ridlon et al., 2006). 
The second enzymatic reaction results in oxidisation and epimerisation of specific 
hydroxyl groups by three bacterial hydroxysteroid dehydrogenases (HSHD): 3-α, 
7-α, and 12-α (Ridlon et al., 2006; Winston and Theriot, 2016). 
 
HSHDs are able to create 27 unique metabolites from the dehydrogenation of 
cholate alone (Ridlon et al., 2006). 7α-dehydroxylation is performed by only a 
small proportion of the microbiota. All bacteria with 7α-dehydroxylation activity 
are anaerobic and the majority are Clostridium species within the Firmicutes 
phylum. The removal of the 7α-dihydroxyl group of primary bile acids is complex 
and requires several intracellular enzymatic steps but ultimately result in the 
formation of secondary bile acids; lithocholate from chenodeoxycholate and 
deoxycholate from cholate (Winston and Theriot, 2016). From here the microbiota 
can further modify deoxycholate and lithocholate into products such as 
taurodeoxycholate and ursodeoxycholate. The various bile salts, their location in 
the gastrointestinal tract and their effect on C. difficile is shown in Figure 1.6. 
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A prediction made by Giel et al. (2010) based on deoxycholate inhibition of C. 
difficile growth and the observed decrease in 7α-dehydroxylation activity following 
antibiotic treatment was recently supported in a pioneering study by Buffie et al. 
(2015). Buffie et al. (2015) was able to correlate resistance to CDI with the presence 
of C. scindens and increased levels of secondary bile acids (principally 
deoxycholate) within allogeneic stem cell transplant patients infected/not infected 
by CDI using microbiome and metabolome systems analysis. Partial protection 
against CDI in mice was demonstrated by the adoptive transfer of C. scindens. This 
protection correlated with deoxycholate levels within the mice.  
Figure 1.6. Bile acid metabolism in relation to C. difficile life cycle. Bile acids are synthesised 
from cholesterol in the liver and are released as conjugated bile acids. The gut flora in the ileum 
deconjugate bile acids to primary bile acids-cholate and chenodeoxycholate using bile salt 
hydrolases. Subsets of bacteria secrete the enzyme 7α-dehydroxylase which digests primary bile 
acids resulting in secondary bile acids such as deoxycholate and lithocholate. Secondary bile acids 
are toxic to C. difficile vegetative cells, while cholate derivatives induce germination in C. difficile 
spores. Glycine acts as a cogerminant. (Modified from Shen, 2015). 
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CHAPTER 2 
Materials and Methods 
 
2.1 General methods 
General methods for working with B. subtilis are described elsewhere (Smith, 
1991). The same methods were used for working with B. licheniformis and B. 
amyloliquefaciens. Work with E. coli including cloning are as described by 
Sambrook and Russell (Wood, 1983).  
 
2.2 Bacterial strains 
630 is a toxigenic (tcdA+ tcdB+) strain of C. difficile isolated from a patient with 
pseudomembranous colitis during an outbreak of CDI  (Wüst et al., 1982) and 
630∆erm is an erythromycin sensitive derivative of 630 (Hussain et al., 2005) used 
for the creation of ClosTron mutants. Both strains were obtained from Neil 
Fairweather (Imperial College, UK). Two previously described cotE ClosTron 
mutants, isogenic to 630Δerm, were used: cotE- (cotE::CT220s) and cotEC- 
(cotE::CT1203s) (Permpoonpattana et al., 2013). A sigK ClosTron mutant JP051 
(sigK::CT266s) carrying an insertion after codon 87 of the coding open reading 
frame (ORF) was previously constructed in this laboratory. The cotE mutants were 
complemented with wild type copies of the respective genes using pRPF185 as 
described previously (Permpoonpattana et al., 2013). Other strains of C. difficile 
including the hypervirulent strain R20291 and the high toxin producing strain VPI 
10463 were laboratory stocks. PY79 is a prototrophic (Spo+) laboratory strain and 
a lab stock, while other B. subtilis, B. amyloliquefaciens and B. licheniformis strains 
were isolated from soil or from humans. For strains and plasmids used in this study 
please refer to Table 2.1. 
 
Unless stated otherwise, C. difficile was routinely cultured in BHIS broth (for 1 
litre: 37 g BHI (Oxoid), 5 g Yeast Extract (BD Bacto), 1 g L-Cysteine (Sigma)) or 
on BHISS agar (as before with 1 g sodium taurocholate (Sigma) and 15 g agar 
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(Sigma)). TY broth comprised 30 g tryptose (BD Bacto), 20 g yeast (BD Bacto) 
and 1 g sodium thioglycolate (Sigma) per litre. C. difficile strains were grown at 
37°C in an anaerobic cabinet (Don Whitley), maintained with an anoxic atmosphere 
(10% CO2, 10% H2, 80% N2). Unless stated otherwise, Bacillus was routinely 
cultured in BHIB broth (for 1 litre: 37 g BHI (Oxoid), 5 g Yeast Extract (BD Bacto)) 
or on DSM agar (for 1 litre: nutrient broth 8 g (Bacto), KCl 1 g (Sigma), 0.25 g 
MgSO4.7H2O (Sigma), 15 g agar (Sigma) and following autoclaving 1 ml of each 
of the following filter sterilised solutions were added: 1 M Ca(NO3)2, 10 mM MnCl2 
and 1 mM FeSO4. 
 
To store a strain (C. difficile or Bacillus), a single colony was used to inoculate 10 
ml of the appropriate media (that favoured sporulation) and incubated overnight at 
37oC. 1 ml of the culture was added to 1 ml of autoclaved 50% glycerol (left in the 
anaerobic cabinet overnight prior to use for C. difficile strains). The sample was 
vortexed before storage at -80°C. 
 
2.3 Sporulation of C. difficile   
Spores of C. difficile were prepared by growth on SMC agar plates using an 
anaerobic incubator as described previously (Permpoonpattana et al., 2011). A 
single colony from a BHISS streaked plate was used to inoculate 10 ml of TGY 
medium (for 1 litre: 30 g tryptic soy broth (Sigma), 20 g glucose (Sigma), 10 g yeast 
extract, 1 g L-cysteine) and incubated overnight at 37oC. 1 ml of TGY culture was 
then sub-cultured into SMC broth (for 1 litre: 90 g peptone (Sigma), 5 g proteose 
peptone (Sigma), 1 g (NH4)2SO4 and 1.5 g Trizma base (Sigma)) containing 0.1% 
L-cysteine (modified from Wilson, Kennedy and Fekety, (1982)) incubated 
overnight and then plated onto SMC agar. Plates were incubated anaerobically for 
7 days at 37oC, sporulation efficiency was confirmed using phase-contrast 
microscopy and spore crops harvested and maintained at 4oC until purification. 
Spores of the complemented strains were prepared in the same way, but all media, 
including agar plates was supplemented with 15 μg/ml thiamphenicol and 500 
ng/ml anhydrous tetracycline (ATC). 
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Table 2.1. Strains used in this study  
Strain Identity Plasmid Source 
E. coli BL21 (DE3) E. coli pET28b- CotEN 
(Met1-K280) 
Permpoonpattana 
et al., 2013 
E. coli BL21 (DE3) E. coli pET28b- CotEC 
(Pro361-Phe712) 
Permpoonpattana 
et al., 2013 
630 C. difficile  Neil Fairweather 
630Δerm C. difficile  Neil Fairweather 
630Δerm cotE::CT220s 
(cotE-) 
C. difficile pMTL007C-E2 Permpoonpattana 
et al., 2013 
630Δerm cotE::CT1203s 
(cotEC-) 
C. difficile pMTL007C-E2 Permpoonpattana 
et al., 2013 
630Δerm sigK::CT266s C. difficile pRPF185 Neil Fairweather 
R20291 C. difficile  Neil Fairweather 
VPI 10463 C. difficile  Neil Fairweather 
SH1 C. difficile  Neil Fairweather 
SH101 C. difficile  Neil Fairweather 
SH102 C. difficile  Neil Fairweather 
R20291 C. difficile  Neil Fairweather 
CD196 C. difficile  Neil Fairweather 
SH104 C. difficile  Neil Fairweather 
CD10 C. difficile  Neil Fairweather 
SH242 C. difficile  Neil Fairweather 
SH200 C. difficile  Neil Fairweather 
SH203 C. difficile  Neil Fairweather 
SH218 C. difficile  Neil Fairweather 
SH210 C. difficile  Neil Fairweather 
SH213 C. difficile  Neil Fairweather 
SH215 C. difficile  Neil Fairweather 
SH220 C. difficile  Neil Fairweather 
SH222 C. difficile  Neil Fairweather 
SH231 C. difficile  Neil Fairweather 
SH236 C. difficile  Neil Fairweather 
SH239 C. difficile  Neil Fairweather 
SH103 C. difficile  Neil Fairweather 
SH3 C. difficile  Neil Fairweather 
PY79 B. subtilis  Bacillus Genetic 
Stock Centre 
10A1 B. amyloliquefaciens  Bacillus Genetic 
Stock Centre 
SG57 B. amyloliquefaciens  Hong et al., 2009 
SG83 B. subtilis  Hong et al., 2009 
SG137 B. amyloliquefaciens  Hong et al., 2009 
SG140 B. subtilis  Hong et al., 2009 
SG185 B. amyloliquefaciens  Hong et al., 2009 
SG277 B. amyloliquefaciens  Hong et al., 2009 
SG297 B. amyloliquefaciens  Hong et al., 2009 
SG378 B. amyloliquefaciens  Hong et al., 2009 
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2.4 Spore purification  
The harvested spore pellet was further purified using centrifugation through a 20% 
(v/v) to 50% (v/v) Histodenz gradient (Sigma) as described elsewhere 
(Phetcharaburanin et al., 2014). Following centrifugation through the Histodenz 
gradient, spores were washed five-times in ice cold dH2O. Spore CFU was 
determined by heat treatment (60°C, 20 min.) and plating on BHISS agar plates.  
 
2.5 Spore coat extractions (Chapter 3) 
Spores (1 x 108) and vegetative cells were heated at 80oC for 20 min. and then 
pelleted by centrifugation and suspended in 40 µl of Bolt extraction buffer 
(Thermo),  10 µl LDS Sample Buffer, 4 µl Bolt Reducing Agent in 26 µl of dH2O 
containing 0.5 mM PMSF and 0.052 mg of benzamide and incubated for 10 min. at 
95oC. The suspensions were then centrifuged (10,000 g, 4oC, 5 min.) and 
supernatants kept on ice until SDS-PAGE analysis. 
 
2.6 Antibody production (Chapter 3) 
Plasmids (pET28b-derived) containing segments of CotE (tagged with poly-His at 
the C-termini) were used to express N (Met1-K280) and C (Pro361-Phe712) 
terminal segments of CotE in E. coli (Permpoonpattana et al., 2013). High levels of 
expression were obtained upon IPTG induction (300 µm) and purification of 
proteins was accomplished by passage of the cell lysate through a HiTrap chelating 
HP column (GE Healthcare) on a Pharmacia AKTA liquid chromatography system. 
Polyclonal antibodies were raised in mice immunised via the intra-peritoneal route 
with 2 μg of purified recombinant proteins on days 1, 14 and 28.  
 
2.7 Western blotting of spore coat proteins (Chapter 3) 
Western blotting was carried out as described previously (Permpoonpattana et al., 
2013). Spore coat proteins were fractionated by size on a 12% SDS-PAGE gels 
using approximately 10 mg of protein per lane. The gels were transferred onto an 
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Immobilon-P PVDF Membrane (Merck) using a Trans-Blot® Turbo™ Transfer 
System (Bio-Rad). Membranes were dehydrated in 100% MeOH and allowed to 
dry for 1 hour at RT. The blot was probed with polyclonal antibodies (anti-CotEC 
or anti-CotEN at a 1/4000 dilution). Membrane were washed 3x with PBS + Tween-
20 (0.05%) (v/v) (PBST) and detected with a goat anti-mouse HRP secondary 
antibody (1/2000 dilution) and developed using Amersham ECL Western blotting 
substrate (GE healthcare) on Amersham hyper-film ECL (GE healthcare). 
 
2.8 Southern blotting (Chapter 3) 
Genomic DNA was isolated from cultures of 630Δerm, CotE- and CotEC- 
vegetative cells grown in BHIS using a phenol-chloroform extraction method, as 
described previously (Wren and Tabaqchali, 1987). The probe was prepared by 
amplifying a 500 bp sequence found within the C. difficile ermR gene of the 
ClosTron plasmid, pMTL007C, used for gene constructions. Primers used were 
ERMF and ERMR (Table 2.1). The amplification product was purified using the 
QIAquick PCR purification kit (Qiagen) and labelled with Dig-High Prime 
following the manufacturer’s instructions. Genomic DNA was digested with 
HindIII and run on an agarose gel (0.8% w/v). DNA was transferred onto a Hybond-
N+ membrane (Amersham) using 0.4 M NaOH as transfer buffer. The probe was 
denatured (100oC for 10 min.) and added to Dig High prime hybridisation buffer 
and the membrane was hybridised overnight at 42oC. The membrane was washed, 
blocked, detected and developed following the manufacturer’s instructions; DIG 
High Prime DNA labeling and Detection Kit I (Roche). 
 
2.9 Germination assays (Chapter 3) 
Spore germination rates were determined using preparations of Histodenz-purified 
spores of wild type and CotE mutants. Spores (106) were resuspended in BHIS 
medium containing 0.1% (w/v) sodium taurocholate, incubated at 37oC 
anaerobically and at appropriate time points (0-60 min.) sampled for the number of 
heat-resistant (60oC, 20 min.) or ethanol-resistant (EtOH) (50% v/v for 30 min.) 
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CFU. The percentage of initial counts at each time point were calculated and 
plotted. 
Table 2.2. Primers used in this study  
Primer Direction Sequence (5’ to 3’) 
ERMF Forward CGAAATTGGAACAGGTAAAGG 
ERMR Reverse GCTTCCAATATTTATCTGGAACATC 
HPRTF Forward GTAATGATCAGTCAACGGGGGAC 
HPRTR Reverse CCAGCAAGCTTGCAACCTTAACCA 
IL-6F Forward ACCGCTATGAAGTTCCTCTCTG 
IL-6R Reverse AATTAAGCCTCCGACTTGTGAA 
MIP-2αF Forward GCTGTCAATGCCTGAAGACC 
MIP-2αR Reverse CCTTGAGAGTGGCTATGACTTC 
TNF-αF Forward CACCACGCTCTTCTGTCTACTG 
TNF-αR Reverse TGAGAAGATGATCTGAGTGTGA 
 
 
2.10 Spore adhesion to hydrocarbon (SATH) assay (Chapter 3) 
The surface hydrophobicity of spores was determined using the spore adhesion to 
hydrocarbon (SATH) assay using n-hexadecane as the hydrocarbon (Seale et al., 
2008). Histodenz-purified spores were washed in 1 M NaCl in dH2O by 
centrifugation at 16,000 g for 10 min. and resuspended in 0.1 M NaCl at a density 
of 1 x 108 spores/ml. Spore suspensions (2 ml) were added to 1 ml n-hexadecane 
(Sigma) and vortexed for 1 min., followed by 10 min. incubation at 37°C, and 
vortexed again for 30 seconds. The absorbance of the aqueous phase was measured 
at OD600. The mean of two measurements was determined. The percent 
hydrophobicity (%H) was determined from the absorbance of the original spore 
suspension (Ai) and the absorbance of the aqueous phase after incubation with 
hexadecane (Af) according to the following equation: %H = [(Ai – Af) / Ai] x 100. 
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2.11 Cell culture (Chapter 3) 
HT29 cells (ATCC, Manassas, USA), a colonic epithelial cell line was seeded at 2 
x 106 cells in a 75 cm2  flask and grown in McCoy's 5A medium (Sigma) 
supplemented with 1% L-glutamine (v/v) (Sigma), 1% (v/v) penicillin and 
streptomycin (Sigma), and 10% foetal bovine serum (FBS) (v/v) (Sigma). HT29-
MTX cells (PHE, UK), a mucus secreting colonic epithelial cell line, was seeded at 
2 x 106 cells in a 75 cm2  flask and grown in Dulbecco’s modified Eagle medium 
(DMEM) (Life technologies, UK) supplemented with 1% (v/v) L-glutamine, 1% 
(v/v) penicillin and streptomycin, 1% (v/v) non-essential amino acids (all Sigma) 
and 10% (v/v) FBS. In both cases cells were incubated at 37C in an atmosphere of 
5% CO2. Once cells reached ~70-80% confluency the cells were passaged and 
reseeded. 
 
To confirm the presence of mucus on HT29-MTX cells monolayers were washed 
with 3% acetic acid for 3 min. 1% (w/v) Alcian blue solution (Sigma) pH 2.5 was 
added to monolayers for 30 min. at RT. Monolayers were briefly rinsed with 3% 
acetic acid and then dH2O to remove excess Alcian blue solution. Nuclear fast red 
solution (Sigma) was added to monolayers for 5 min. and the excess removed by 
washing with distilled dH2O. Coverslips were mounted and sealed using clear nail 
varnish. Slides were visualised using an EVOS FL digital microscope (Life 
technologies, UK) with mucus visualised by blue staining of polysaccharide 
residues. Experiment performed in collaboration with fellow student, Saba Anwar. 
 
2.12 Cytotoxicity assays (Chapter 3) 
Assays were based on those that have been described previously (Kuehne et al., 
2010). Overnight cultures of C. difficile in TY broth were used to inoculate a 
starting culture in TY medium at a starting optical density at 600 nm of 0.05. 
Samples were taken at 6, 12, 24 and 48 hours, centrifuged (10,000 g, 10 min.) and 
supernatants filter-sterilised through 0.2 μm filters. The samples were then 
normalised proportionally according to the OD taken at collection using PBS. 
Samples were serially diluted in PBS and 10 μl was added to 90 μl of DMEM (2% 
69 
 
v/v FCS) media above confluent HT29 (for TcdA) or VERO (for TcdB) cells giving 
a 1:10 dilution. Cells were incubated for 24 hours at 37oC, 5% CO2 before being 
scored for toxin endpoints using an Olympus CKX41 light microscope. End point 
titers were taken at the point where cell rounding was less than 50%. 
 
2.13 Induction of cytokines (Chapter 3) 
J774A.1 macrophages (1 x 106) were seeded into a 24-well plate in DMEM 
complete medium and incubated overnight at 37oC (at 5% CO2). To investigate the 
capability of the recombinant proteins to elicit an inflammatory response, the 
seeded cells were washed twice with DMEM and then rCotEN, rCotEC or LPS 
were diluted in DMEM to final concentrations ranging from 1-10,000 ng/ml and 
added to wells. The plate was incubated for 5 hours prior to harvesting cells. For 
analysis using spores, seeded cells were washed with DMEM twice and replaced 
with spores (630Δerm, CotE- or CotEC-) re-suspended in DMEM (MOI of 10:1) 
with one well retained as a ‘media only’ control. The plate was spun at 1,500 g for 
5 min. to sediment material and was then incubated at 37oC at 5% CO2 for 3 hours. 
All media was removed after incubation and 500 μl of TRI reagent (Sigma) was 
added. Total RNA was isolated according to the manufacturer’s protocol for TRI 
reagent. RNA was then frozen at -80oC prior to use. Possible DNA contamination 
was removed with the use of DNase 1 (Sigma) and RNA quantified (NanoDrop 
2000, Thermofisher) prior to cDNA synthesis. The ‘High Capacity’ cDNA reverse 
transcription kit (Applied Biosystems) was used to prepare cDNA. PCR 
amplification of specific genes was performed using a Rotor Gene 6000 and SYBR 
Green JumpStart Taq ReadyMix (Sigma). Primers for IL-6, MIP-2α and TNF-α 
were analysed with the housekeeping gene HPRT (hypoxanthine guanine 
phosphoribosyltransferase) being used as an endogenous control. Amplification of 
these genes was quantified using the plasmid pCCy17. pCCy17 is a mouse multi-
gene quantification plasmid containing two housekeeping genes (β-actin & HPRT) 
and provided by Dr Ian Teo, Imperial College, London. Gene expression was 
analysed by comparing the mRNA copy numbers of a specific cytokine gene versus 
that of HPRT. Primer sets used are described in Table 2.1.  
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2.14 Spore adhesion assays (Chapter 3) 
The method was performed as described previously (Hong, Hitri, et al., 2017). 
HT29-MTX and HT29 cells were seeded at 4 x 104 cells/well in 24-well plates for 
14 days at 37°C with 7.5% carbon dioxide with regular changes of culture media 
(DMEM for HT29-MTX cells or McCoy’s 5A media for HT29 cells) at 37C in an 
atmosphere of 5% CO2. Mucus production was checked using Alcian blue staining. 
On the day of experimentation, cell monolayers were washed once with Dulbecco’s 
Phosphate-Buffered Saline (DPBS) (Life technologies, UK) and monolayers were 
incubated with 500 µl/well of culture medium (without supplements) (DMEM for 
HT29-MTX cells or McCoy’s 5A media for HT29 cells) containing C. difficile 
spores at a multiplicity of infection (MOI) of 100 for 2 hours at 37ºC, 5% CO2. 
Non-adherent spores were removed by washing with PBS 5-times and the cells 
were lysed with Triton X-100 (0.1% w/v) in PBS for 10 min. For assessing the total 
count of adherent C. difficile, samples were serially diluted and plated on BHISS 
plates. For measurement of adherent C. difficile spores, samples were heat treated 
at 60oC for 20 min. Plates were incubated anaerobically for 48 hours and % of 
adhesion calculated using the following formula: % of adhesion = (CFU count / 
initial number of spores added) x 100. For antibody-blocking adhesion 
experiments; the same procedure as described above was used, but spores were pre-
incubated with anti-CotEC antibody (1/10) for 30 min. at 37°C before being added 
to the wells. Data were presented as the percentage proportion of binding 
demonstrated by that of spores of strain 630. Experiments were repeated three-times 
in triplicate. Error bars represent standard deviation. Statistical significance 
between groups was calculated using an unpaired t-test. 
 
2.15 Spore binding to pig mucus explants (Chapter 3) 
Intestinal tissue was removed from the terminal ileum and caecum of a four-week-
old piglet. Tissue was pre-incubated at 40oC and then segments (2 cm2) were placed 
in 6-well plates. For each sample well 1 ml of a suspension of spores (2 x 107) in 
PBS was added, while controls received PBS only. Plates were centrifuged (1,300 
g, 2 min.) and 1 ml of PBS was added to the samples (ileum, caecum). Plates were 
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incubated anaerobically for 30 min., 1 hour or 3 hours at 37oC. Plates were then 
washed twice with 1 ml PBS after which the mucus layer was removed and stored 
at -20oC till use. Adherent viable counts were determined by serial dilution and 
plating on BHISS plates. 
 
2.16 Spore binding to ligands (Chapter 3) 
Ligands, conjugated to human serum albumin (HSA), were synthesised by Dextra 
(Reading, UK) and were dissolved in PBS (pH 7.4) and used to coat 96-well 
microplates at a concentration of 10 μg/ml (overnight at 4oC). For mucin, porcine 
stomach type III (Sigma), a solution was made fresh in PBS (pH 7.4) and used to 
coat plates at 1 μg/ml (overnight at 4oC). Plates were washed three-times with PBST 
+ Tween-20 (0.05%) (v/v) (PBST) at RT and then blocked using 2% (w/v) BSA in 
PBS (1 hour, 30oC) followed by three further washes with PBST. Recombinant 
proteins (rCotEN or rCotEC) were diluted in 1% (w/v) BSA to a concentration of 
500 nM and then diluted 2-fold on the coated plates. Plates were incubated for 2.5 
hours at 30oC and then washed 3-times with PBST. For detection, primary mouse 
antibodies to rCotEN and rCotEC were used at a 1/1000 dilution with a 1-hour 
incubation at 30oC. Plates were then washed three-times and a secondary goat, anti-
mouse IgG (DAKO) was used for detection of bound primary antibody (1 hour at 
RT). Plates were developed with tetramethyl benzidine (TMB) (Sigma) to develop 
colour and the reaction was stopped with 2 M sulphuric acid and absorbance read 
at OD450.  
 
2.17 Mucin degradation using amido black staining (Chapter 3) 
Three millilitres of sterile molten 0.5% (w/v) agarose containing 0.5% (w/v) of 
mucin (porcine type III, Sigma M1778) was overlaid onto sterile microscope slides 
(76 × 26 mm) rapidly. The sterile slide was placed into a petri dish and the agarose 
left to solidify, after which 3-mm-diameter holes were punched out of the medium. 
Ten microliters of spores (1 × 1010/mL) was added to the wells. The petri dish was 
closed and sealed with parafilm and incubated for 48 hours at 37°C. Before staining 
with amido black solution for 30 min. (Sigma), the agarose was compressed to a 
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thin layer using a 500 g weight (30 min. with Whatman No. 3 between agarose and 
weight). The slide was then de-stained several times with 7% (v/v) acetic acid. 
Degradation exhibited as zones of clear agarose on a black agarose (no-
degradation) background. 
 
2.18 Mucin degradation using amido black staining using RP-
HPLC (Chapter 3) 
A freshly made solution of mucin was labelled fluorescently with Rhodamine B 
isothiocyanate (RBITC, mixture of isomers, Sigma-Aldrich) and purified by 
gravity-flow chromatography using 10DG Desalting Columns filled with Bio-Gel® 
P-6DG Gel (Bio-Rad) and equilibrated in PBS pH 6.4 buffer prior to the 
experiment. Equal aliquots of mucin spiked with the fluorescently labelled RBITC-
mucin in PBS (pH 6.4) were added to purified wild type and mutant cotEN- spores 
of C. difficile. Suspensions were incubated for 36 hours at 37oC under anaerobic 
conditions with continuous gentle agitation. Mixtures were pelleted (10,000 g, 10 
min.). SDS was then added to all samples (final concentration 0.2% w/v) to stop 
any further interactions and to ensure stability and solubility. Before HPLC analysis 
samples were again pelleted. A TSKgel® Size Exclusion HPLC Column (PWXL-
Type, L. x I.D. 300 mm x 7.8 mm) was used to simultaneously exchange buffer in 
mucin samples and then to conduct reverse phase separation of the absorbed and 
washed mucins by gradient elution using mobile phases with decreasing salt 
concentration and increased concentration of organic modifier. A FLEXAR 
programmable HPLC setup included a quaternary solvent delivery system, 
autosampler and a column oven (30oC). The eluted mucins were detected using an 
Altus A-10 FL fluorescence detector (excitation was at 550 nm, emission was at 
575 nm). All samples were injected in 50mM PBS pH 6.4 (0.4 ml/min.) and the 
isocratic flow was maintained for up to 30 min. to allow elution of hydrophilic 
sample constituents. Under these conditions mucins remain associated with weakly 
hydrophobic hydroxylated polymethacrylate PWXL polymer stationary phase, thus 
allowing an extended washing and equilibration cycle (column eluates were 
monitored by measuring fluorescence excitation 550 nm, emission at 575 nm). For 
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gradient elution the mobile phase was changed from 0/0/100 to 100/0/0 A/B/C in 
25 min. (eluent A: 100% Methanol (MeOH); eluent B: dH2O; eluent C: 50mM PBS, 
pH 6.4). The column was regenerated and re-equilibrated after each separation by 
washing with individual eluents A, B and C (15 min. each wash). This experiment 
was performed under the guidance and expertise of Dr. Mikhail Soloviev. 
 
2.19 Animal experiments using wild type and CotE mutants 
(Chapter 3) 
All animal procedures were performed under the Home Office project license PPL 
70/8276. For Golden Syrian hamster experiments females, aged 16-18 weeks were 
used (Harlan UK Ltd.). For challenge, animals were transferred to individually 
ventilated cages (IVCs) and dosed by intra-gastric gavage (i.g.) with clindamycin 
(clindamycin-2-phosphate, Sigma; 30 mg/kg body weight). After 16 hours they 
were dosed i.g. with spores or vegetative cells (106) of wild type or mutants. 
Animals were monitored for symptoms of disease progression and culled upon 
reaching the clinical endpoint. The symptoms of CDI were scored as severe/clinical 
endpoint (wet tail >2 cm, high lethargy), mild (wet tail < 2 cm), or healthy. Faeces 
was sampled periodically, and caeca taken from culled animals. For mice a non-
fatal colonisation model was used referred to as the ‘Holloway model’ (Colenutt 
and Cutting, 2014). C57 BL/6 mice (6-8 weeks old, female) animals were dosed 
i.g. with clindamycin (30 mg/kg) and transferred to IVCs. One day later animals 
were given a single dose (i.g.) of spores or vegetative cells (106) of wild type or 
mutants and faecal samples were sampled periodically afterwards. ID50s were 
determined using the non-fatal murine model as described previously 
(Phetcharaburanin et al., 2014). 
 
2.20 In vivo toxin production (Chapter 3) 
Clindamycin-treated mice (n= 6/gp) were dosed (i.g.) with 103 spores of wild type 
C. difficile 630 or one of the two cotE mutants 24 hours post clindamycin treatment 
(30mg/kg). Faeces was collected at 24, 48- and 72-hours post-infection. The 
extraction of toxins A and B from faecal samples is described below in Section 
74 
 
2.22. Levels of toxin A and toxin B were determined by ELISA in faeces sampled 
at 24, 48- and 72-hours post-infection. The presence of functional toxins A and 
toxin B was also verified using cytotoxicity assays using HT29 (toxin A) and VERO 
(toxin B) cells. 
 
2.21 Evaluation of GlcNAc and glucosamine in a CDI murine model 
(Chapter 3) 
The non-fatal colonisation model, the ‘Holloway model’ model was used ( Figure 
3.23) with a challenge dose of 102 spores of CD630 per mouse. From day -2 until 
the end of the experiment, mice received sterile drinking water with solublised N-
Acetyl-D-glucosamine (Sigma) or glucosamine hydrochloride (Sigma) at various 
concentrations (20, 50 or 100 mg/ml) ad libitum, while naïve mice received sterile 
drinking water only. Average water consumption was measured for each group and 
quantity of GlcNAc/glucosamine ingested calculated. At 24 hours post challenge 
mice were culled and caecum samples were tested for toxins using ELISA and 
EtOH resistant CFU counts.   
 
2.22 Analysis of correlates of infection (Chapter 3 and 4) 
The infectivity of spores (expressed as the 50% infectious dose, ID50) was 
determined in mice using Histodenz-purified spores (doses of 101, 102 and 103 
CFU) of 630 or cotE mutants as described elsewhere (Phetcharaburanin et al., 
2014). Caeca were removed 24 hours post-infection and colonisation was defined 
by the presence of toxins and spore CFU counts 2-logs higher than the initial dose. 
Colonisation in mice and hamsters was assessed from both counts of C. difficile 
spores and the presence of toxins in faecal and/or caecum samples. Caecum samples 
were homogenised in PBS containing a protease inhibitor (Pierce) and incubated 
for 30 min. at 4oC. Homogenates were centrifuged (10,000 g) and the supernatant 
collected for toxin analysis by ELISA as described elsewhere (Phetcharaburanin et 
al., 2014).  The pellet was resuspended in 70% v/v ethanol and serially diluted and 
plated. Spore counts were determined by 30 min. treatment of homogenised faeces 
in ethanol (70% v/v) followed by serial dilution and plating on BHISS agar. The 
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presence of TcdA and TcdB was determined by sandwich ELISA as described 
elsewhere (Phetcharaburanin et al., 2014) and each sample was validated for 
functional toxin using toxin cytotoxicity assays using HT29 (TcdA) and VERO 
(TcdB) cells as described previously (Permpoonpattana, Hong, et al., 2011).  
 
2.23 Characterisation of intestinal spore formers in mice and 
hamsters (Chapter 4) 
C57BL/6 mice (6 weeks, female) housed in groups of 4/cage were kept in IVCs for 
10 days prior to being dosed with clindamycin (30 mg/kg). Freshly voided faeces 
was collected 24 hours before and after clindamycin treatment and then 
homogenised in PBS, heat-treated (68oC, 1 hour) serially diluted and plated on LB 
for aerobes or BHISS agar for anaerobic bacteria, a medium used for culture of the 
human gut microbiota (Lau et al., 2016). Plates were incubated aerobically or 
anaerobically at 37oC for 2 days. 500 colonies were randomly picked and 
restreaked. The presence of spores in colonies was checked microscopically and 
each colony was grown for 16 hours at 37oC in liquid culture (2 ml) using aerobic 
or anaerobic conditions as required before sub-culturing (1/100) overnight in the 
same conditions. The cell free supernatant was then obtained using centrifugation 
and filtering through a 0.45 μm syringe filter. Activity against CD630 was 
determined using a microdilution assay (see below). Biosurfactant activity was 
determined using an oil displacement assay (Youssef et al., 2004). gyrA sequencing 
used protocols and primers previously described for Bacillus (Chun and Bae, 2000). 
Antibiotic minimal inhibitory concentrations were made using a microdilution 
method as stipulated by the Clinical and Laboratory Standards Institute (CLSI, 
2019).  
 
2.24 In vitro analysis of anti-C. difficile activity (Chapter 4 and 5)  
2.24.1 Agar diffusion assay 
Aerobic Bacillus strains were grown in LB medium at 37oC for 16-18 hours while 
anaerobic spore formers were grown in BHISS broth overnight in an anaerobic 
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chamber. Samples were centrifuged (microfuge, 10,000 g, 10 min.) and 
supernatants filter-sterilised (0.45 μm syringe filter) and stored on ice till use. TGY 
agar plates (for 1 litre: 30 g tryptic soy broth, 20 g glucose, 10 g yeast extract, 1 g 
L-cysteine and 15 g agar) were pre-reduced and after spreading with an overnight 
C. difficile culture (~100 μl) allowed to dry for 30 min. after which 4-6 wells were 
cut per plate. Plates were reduced for 4 hours in an anaerobic chamber before use. 
5 mm diameter wells were cut in the TGY agar and 50 μl of Bacillus supernatants 
applied to labelled wells and the plates incubated at 37oC for 48 hours in an 
anaerobic chamber and the diameter of the zones of inhibition measured. 
 
2.24.2 Microdilution assay 
Indicator culture:  
A single colony of the relevant C. difficile strain was inoculated into 10 ml of BHIS 
and incubated overnight at 37oC in an anaerobic chamber. The overnight culture 
was then sub-cultured 1:100 into BHIS (typically 0.1 ml into 10 ml BHIS) and 
incubated at 37oC for 6 hours after which the culture was ready for use. 
 
Plate set up:  
180 μl of sterile BHIS was pipetted into the first row of a 96-well U-bottom 
microplate (Sigma) and 100μl into each subsequent row. 20 μl of the sample to be 
tested was pipetted into the first row (1:10 dilution factor) and serially diluted in a 
2-fold dilution series until the last row (1:1280 dilution factor) on the microplate. 
For one serial dilution a ‘media only’ control was also pipetted into a single well 
on the first column. 10 μl of the 6 hours C. difficile ‘indicator culture’ was pipetted 
into each well and the plate was incubated overnight at 37oC in an anaerobic 
chamber. After overnight growth the microplate contents were agitated on a rotary 
plate shaker at 200 rpm for 2 min. after which the OD600 was measured using a 
microplate plate reader. Positive inhibitory activity was defined as an OD600 < 50% 
of the CD630 media only control. 
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2.24.3 Co-culture assays 
C. difficile strains were grown in BHIS medium overnight at 37oC under anaerobic 
conditions. The following day 9 ml BHIS was inoculated with 90 μl of overnight 
culture and incubated at 37oC until the optical density reached ~ 0.2-0.3 OD600. At 
this point 1 ml of a freshly prepared supernatant was aseptically added to the 
growing C. difficile cultures and growth resumed, and the OD600 recorded hourly. 
For cell viability counts, aliquots were taken alongside OD readings, serially diluted 
and plated on BHISS agar plates. For experiments involving HPLC separated 
fractions, vacuum evaporated (Genevac EZ-2) fractions were resuspended in 1 ml 
of PBS, and the quantity resuspended normalised to the original filtrate, using 
activity previously determined by microdilution assay. In the case of the SG277 
SEC, surfactin and AmSO4 fractions, samples were normalised by dilution with 
PBS so that activity (in microdilution assay) was equivalent to that of the 
supernatant (Figure 5.14). The same volume for each sample as was used for the 
supernatant (1 ml) was then used in the co-culture assay. For experiments involving 
a variety of C. difficile strains (Table 5.4), C. difficile cultures were grown for 10 
hours at 37oC in BHIS and 18 ml was moved to a falcon tube followed by an 
addition of 2 ml of SG277 filtrate. The cultures were incubated for 18 hours at 37oC 
after which the OD600 was read to assess the inhibitory activity against the strains. 
 
2.25 In vivo analysis of allochthonous intestinal aerobic spore 
formers (Chapter 4) 
C57BL/6 mice (6 weeks, female) (n = 6) were housed in either conventional cages 
or IVCs with three animals per cage. Faeces was sampled every 10 days, 
homogenised in PBS, and the total counts or heat-resistant (68oC, 1 hour) spore 
counts were determined following serial diluting and plating on LB agar (37oC, 
O/N). Colonies were quantified and calculated to give values per gram of faecal 
matter. 
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2.26 Ex vivo germination of C. difficile spores in intestinal contents 
(Chapter 4) 
C57BL/6 mice (6 weeks, female) housed in groups of four/cage were dosed with 
clindamycin (30 mg/kg) or left untreated. 24 hours post dosing with clindamycin, 
mice from the treated and non-treated cages were culled and the contents removed 
from the small intestine and weighed. Intestinal contents were diluted 1:2 (w/v) in 
saline (with Clostridium difficile supplement (CD supplement); cefoxitin and D-
cycloserine, Sigma), homogenised, centrifuged (21,000 g, 15 min.) and the 
supernatant was removed. Centrifugation was repeated twice more. CD630 spores 
were added to a final concentration of 106 CFU/ml to the samples and they were 
incubated at 37oC in anaerobic conditions. Total counts and heat resistant counts 
(60oC, 20 min) at different time points were plated on BHISS supplemented with 
CD supplement. 
 
2.27 In vivo germination of C. difficile spores (Chapter 4) 
C57BL/6 mice (6 weeks, female) housed in groups of three/cage were dosed with 
clindamycin (30 mg/kg) or left untreated. Three untreated and three treated mice 
were dosed i.g. with 107 CD630 spores and a single mouse culled at each time point 
(1, 2 and 3 hours). The stomach, small intestine and large intestine contents were 
removed, added to pre-reduced PBS (1 ml), homogenised, serially diluted and 
plated on BHISS (CD supplement) for total counts. Homogenised sample was then 
heat treated (60oC, 20 min.) and plated on BHISS (CD supplement). The 
germination rate was calculated as follows: 100 – (Heat resistant count/Total count 
x 100). 
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2.28 Ex vivo analysis of anti-C. difficile activity of intestinal contents 
(Chapter 4) 
2.28.1 Intestinal contents extraction  
C57BL/6 mice (6 weeks, female) housed in groups of four/cage were dosed with 
clindamycin (30 mg/kg) or left untreated. 24 hours post dosing with clindamycin, 
mice from the treated and non-treated cages were culled and the contents were 
removed from the small intestine and weighed. Intestinal contents were 
homogenised in 1 ml dH2O and shaken vigorously for 1 hour at RT. After 
incubation, 9 ml of 100% MeOH was added to the sample and incubated for 3 hours 
at RT before being centrifuged (10,000 g, 15 min.). The supernatant was removed 
and evaporated in a vacuum evaporator for 24 to 36 hours until only a dry pellet 
remained. The pellet was resuspended in saline at a ratio of 1:3 (w/v) according to 
the original weight. The samples were incubated for 3 hours at RT prior to being 
centrifuged at 21,000 g for 10 min. and the supernatant removed. Centrifugation 
was repeated twice more under the same conditions and the supernatant was 
removed and stored at -20oC. 
 
2.28.2 Spore recovery assay  
The assay was performed at 37oC in anaerobic conditions. Intestinal contents 
samples were diluted 1:1 in BHIS (+ 2% sodium taurocholate and CD supplement) 
and spores were added to a final concentration of 106 CFU/ml. Samples were taken 
at 0, 1, 2 and 3 hours and total CFU plated on BHISS agar supplemented with CD 
supplement. Heat resistant counts (60oC, 20 min.) were also enumerated to confirm 
that germination was occurring. Saline and supernatant from SG277 O/N BHIB 
culture (0.45 µm filter) were utilised as negative and positive controls. SG277 
filtrate was diluted 1:5 in saline which was then diluted 1:1 in BHIS + 2% (w/v) 
sodium taurocholate before addition of spores.  
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2.29 RP-HPLC analysis of small intestinal contents (Chapter 4) 
Following extraction of intestinal contents (2.28.1), samples (1.5 ml) were diluted 
with 100% MeOH to a final concentration of 20%. All the following buffers used 
with Sep-Pak C18 cartridges (Waters) were acidified with acetic acid to a final 
concentration of 0.1%. Sep-Pak C18 cartridges were activated with 10 ml of 100% 
MeOH before being equilibrated with 10 ml of 20% (v/v) MeOH. The sample was 
then pushed through the column gently and collected. This was repeated twice 
more. The column was washed with 10 ml of 20% (v/v) MeOH and elution was 
performed with 2 ml of 100% MeOH. The eluted fractions were evaporated for 3 
hours using a vacuum evaporator. Dried samples were resuspended at a 10:1 (w/v) 
ratio in 60% (v/v) MeOH according to the original weight of the intestinal contents. 
Samples were then either tested for activity or 50 μl (representing 0.5 g intestinal 
contents) was analysed using RP-HPLC (2.31). All fractions were identified using 
MALDI-TOF analysis (2.31) and peaks within regions corresponding to different 
lipopeptides were combined and tested for activity. Activity was measured using 
the microdilution assay, with dilution values representing the final dilution of the 
newly resuspended sample at which activity is still present.    
 
2.30 Prophylactic treatments in animals (Chapter 4) 
For animal experiments, methods were followed from that described previously 
(the Holloway model) in Section 2.19 and 2.22 (Permpoonpattana et al., 2011; 
Hong, Ferreira, et al., 2017). 
 
2.30.1 Preparation of prophylactic treatments  
SG277 and SG378 were grown overnight (18 hours, 37oC) in 100 ml BHIB and 
after centrifugation the pellet suspended in 2 ml of PBS or supernatant to give an 
approximate 200 μl dose of 5 x 109 CFU. For strains comprising the cocktail of 
bacteria isolated from mouse faeces with in vitro activity against C. difficile (B. 
amyloliquefaciens, B. licheniformis, B. subtilis), a single colony of each was 
resuspended in individual flasks containing 25 ml BHIB and grown overnight (18 
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hours, 37oC), and after centrifugation the resultant pellets were mixed and 
resuspended in 2 ml of PBS to give an approximate 200 μl dose of 3 x 109 CFU (1 
x 109 /strain). The same procedure was followed for the negative control in this 
experiment, the cocktail comprising three Bacillus isolates that showed no in vitro 
activity against C. difficile. For use of the supernatant an aliquot was filter sterilised 
(0.45 μm). For spores SG277 was grown on DSM agar for 72 hours at 37oC. Spore 
crops were harvested from the plate using a cell scraper, washed three-times in 
dH2O and then heat-treated to kill residual vegetative cells. Spores were suspended 
in dH2O to give a concentration of 2.5 x 10
10 spores/ml, with a 200 μl dose 
providing 5 x 109 spores. For lyophilised SG277, a single colony was grown in 25 
ml BHIB (18 hours, 37oC). Cell pellets were frozen at -20°C O/N. The next day 
tubes containing frozen pellets from 25 ml culture were covered with perforated 
parafilm and lyophilised O/N. When ready, they were stored at -20°C. On the day 
of use, pellets from four flasks were harvested and resuspended in 2 ml of PBS 
(approximate 200 μl dose of 5 x 109). For preparation of the SG277 preparative 
SEC fraction for dosing to mice, culture was precipitated using 20% (w/v) 
ammonium sulphate (AmSO4) and resuspended at a 30x concentration in PBS (pH= 
7.4). 1 ml of the AmSO4 precipitate was separated on a gel filtration, size exclusion 
chromatography (SEC) column (Superdex 200) using PBS as an isocratic buffer 
and fractions tested for activity against CD630 in a microdilution assay. Active 
fractions were combined, washed using a 10 kDa molecular weight cut off 
centrifugal filter (MWCO, Vivaspin) and concentrated to a final volume of 1 ml in 
dH2O. Mice were dosed with 200 μl of this SEC fraction. 
 
2.30.2 Mouse colonisation experiments 
Animals (C57BL/6, female, aged 6-7 weeks) were dosed i.g. with clindamycin (30 
mg/kg) and 24 hours later challenged with 102 spores of CD630. Animal groups 
were dosed (0.2 ml, i.g.) with prophylactic treatments before and after challenge 
with CD630 using the regimen shown in Figure 4.12. Caeca were removed 24 hours 
post-infection for analysis of colonisation.  
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2.30.3 Hamster experiments 
Golden Syrian Hamsters (female) were 16-18 weeks old. For the hamster challenge, 
animal groups (n = 6) were dosed (i.g.) with clindamycin (30mg/kg body weight) 
and then challenged three days later with 102 spores of CD630. Before and after 
CD630 challenge animals were dosed (i.g.; 2 ml/dose) with the treatments 
described above. The treatment regimen was six doses before CD630 challenge (-
48, -36, -24, -12, -4 and -1 hours) and then three-times/day post-challenge for 
twelve days. Animals were monitored for symptoms of disease progression and 
culled upon reaching the clinical endpoint. The symptoms of CDI were scored as 
severe/clinical end point (wet tail >2 cm, high lethargy), mild (wet tail <2 cm) or 
healthy. Caeca were removed and analysed for CD630 ethanol resistant CFU and 
toxins A and B. Figure 4.15 is a diagrammatic representation of the regimen. 
 
2.31 Extraction and purification of the active molecule/s from 
bacterial culture (Chapter 4 and 5) 
For purification, SG277, amongst the most active of the B. amyloliquefaciens 
strains was selected. For figures comparing various Bacillus strains (SG297, SG83, 
SG140), the same purification method was used (Figure 5.12). After cultivating the 
cells overnight in BHIB broth at 37oC bacterial cells were removed from the 
supernatant by centrifugation at 8000 g for 10 min. and the supernatant was filter-
sterilised through a 0.45 µm membrane. The sterile supernatant (54 ml) was then 
precipitated with AmSO4 overnight at 4
oC using saturated AmSO4 solution (6 ml) 
giving a final concentration of 20% (w/v). Following centrifugation at 8000 g for 
15 min. the supernatant was removed, and the precipitate resuspended in 1.8 ml 
PBS. To remove excess AmSO4 the filtrate was dialysed overnight at 4
oC. After 
dialysis, 1.5 ml of 0.1% (w/v) SDS in PBS was added to the 1 ml of the resulting 
filtrate and 2.5 ml applied to a Superdex 200 column (L × I.D. 30 cm × 10 mm) and 
fractionated by SEC under denaturing conditions using PBS (0.1% w/v SDS) as the 
running buffer. Fractions were tested for activity against CD630 using a 
microdilution assay and positive fractions were combined and dialysed overnight 
in PBS at 4oC to remove remaining SDS. The solution was concentrated using a 10 
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kDa molecular weight cut off (MWCO) (Vivaspin) to a final volume of 1 ml of 
dH2O. This material will henceforth be referred to as SG277 preparative SEC 
fraction. The sample (ordinarily 30 µl) was loaded on a uBondapack Phenyl, 125 
µm 30 cm x 3.9 mm (Waters) column and separated by RP-HPLC using a Waters 
600E system controller with a 600 pump and an ABI Kratos 757 absorbance 
detector. The mobile phase components were (A) 0.5% acetic acid in 60% MeOH 
and (B) 0.5% acetic acid in 95% MeOH. The fractions were injected in buffer A 
and the products were eluted at a flow rate of 0.5 ml/min. with a linear gradient of 
solvent B, developed from 0% to 100% (60 min). The elution pattern was monitored 
by determining absorbance at 220 nm, and resultant fractions were concentrated 
using EZ-2 Genevac centrifugal evaporator and then either tested for activity 
against CD630 using a microdilution assay (2.24.2) or identified by mass 
spectrometry. For experiments involving combinations of components, specific 
fractions were combined and then vacuum evaporated. Fractions were resuspended 
in dH2O and tested for activity against CD630 in a microdilution assay. MALDI-
TOF-MS analysis was performed on a Bruker Reflex III system equipped with a 
sealed nitrogen pulsed laser (337 nm, line width 0.1 nm, 4 ns pulse duration, 300 
microjoules rated pulse energy, average power 5 mW at 20 Hz). A working solution 
of matrix was prepared by mixing 60 μl of the alpha-cyano-4-hydroxycinnamic acid 
matrix stock solution in MeOH (MALDI-QUALITY TM, Agilent Technologies), 30 
μl of acetone and 1 μL of 1% (v/v) TFA in a glass vessel. Individual RP-HPLC or 
SEC-HPLC fractions were mixed with the matrix solution and deposited onto a 
stainless steel MALDI plate. Mass spectra were acquired using the reflection mode. 
The instrument was calibrated to the mass accuracy of at least 30 ppm. HPLC and 
MALDI-TOF analysis performed in close collaboration with Dr Mikhail Soloviev, 
University of London.   
 
2.32 SEC-HPLC separation of SG277 (Chapter 5) 
SG277 preparative SEC fraction were fractionated under denaturing conditions in 
organic solvent on a SEC-HPLC and TSK Gel G2500PW XL column (7.6 x 300 
mm) with isocratic elution at a flow rate of 1 ml/min using a Waters 600E system 
controller with a 600 pump and an ABI Kratos 757 absorbance detector. The mobile 
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phase was 65% acetonitrile (ACN) and 0.1% Acetic acid. The eluted material was 
detected by absorbance at 220 nm. Fractions were collected and dried using a 
vacuum evaporator prior to further analysis by microdilution assay against CD630 
(2.24.2), and MALDI-TOF-MS (described above in 2.31). 
 
 
2.33 Cumulative activity of HPLC purified fractions (Chapter 5) 
SG277 SEC fraction was separated using RP-HPLC (as described above); 
chlorotetaine, iturin, fengycin and surfactin were collected as individual peaks. On 
a replicate separation all individually collected peaks were collected into a single 
tube. All fractions were vacuum evaporated for 5 hours until only a pellet remained. 
Samples were resuspended in PBS and tested for activity against CD630 in a 
microdilution assay as a proportion of the initial injection volume. The 
mathematical sum of the activity was calculated by addition of all activities 
demonstrated by individual peaks while total activity was determined by testing the 
individual peaks collected together in a single tube. SG277 SEC fraction pre-
separation was used as a control. Commercially produced lipopeptides iturin, 
fengycin and surfactin (Sigma) were dissolved in 50% MeOH at a concentration of 
2 mg/ml. To test commercially produced lipopeptides together, equal volumes of 
each lipopeptide was combined, vacuum evaporated and resuspended in 50% 
MeOH at a third of the original volume so that each lipopeptide would be at a final 
concentration of 2 mg/ml. These solutions were then tested against CD630 in a 
microdilution assay. 50% MeOH was used in isolation as a control.  
 
2.34 PEG precipitation and caesium chloride centrifugation 
(Chapter 5) 
1 L of a SG277 culture in BHIB was grown from a single colony O/N at 37oC and 
supernatant collected after centrifugation at 8,000 g for 10 min. The supernatant 
was then filter-sterilised through a 0.20 µm membrane. Saturated polyethylene 
glycol (PEG) solution (Sigma) was added to the sterile supernatant to a final 
concentration of 8% and incubated for 4 hours at 4oC. After incubation, the solution 
85 
 
was centrifuged (10,000 g for 30 min. at 4oC) and the pellet suspended in 10 ml of 
SM buffer (per litre; 5.8 g NaCl, 2 g MgSO4.7H2O, 50 ml 1 M Tris-HCl pH 7.5). 4 
ml of the filtrate was then layered on top of a caesium chloride (CsCl) gradient 
consisting of: 4 ml of 1.3 g/cm3 CsCl, 4 ml of 1.4 g/cm3 CsCl and 4 ml of 1.5 g/cm3 
CsCl in that order. This gradient was centrifuged in an Optima XPN-90 
Ultracentrifuge (Beckman Coulter) with a SW32 rotor (150,000 g, 18 hours, 4oC). 
Following centrifugation bands were carefully removed using a pipette, tested for 
activity and analysed by transmission electron microscopy (TEM). 
 
2.35 SDS-PAGE and soft-agar overlay (Chapter 4 and 5) 
Samples of supernatants were fractionated by 20% SDS-PAGE at 120 V for 1 hour. 
The gel was fixed for 1 hour with isopropanol (20%) and acetic acid (10%) and 
SDS was removed by soaking overnight at 37oC in dH2O. Gel lanes were carefully 
excised and placed on BHIS agar supplemented with CD supplement to inhibit 
contamination but not C. difficile. Strips were overlaid with 10 ml soft BHIS agar 
(CD supplement) (0.7%) containing 1 ml of a logarithmic culture (OD600 of 0.4-
0.5) of CD630. Plates were incubated anaerobically overnight at 37oC and observed 
for zones of inhibition.  
 
2.36 Stability of SG277 filtrate and lyophilised supernatant 
(Chapter 5) 
SG277 was produced by growing a culture for 16 hours in BHIB at 37oC from a 
single colony, after which the bacterial cells were removed from the supernatant by 
centrifugation at 8000 g for 10 min. and the supernatant was sterile-filtered through 
a 0.45 µm membrane and aliquoted (1 ml) into sterile Eppendorf tubes. For 
lyophilised samples, 1 ml aliquots of the same filtered supernatant were freeze dried 
for 24 hours. Aliquots were stored at either -20oC, 4oC, RT or at 37oC for (up to 8 
weeks) and one aliquot from each storage regimen was frozen at -20°C every week. 
A sample stored at -20°C was tested weekly to control for activity loss of already 
collected samples. For testing of inhibitory activity against CD630 using the 
microdilution assay, fresh supernatants were thawed and lyophilised supernatants 
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were dissolved in 1 ml of dH2O on the day of use. 200 µl was removed from each 
sample and half of this volume was pre-heated for 15 min. at 65°C prior to the 
assay. Activity was then calculated as a percentage of the original sample activity. 
 
2.37 Characterisation of SG277 and SG297 extracellular activity 
(Chapter 5) 
The no treatment control was diluted 1:1 in dH2O (v/v) prior to activity testing, and 
all samples diluted by treatments were further diluted if necessary, with dH2O so 
that filtrate was at a final concentration of 1:1 (v/v). For heat treatments, filtrates 
(0.5ml) were incubated in an oven at the selected temperature (60oC, 70 oC, 80 oC, 
90 oC and 100 oC) for 30 min. and allowed to cool to RT before the assay. 
Autoclaving of filtrate was performed at 121oC, 20 psi for 20 min. For simulated 
gastric fluid (SGF; 0.2% w/v NaCl, 3.5 mg/ml pepsin), three solutions were used at 
pH, 2, 3 and 4 by adjusting with HCl. Filtrates (0.5 ml) were incubated with an 
equal volume of SGF for 1 hour at 37oC before assay. Supernatants (0.5 ml) were 
incubated with the following enzymes (all from Sigma) at 1 mg/ml final 
concentration for 1 hour at 37oC before assay; lysozyme, lipase, amylase. For the 
proteases, pronase, trypsin and proteinase K (Thermo Scientific) were used under 
the same conditions as the prior mentioned enzymes. For solvent treatments, 0.5 ml 
of filtrate was vortexed for 1 min. with 0.5 ml of 100% toluene, chloroform or 
acetone and incubated for 1 hour. A final concentration of 0.1% SDS (w/v) was 
mixed with 0.5 ml of filtrate and incubated at RT for 3 hours. Various 
concentrations of glutaraldehyde (0.1, 0.25, 0.5 and 1%) were incubated with 0.5 
ml filtrate at 37°C for 2 hours. Glutaraldehyde was neutralised by glycine at a molar 
ratio of 1:10. All samples were tested against CD630 in a microdilution assay. The 
highest dilution factor that showed inhibitory activity was recorded. Treatment only 
controls (no filtrate) was used for all tests. 
 
2.38 Determination of surface associated lytic activity (Chapter 5) 
A single colony of SG277 was grown in BHIB (25 ml) for 8 hours at 37oC. Cells 
were pelleted, the supernatant retained, and the pellet washed three-times with 
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sterile PBS. The pellet was suspended in pre-reduced BHIS broth (25 ml). Aliquots 
of washed cells and the supernatant were also, separately, heat-treated (80oC, 30 
min.) to kill any residual cells. 0.5 ml of a tenfold dilution of the suspensions 
(washed cells, and heat-treated suspensions), or 0.5 ml of the retained supernatant 
(no heat or heat-treated), were individually mixed with 0.5 ml of CD630 that had 
been grown (anaerobically) in BHIS medium (6 hours, 37oC) and left for 15 min. 
in an anaerobic chamber. 0.5 ml of the mixture was added to 4.5 ml of soft (0.6%) 
micropropagation agar (Apollo Science) and poured onto a pre-reduced BHIS agar 
plate. Plates were incubated overnight at 37oC anaerobically. Activity was shown 
by complete lysis of the bacterial lawn. SG277 cell suspensions were mixed with 
soft agar and incubated overnight as a control and as aerobes, exhibited no growth. 
 
2.39 Determination of approximate molecular weight using 
molecular weight cut-offs (Chapter 5) 
Using filter sterilised (0.45 m) supernatant of SG277 grown O/N in BHIB, 
supernatant was centrifuged (8000 g, 30 min.) through a succession of MWCOs 
(100 kDa, 30 kDa and 10 kDa). Each time an aliquot of filtrate was removed for 
testing and the remainder was passed through the proceeding MWCO. After each 
centrifugation the retentate was removed and normalised using BHIB to the original 
volume placed into the MWCO. All samples were tested against CD630 in a 
microdilution assay.  
 
2.40 Effect of MeOH on the molecular weight of the active complex 
(Chapter 5) 
SG277 SEC fraction in dH2O was centrifuged (8,000 g, 15 min.) through a 30 kDa 
MWCO filter to ensure activity measured was above 30 kDa. The retentate 
containing the high MW micelles was collected and MeOH added to a final 
concentration of 50% (v/v) and incubated for 1 hour at RT. The resulting mixture 
was centrifuged under the same conditions as described above using a 5 kDa 
MWCO filter and the filtrate containing the low MW, MeOH disrupted 
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biosurfactant molecules were collected, aliquoted in equal volumes into 2 separate 
Eppendorfs and vacuum evaporated. The remaining pellets were resuspended in 
either dH2O or 50% MeOH (v/v) and centrifuged using 30 kDa MWCO filters or 5 
kDa MWCO filters, respectively. Retentates and filtrates were collected from every 
step. All fractions were normalised by volume and tested for activity against CD630 
using a microdilution assay in order to trace the path of the activity.  
 
2.41 Dynamic light scattering (DLS) analysis (Chapter 5) 
Samples were diluted or reconstituted from dried in 150 mM sodium phosphate 
buffer (pH 7.2) and cleared by centrifugation at 17,000 g for 1 hour prior to analysis. 
100 µl was transferred to a micro-cuvette, equilibrated at 25°C and measured in 
triplicate using Zetasizer Nano ZS (Malvern). The diameter was estimated from the 
Z-average size. Polydispersity index and intercept were obtained from the 
cumulants fit using the Zetasizer software v7.11 (Malvern). Individual RP-HPLC 
peaks used in this experiment; iturin, fengycin and surfactin (1-3) can be viewed in 
Figure 4.9. This experiment was performed in close collaboration with Dr Enrico 
Ferrari, University of Lincoln and Dr Mikhail Soloviev, Royal Holloway. 
 
2.42 Protein analysis of SG277 preparative SEC separation 
(Chapter 5) 
As previously described, 1 ml of AmSO4 precipitated SG277 in 1.5 ml PBS (0.1% 
SDS) was run through a Superdex 200 gel filtration column, and the resulting 
fractions eluted tested for activity against CD630 in a microdilution assay and for 
protein concentration using a NanoDrop 2000 at A280nm. In order to ascertain the 
approximate molecular weight of the eluted active complex, bovine serum albumin 
(BSA) and lysozyme were dissolved in 2.5 ml PBS and run through the column as 
standards (2 mg per injection). The presence of these eluted proteins was detected 
using a NanoDrop at A280nm. For MW approximation under non-denaturing 
conditions, separation of AmSO4 ppt. SG277 was performed using PBS without the 
presence of SDS. Four internal standards were used, all of which were dissolved in 
2.5 ml PBS prior to injection; IgG (150 kDa), BSA (66.5 kDa), lysozyme (14.3 
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kDa) and insulin (5.8 kDa) (2 mg per injection). The presence of these eluted 
proteins was detected using a NanoDrop at A280nm and activity against CD630 in 
a microdilution assay was tested for. The retention time (min.) was plotted as a 
function of the log(MW) and used to plot a trendline. The straight-line equation (y 
= -0.05561 x x + 6.260) was solved for y (SG277 retention time: 26 min.) to 
determine the molecular weight of the complex.          
 
2.43 Statistical analysis 
Statistical analysis was calculated, and significance determined (p <0.05) using 
Welch’s t-test for unequal variance unless stated otherwise. All statistical analysis 
was performed using Graphpad Prism software. 
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CHAPTER 3 
Characterisation of C. difficile spore coat protein CotE 
 
3.1 Introduction 
C. difficile is a Gram positive, spore-forming human and animal pathogen and one 
of the leading causes of nosocomial antibiotic-associated diarrhoea in developed 
countries (Smits et al., 2016). Symptoms of C. difficile infection (CDI) range from 
mild, self-limiting diarrhoea to a more severe pseudomembranous colitis and toxic 
megacolon that may result in death. The disease results from antibiotic-induced 
dysbiosis of the gut microflora that allows spores of C. difficile to germinate, 
proliferate and produce at least two inflammatory cytotoxins (TcdA and TcdB) 
resulting in tissue damage (Rupnik et al., 2009; Shen, 2012). Toxins A and B are 
the main virulence factors for CDI. It has been demonstrated that vegetative cell 
adherence is important and a number of adhesins have been found, including SlpA, 
an S-layer protein involved in adhesion (Merrigan et al., 2013), flagellin, that could 
enable cells to penetrate the mucus (Baban et al., 2013), a binary toxin that may be 
involved in adhesion and Cwp84, a protease that can break down matrix proteins 
such as fibronectin and laminin (Pechine et al., 2005).  
 
As with many bacterial diseases CDI involves both host colonisation and toxin 
production. Colonisation comprises a number of distinct phases starting with 
acquisition of C. difficile spores, spore germination, outgrowth and proliferation. 
Two aspects of CDI are notable. The first is its fulminance with large numbers of 
spores being produced concurrent with toxin production. In animals, an infective 
dose of 100 spores can lead to intestinal populations of C. difficile 6-logs higher in 
as little as 24 hours (Lawley et al., 2009). The second is self-limitation, and once 
antibiotics are withdrawn, infection rapidly subsides (Smits et al., 2016). Studies 
on C. difficile colonisation have mostly focused on the role of the vegetative cell 
since it had been assumed that the primary role for the spore is in transmission and 
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dissemination of this strict anaerobe. Whether it is necessary for the spore to attach 
to the intestine prior to germination is unknown. 
 
The mortality linked to CDI has increased due to the emergence of epidemic and 
hypervirulent C. difficile strains such as the 027/B1/NAP1 strains (Kansau et al., 
2016). Over the past decade a multitude of studies have been carried out to try to 
discern the mechanism behind the severity of 027/B1/NAP1 strains, but the precise 
causative mechanisms are yet to be found. There are, however, links between a high 
sporulation rate and hypervirulence, and recently Kansau et al. (2016) found that in 
a mouse model, sporulation of R20291 initiated earlier than in other strains. 
 
Attention has understandably focused on the acute stage of infection, the role of the 
toxins and the ability of this bacterium to colonise the GI tract. However, a hallmark 
of CDI is the transient production of enormous numbers of spores (>107 spores/g 
of faeces) in the intestine that are ultimately shed to the environs (Lawley et al., 
2009). These spores are refractive to antibiotic treatment and the ‘supershedder’ 
state resulting from antibiotic therapy would occur in infected patients (and 
presumably livestock also), but their role during CDI is unknown (Lawley et al., 
2009). A number of clues suggest that the spore may contribute to CDI. For 
example, hamsters challenged with spores of a non-toxigenic strain of C. difficile 
(CD1342) experienced cell damage in the caecum as well as an inflammatory 
response (Buckley et al., 2013). In a murine model, a C. difficile spo0A mutant is 
unable to persist within and effectively transmit between mice but no conclusion 
can be made regarding the spore’s effect on disease severity due to possible 
regulatory mechanisms of virulence factors including toxins A and B (Deakin et 
al., 2012). Interestingly, pre-treatment of rodents with non-toxigenic strains of C. 
difficile have demonstrated that the strain colonises the GI tract yet, following 
challenge ~40-60 days later with a toxin-producing C. difficile strain, these animals 
were fully protected against CDI (Nagaro et al., 2013). 
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Other than being an agent of transmission an intriguing question that has not yet 
been addressed is whether the spore per se plays a direct role in the acute stages of 
infection. The outermost layer of C. difficile spore is distinguished by hair-like 
projections superficially resembling the exosporial layers of B. anthracis and B. 
cereus spores (Henriques and Moran, 2007). In recent studies, this outermost layer 
has been re-defined as a ‘shroud’ that is thought to consist partly of biomass 
originating from ruptured vegetative cells (Semenyuk et al., 2014). Beneath the 
shroud, the electron-dense spore coat comprises thirty or more different proteins 
(Paredes-Sabja et al., 2014). Of note is the number of antioxidant enzymes 
including three manganese catalases and a superoxide dismutase  
(Permpoonpattana et al., 2011, 2013). Finally, and the subject of this chapter is 
CotE, an 81 kDa bifunctional protein that carries two distinct domains, an N-
terminal peroxiredoxin domain and a C-terminal chitinase domain 
(Permpoonpattana et al., 2011). The peroxiredoxin domain resembles a 1-Cys 
peroxiredoxin suggesting it may be involved in reducing hydrogen peroxide (H2O2) 
arising as a by-product of SodA-mediated cross-linking of spore coat proteins 
(Permpoonpattana et al., 2011). The chitinase domain, belonging to the 
glycohydrolase family 18, might prima facie play a nutritional role in the turnover 
of macromolecules such as chitin.  
 
In this chapter, the possibility of CotE having a more sophisticated function, and 
potentially a role in pathogenesis will be investigated. This hypothesis is based on 
two observations. First, some chitinases have been shown to bind mucin and carry 
mucolytic activity (Kirn et al., 2005; DebRoy et al., 2006; Sanders et al., 2007; 
Chaudhuri et al., 2010; Low et al., 2013) thus providing a mechanism for 
colonisation via spore interaction with mucus and potentially targeting toxins to the 
underlying mucosal epithelium. Second, both peroxiredoxins and chitinases have 
been shown to be inflammatory or to be associated with inflammatory conditions 
(Kawada et al., 2007; Sanders et al., 2007; Lee et al., 2011; Salzano et al., 2014; 
Knoops et al., 2016). Since symptoms of CDI closely resemble other inflammatory 
enteric diseases such as Inflammatory Bowel Disease (IBD) (Goudarzi et al., 2014), 
is it perhaps possible that CotE could contribute to symptoms of disease? 
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This chapter focuses on the chitinase domain of CotE, and its role in the infection 
process.  In vitro and ex vivo experiments are described that examine whether CotE 
can bind mucus via interaction with the glycoprotein N-acetylglucosamine 
(GlcNAc), a component of mucin, and whether this affects colonisation in mice and 
hamsters. In vivo, using hamster and murine models it has been examined whether 
isogenic mutant spores lacking CotE have differing rates of colonisation, and 
whether any effect is seen upon symptoms and morbidity within infected animals. 
The potential of CotE in eliciting an immunogenic response has also been 
investigated in vitro.  
 
3.2 Results 
3.2.1 Confirmation of the phenotype of CotE mutants 
The two mutants of cotE and their complements were created previously and have 
been described by Permpoonpattana et al. (2013). cotE::CT220s carries an insertion 
at the N-terminus preceding both the peroxiredoxin and chitinase domains, while 
the insertion in cotE::CT1203s is centrally positioned and precedes the C-terminal 
chitinase domain. For simplicity these mutants will be described here as CotE- 
(cotE::CT220s) and CotEC- (cotE::CT1203s). The schematic below visualises the 
insertions for both the mutants (Figure 3.1). The crystal structure of CotE has been 
determined by Tony Wilkinson (University of York, UK) and is shown in Figure 
3.2.  
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Figure 3.1. Insertional mutation of cotE. Shown is a schematic of the CotE polypeptide with 
showing the peroxiredoxin and chitinase domains together with the ClosTron insertions within the 
cotE::CT220s (cotE-) and cotE::CT1203s (cotEC-) mutants. The segments of cotE expressed in 
pET28b expression vectors for expression of rCotEN and rCotEC are also shown. 
 
 
 
Figure 3.2. CotE structure. Ribbon rendering of CotE (348-718) with the subdomain comprising 
residues 605-655 in darker blue, the peptide ligand shown as spheres (red - oxygen, green - carbon) 
and the disulphide bonds as cylinders (yellow). A transparent electrostatic surface emphasises the 
active site groove. Structural analysis courtesy of Professor Anthony Wilkinson, University of York. 
 
To demonstrate the integrity of both mutants, it was shown that each carried two 
copies of the erm gene, whereas the isogenic 630Δerm parent strain carried one 
(Figure 3.3). This confirmed the presence of one ClosTron insertion on the 
chromosome, which was further verified using DNA sequencing. Therefore, the 
phenotypes observed for the two cotE mutants can be directly assigned to the 
absence of CotE or, alternatively, a pleiotropic effect (e.g., disruption or 
misassembly of the spore coat resulting from the absence of an intact CotE).  
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Figure 3.3. Southern blot hybridisation analysis of wild type and CotE mutants. HindIII 
digested chromosomal DNA from wild type and mutants probed with a labelled probe recognizing 
the erm gene. 630Δerm carries one inactivated erm gene accounting for one band while both isogenic 
mutants carried an additional band indicating the presence of a Clostron intron. 
 
Using polyclonal antisera raised in mice to the N-terminal (residues 1–234) and C-
terminal (residues 381–712) domains of CotE, it was confirmed that neither mutant 
produced CotE (Figure 3.4). This had been shown previously, whereby an antibody 
recognizing the N-terminus of CotE was unable to detect CotE on spores of both 
mutants (Permpoonpattana et al., 2013). Similarly, the study showed that antibodies 
that recognised the C-terminal domain were unable to detect CotE in either mutant. 
Theoretically, CotEC- could encode a 133-residue polypeptide carrying the entire 
peroxiredoxin domain that might be functional whether assembled onto the spore 
or not; however, it seems that this protein species is unstable and therefore 
degraded. By contrast, in wild type spores a number of bands were recognised 
including an 81 kDa species corresponding to the full-length protein and a band of 
approximately 40 kDa which most likely was a breakdown product. As noted 
previously CotE is labile and the breakdown products could result from the 
extraction procedure (Permpoonpattana et al., 2011).  
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Figure 3.4. Western blot of spore coat extracts from wild type and CotE mutants. Spore coat 
proteins extracted from 630Δerm, cotE- and cotEC- Histodenz-purified spores were fractionated on 
a 12% SDS-PAGE gel. The blot was probed with a polyclonal antibody (1/4000 dilution.) 
recognizing the C-terminus and N-terminus. Mwts (kDa.) of CotE species are indicated. 
In previous work, a pRPF185-CotE complementation plasmid that carried full-
length cotE was reported (Permpoonpattana et al., 2013). The cotE mutant cells 
carrying this plasmid produced spores that were confirmed to express CotE using 
Western blotting (Figure 3.5). Functional complementation of the CotE mutant 
phenotype was demonstrated in this work and will be described here. 
 
Figure 3.5. Western blot of spore coat extracts from wild type, CotE mutants and 
complements. Proteins extracted from the Histodenz-purified spore coats of 630Δerm, and the two 
cotE mutants together with each cotE mutant carrying pRPF185-CotE, fractionated on a 12% SDS-
PAGE gel. The blot was probed with a polyclonal antibody (1/4000 dilution.) recognizing the C-
terminus. Mwt (kDa.) of full-length CotE species is indicated. 
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For in vivo assessment of the role of CotE in pathogenesis it was necessary to 
establish that the mutants had normal levels of toxins since toxin production is 
linked to stationary phase events such as spore formation and biofilm development 
(Semenyuk et al., 2014). A cell cytotoxicity assay was performed to confirm that 
in vitro production of TcdA and TcdB was indistinguishable from that of the 
isogenic wild type (630Δerm) strain (Figure 3.6). No significant difference was 
observed between 630Δerm and either the CotE mutants or the sigK- mutant. 
 
Figure 3.6. Cytotoxicity levels of toxins A and B in wild type, CotE mutants and the sigK- 
mutant. Cultures of 630Δerm, the CotE mutants or sigK- were grown in TY media. Culture 
supernatants were prepared at various time points. Samples were normalised for optical density of 
the culture and analysed for the presence of toxins A and B by cytotoxicity on HT29 cells (A) or 
Vero cells (B) respectively. The experiment was independently performed three times. Error bars 
represent standard deviations. 
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A second factor that might affect the behavior of spores during infection is their 
ability to germinate. Since CotE is present on the spore surface, its absence might 
pleiotropically affect germination. The ability of mutant and wild type spores to 
germinate was examined, but no differences were observed between wild type and 
mutant spores, by the measurement of both heat-resistant and ethanol-resistant CFU 
counts (Figure 3.7). 
 
 
Figure 3.7. Germination of 630 and cotE mutants. Spore germination was determined using 
preparations of Histodenz-purified spores of wild type and mutants. Spores (106) were resuspended 
in BHIS medium containing 0.1% sodium taurocholate, incubated at 37oC and at the specified time 
points (0-60 min.) sampled for the number of heat-resistant (60oC, 20 min.) (A) or ethanol-resistant 
(30 min. exposure) CFU (B). Percentage of initial counts are plotted. 
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Finally, using the SATH assay the hydrophobicity of wild type and the CotE 
mutants was determined. Differences in hydrophobicity between the strains may 
contribute to adhesive properties and therefore be a factor in adhesion assays and 
in vivo experiments. The SATH method measures the hydrophobicity of spores and 
has been used elsewhere as a reliable indicator of spore hydrophobicity (Seale et 
al., 2008; Huang et al., 2010). However, it was observed (Figure 3.8) that the 
hydrophobicity of wild type and cotE mutant spores was equivalent (630Δerm 75%, 
CotE- 77% and CotEC- 79%). 
 
Figure 3.8. Surface hydrophobicity of 630Δerm and CotE mutant spores. The SATH assay was 
used to calculate % hydrophobicity of Histodenz-purified spores. The experiment was independently 
performed three times. Error bars represent standard deviations. 
 
To rule out the possibility that a difference in CDI pathology could be due to a 
difference in toxin production, in addition to checking toxin production in vitro, 
toxin production in vivo was determined by measuring toxin A and B levels in 
collected faecal samples from C57BL/6 mice over 72 hours and confirmed that 
these were of essentially equivalent levels between all three strains (Figure 3.9).  
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Figure 3.9. In vivo toxin production using a mouse model. Clindamycin-treated mice (n = 6/gp) 
were dosed (i.g.) with 103 spores of wild type CD630 or the cotE mutants. Levels of toxin A (A) 
and toxin B (B) were determined by ELISA in faeces sampled at 24, 48- and 72-hours post-infection. 
Error bars represent standard deviations. 
 
3.2.2 CotE mediated spore adhesion to mucus 
Adhesion of mutant and wild type spores to mucus was evaluated by using the 
human intestinal cell line HT29-MTX. HT29-MTX is a mucus-secreting cell line 
that exhibits differentiated goblet cells that secrete low levels of MUC2 mucins 
typically found in the small and large intestine. Studies using Salmonella have 
shown that HT29-MTX is more physiologically relevant than HT-29 cells for 
studies of pathogen interactions with the mucus layer (Gagnon et al., 2013). Cells 
were grown for 14 days to allow for maximal levels of mucus in HT29-MTX and 
then inoculated with spores and counts were determined after 2 hours of incubation 
(Figure 3.10). The presence of mucus was confirmed in HT29-MTX cells using 
alcian blue staining (data not shown). Wild type 630Δerm spores exhibited higher 
levels of adhesion (15-20%) to HT29-MTX cells compared to both cotE mutants, 
which showed significantly (p ≤ 0.001) lower levels of adhesion. In cotE mutant 
strains carrying the pRPF185-CotE plasmid, levels of adhesion were equivalent to 
wild type demonstrating functional, in trans, complementation of the CotE 
phenotype. In liquid cell culture medium, it was confirmed that no germination of 
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spores took place over a 2-hour incubation period (data not shown). Image analysis 
of antibody-labelled spores adhering to HT29-MTX cell lines (day 14) was also 
used to confirm that wild type spores were more abundant on mucus-producing 
HT29-MTX monolayers (Appendix A, Figure 1).  
 
Figure 3.10. HT29-MTX adhesion assay. Spores of 630Δerm, (cotE+), cotE–, and cotEC– isogenic 
strains or cotE mutants carrying the pRPF185-CotE plasmid were tested for their adherent properties 
to HT29-MTX cell monolayers (MOI 100:1). The experiment was independently performed three 
times. Error bars represent standard deviations. ***p ≤ .001 by the Welch unequal variance t-test. 
 
In a second, ex vivo approach the adhesion of wild type and mutant spores to ileum 
and caecum biopsies obtained from a piglet was measured. These regions of the GI 
tract are most frequently colonised by C. difficile (Goulding et al., 2009; Buckley 
et al., 2011) and exhibit the highest levels of epithelial cell damage. Samples carried 
a thick mucus layer allowing direct application of spores to the mucus matrix. 
Histodenz-purified spores of 630Δerm, CotE- and CotEC- were incubated with 
explants for 1 and 3 hours. The mucus layer was then washed, and the number of 
adhering spores determined by counting on BHISS agar plates. This analysis 
revealed that for both cotE mutants spore adhesion to ileum (Figure 3.11A and B) 
and caecum (Figure 3.11C and D) explants was significantly reduced (~2-fold) 
compared to adhesion of wild type spores at both incubation times. 
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Figure 3.11. Adhesion to pig mucus ex vivo. Adhesion of spores of 630Δerm, CotE- and CotEC- to 
pig mucus isolated from tissues ex vivo. Tissues were obtained from the terminal ileum (TI, A and 
B) and caecum (C and D). Spores were incubated with tissues for 1 hour (A and C) and 3 hours (B 
and D). Results, expressed in CFU per gram of tissue, are from experiments conducted in triplicate. 
*p < .05, **p ≤ .01, *** p ≤ .001 by the Welch unequal variance t-test. 
 
A further experiment, confirming that cotE is involved in binding of spores to 
mucus, was performed using wild type spores preincubated with antibodies 
recognizing the C-terminal domain of cotE before being added to HT29-MTX cells 
(Figure 3.12). The data showed that adhesion of wild type spores could be 
significantly reduced by preadsorption with CotE antibodies.  
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Figure 3.12. Antibody blocking of CotE. Spores of 630Δerm (CotE+) were preincubated with anti-
CotEC antibody or naive serum before adding to HT29-MTX cells. Data for untreated spores and 
spore incubated with naive of anti-CotEC serum are shown. The experiment was independently 
repeated three-times. Error bars represent standard deviations. **p ≤ .01 by the Welch unequal 
variance t-test. 
 
The in vitro studies with cell lines and ex vivo studies using explants demonstrate 
that cotE mutants devoid of either the chitinase domain or both the chitinase and 
peroxiredoxin domains have a reduced ability to adhere to cells and that this binding 
is to the mucus layer.   
 
3.2.3 CotE mediates spore binding to mucin and enhances colonisation 
To dissect CotE’s affinity for mucus, an ELISA-based method was performed to 
examine binding of recombinant CotE protein fragments to mucin, the main 
component of mucus, as well as GlcNAc and GalNAc. GlcNAc is the repeating unit 
in chitin and is also present in mucin glycoproteins (McGuckin et al., 2011) and 
glycosylated proteins present on intestinal epithelial cells (Finne et al., 1989). 
GalNAc is the C4 epimer of GlcNAc and is found (together with GlcNAc) in mucin. 
These sugars are also components of the glycosaminoglycan side chains present on 
chondroitin sulfate proteoglycan 4, which is a potential human receptor for C. 
difficile toxin B (Yuan et al., 2015). Significantly more binding of rCotEC, 
comprising the C-terminal chitinase domain, to mucin, GlcNAc, and GalNAc was 
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observed compared to rCotEN that carried the N-terminal peroxiredoxin domain 
(Figure 3.13).  
 
Figure 3.13. Binding of CotE to mucin, GlcNAc and GalNAc. The binding of proteins 
corresponding to the N-terminal (rCotEN) and C-terminal (rCotEC) domains of CotE to mucin or 
ligands was measured by enzyme-linked immunosorbent assay (ELISA) at optical density 450 nm. 
The bars represent the OD450 of recombinant proteins at a concentration of 500 Nm. The experiment 
was performed independently three times. Error bars represent standard deviations. ***p ≤ .001 by 
the Welch unequal variance t-test.  
  
In many vegetative pathogenic bacteria, binding to mucus and mucin is a 
mechanism for attachment to the intestinal epithelium and host colonisation (Kirn 
et al., 2005; McGuckin et al., 2011). It could be speculated then that CotE enables 
C. difficile spores to interact with mucus. To address this, the ID50 of mutants in a 
murine model was determined (Table 3.1), as previously described by 
Phetcharaburanin et al. (2014). In this model, animals do not show symptoms of 
disease, and colonisation is measured by the presence of toxin and CFU (2–3 logs 
higher CFU than initial dose) in the caecum. Wild type 630 spores had an ID50 of 
101 whereas values for the cotE– (103) and cotEC– (102.3) mutants were 1–2 logs 
higher, demonstrating that CotE had a role in the ability of spores to infect and 
colonise the host. 
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Table 3.1. The 50% infectious dose of C. difficile strain 630 and mutant spores in a murine 
colonisation modela 
Strain ID50 
630 (CotE+) 101 
CotE- 103 
CotEC- 102.3 
a Mice are considered positive for CDI when caecum tests positive for toxin and CFU were 2-logs 
higher than the initial dose. The ID50 calculation was based on the Reed and Muench method (Reed 
and Muench, 1938).  
 
3.2.4 CotE facilitates the degradation of mucin 
Chitin-binding proteins in bacteria can also function as mucolytic enzymes and so 
CotE was investigated for this trait (Sanders et al., 2007; Mondal et al., 2014). The 
ChiA2 chitinase from Vibrio cholerae utilises intestinal mucin as a source of 
nutrients enabling proliferation of this pathogen and contributing to virulence 
(Mondal et al., 2014). Using a modified mucin degradation assay (Zhou et al., 
2001), it was shown that CotE facilitated the breakdown of mucin. After 48 hours 
of incubation, a zone or halo of mucin degradation was observed in amido black–
stained mucin agarose wells containing wild type spores (Figure 3.14). By contrast, 
very limited degradation was apparent in wells containing an identical number of 
spores for either of the cotE mutants. This phenotype, however, was restored in 
cotE mutant spores carrying pRPF185-CotE. Chitinases have been reported to have 
mucolytic activity and it has been suggested that low levels of proteases present in 
chitinase preparations may account for mucin degradation (Sanders et al., 2007). 
Vegetative cells of C. difficile have been shown previously to be unable to degrade 
mucin (Wilson and Perini, 1988) and this was confirmed with the wild type and 
mutant strains (data not shown).  
 
106 
 
 
Figure 3.14. Spore degradation of mucin using amido black staining. Mucin degradation assays 
for 630Δerm, cotE mutants, and complemented strains (carrying pRPF185-CotE). Spores were 
applied to wells cut in agarose containing mucin and were incubated aerobically for 48 hours at 
37°C before staining with amido black. 
 
Degradation of mucin by CotE was confirmed using fluorescently labelled mucin 
and reversed phase high-performance liquid chromatography analysis. Incubation 
of mucins with wild type C. difficile spores resulted in the appearance of a distinct 
peak, which elutes from the mildly hydrophobic stationary phase by the gradually 
increasing concentration of organic eluent (Figure 3.15). Although the original 
mucin preparation is polydisperse and does appear to have two to three distinct 
fractions under the current separation conditions, the new peak was unique to the 
wild type spores. This component is positioned ahead of the main mucin elution 
peak (under the RP mode conditions used), which may indicate reduced overall 
hydrophobicity of that component compared to the main mucin elution peak. Such 
a change could be caused by limited proteolysis or cleavage of a small part of the 
mucin glycoprotein, such as, for example less hydrophilic N or C terminal vWF or 
Cytseine-rich domains. The latter might be a mechanism used by C. difficile to 
breach the defensive mucus barrier in the gut or simply to generate a more soluble 
and digestible nutrient source. Both of these are consistent with the need to generate 
more soluble mucins and to change viscoelastic properties of mucus and are 
consistent with the presence of mucolytic activity in wild type C. difficile spores. 
The inability of the CotE- mutant to produce an equivalent increase of the less 
hydrophobic mucins indicates the absence of either proteolytic or chitinolytic 
activity on the spore surface.  
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Figure 3.15. Reversed phase HPLC analysis of mucin degradation. The distinct peak (black 
arrow) indicates the appearance of more polar components and increased solubility of mucins after 
incubation with wild type (630Δerm) spores only (red line). Treatment of mucin with pure CotE- 
spores had no such effect (green line). Untreated mucin (blue line). The red arrow represents the 
start of the gradient elution. Material detected at 220 nm. Analysis performed in collaboration with 
Dr Mikhail Soloviev, Royal Holloway University.  
 
3.2.5 The inflammatory properties of CotE 
Inflammation is a primary outcome of CDI and is assumed to result from the action 
of the toxins TcdA and TcdB. Interestingly, as mentioned earlier peroxiredoxins 
and chitinases are known to be inflammatory and might contribute to symptoms. 
This is particularly salient if one considers the rapid and exponential increase in 
spore numbers that typify CDI (Lawley et al., 2009). In vivo assessment of the 
contribution of CotE to inflammation is complicated because as noted already, 
TcdA and TcdB secreted by vegetative C. difficile cells are also inflammatory 
(Madan and Petri, 2012). Accordingly, qRT-PCR was performed to assess 
expression of the inflammatory cytokines IL-6, MIP-2α and TNF-α (Figure 3.16) 
in J774A.1 macrophages that had been incubated with rCotEN and rCotEC 
proteins. rCotEN was clearly able to induce all three cytokines at significant levels 
equivalent to lipopolysaccharide (LPS) used as a control. By contrast rCotEC 
showed no induction of IL-6 and MIP-2α and a low level of TNF-α induction. 
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Figure 3.16. In vitro cytokine induction using recombinant proteins. J774A.1 macrophages (1 x 
106) were incubated (5 hours) with different amounts of rCotEN, rCotEC and LPS. qPCR was used 
to determine levels of expression of IL-6 (A), MIP-2α (B) and TNF-α (C) compared to endogenous 
expression of the housekeeping gene HPRT. The experiment was independently performed three 
times. Error bars represent standard deviations.   
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In addition, cytokine induction in macrophages incubated (3 hours) with 630Δerm, 
CotE- or CotEC- spores was measured. Under these conditions the time period was 
too short to allow spores to germinate, grow and produce toxins. The data showed 
that spores of wild type and both mutants induced expression of all three cytokines 
but for the cotE mutants, expression was significantly reduced in all cases except 
for TNF-α expression in the CotEC- mutant (Figure 3.17). The greatest reduction 
was observed for the N-terminal cotE mutant (CotE-) that lacks both peroxiredoxin 
and chitinase domains. Interestingly, there were also significant differences in 
expression of MIP-2α and IL-6 between the cotE mutants with the CotE- mutant 
being less stimulatory. In these experiments, Histodenz-purified spores were used 
to ensure that there was no contamination with residual vegetative cells, and it was 
also confirmed that no spore germination occurred during the 3-hour incubation 
period in the culture medium alone (data not shown). This in vitro data suggests 
that C. difficile spores themselves have the potential to induce inflammatory 
responses and this can be partially attributed to the CotE peroxiredoxin domain. 
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Figure 3.17. In vitro cytokine induction using spores. J774A.1 macrophages (1 x 106) were 
incubated (3 hours) with spores of CotE+ (630Δerm), cotE- and cotEC- at a MOI of 10. qPCR was 
used to determine levels of expression of MIP-2α (A), IL-6 (B) and TNF-α (C) compared to 
endogenous expression of the housekeeping gene HPRT. The experiment was independently 
performed three times. Error bars represent standard deviations.   *p < .05, **p ≤ .01, *** p ≤ .001 
by the Welch unequal variance t-test. 
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3.2.6 The effect of CotE on virulence in hamsters 
Degradation of mucin by intestinal pathogenic bacteria has been shown to 
contribute to virulence (McGuckin et al., 2011). Accordingly, the effect of CotE on 
virulence using the hamster model of infection was investigated (Goulding et al., 
2009). In this model, the colonisation of the host can be observed from specific 
symptoms, or the presence of toxins and/or spore CFU in the caecum or faeces. 
Virulence is reflected by survival rate and/or by the time from colonisation to 
clinical endpoint (severe symptoms). In both mutants, 17% of hamsters were not 
colonised and survived until the end of the experiment (ten days) whereas with wild 
type, 100% of hamsters were colonised and eventually succumbed to infection 
(Figure 3.18A). While the time from colonisation to clinical endpoint for 630 was 
approximately six hours, with CotE– and CotEC– the time was 28 and 27 hours, 
respectively (Figure 3.18B).  
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Figure 3.18. Virulence of wild type and cotE mutant spores in hamsters. Groups of hamsters 
(n = 6) were administered clindamycin and, 16 hours later, dosed by intragastric gavage with spores 
(102) of 630, cotE–, and cotEC–. Kaplan–Meier survival (A). Time from initial symptoms (wet tail 
and/or presence of faecal toxins) to clinical endpoint (virulent phase) are shown (B). Note that one 
hamster from each mutant group was not colonised and did not show symptoms. 
 
Interestingly, among colonised hamsters (5/6), there was one hamster from each of 
the mutant groups which was positive for toxin in faeces but developed no 
symptoms and only reached clinical endpoint after approximately 90 hours (Figure 
3.18B). At 82 hours post-inoculation, 100% of hamsters infected with strain 630 
spores had reached clinical endpoint, whereas with cotE– and cotEC– only 33% and 
50%, respectively, had become moribund (Figure 3.19A–C). 
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Figure 3.19. Symptom score for 630 and cotE mutants challenge in hamsters. Symptoms in the 
hamster study of Figure 3.18 displayed according to severity. Animals dosed with wild type 630 
spores (A). CotE– spores (B). CotEC– spores (C). Light grey – healthy, dark grey – moderate 
symptoms, black – moribund.  
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Once hamsters reached clinical endpoint, caeca were checked to confirm the 
presence of toxins and C. difficile spores at roughly equivalent levels between 
groups (Figure 3.20). To rule out the possibility that the delay in symptoms and 
morbidity of hamsters could be due to a difference in toxin production, the kinetics 
of toxin production both in vitro (Figure 3.6) and in vivo were determined (Figure 
3.9) and confirmed that they were of essentially equivalent levels between all three 
strains. The germination rate of the mutant and wild type spores was also checked 
and confirmed to be the same (Figure 3.7).  
  
 
Figure 3.20. Levels of toxin A and spore CFU counts in hamster caecal samples. Hamsters were 
dosed (i.g.) with 102 spores of wild type C. difficile 630 or cotE mutants. Levels of toxin A 
(determined by ELISA) (A) and counts of ethanol resistant spores (CFU/g) (B) in caecum samples 
of infected animals were determined. The presence of functional toxins A and toxin B was also 
verified using cytotoxicity assays using HT29 (toxin A) and VERO (toxin B) cells (data not shown). 
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To investigate whether sporulation affects virulence, vegetative cells of wild type 
and a sporulation defective sigK– mutant were used to infect hamsters following the 
same dosing regimen as that used above with spores. Mutation of sigK (encoding a 
sporulation-specific sigma factor controlling spore coat biosynthesis (Haraldsen 
and Sonenshein, 2003) will affect the terminal stages of sporulation-specific gene 
expression in the mother cell chamber and, unlike spoOA, is less likely to exert 
pleiotropic effects on expression of additional virulence genes. While it took 72 
hours for all strain 630–infected hamsters to reach clinical endpoint, 168 hours was 
required for all sigK– infected animals to succumb (Figure 3.21). 
 
Figure 3.21. sigK- mutants display lower virulence in hamsters. Groups of hamsters were 
administered clindamycin and then, 16 hours later, dosed by intragastric gavage with vegetative 
cells (106) of 630 (cotE+) or JP051 (sigK-). Data represented as time from inoculation of C. difficile 
vegetative cells until time of clinical endpoint combined with ethanol-resistant spore counts from 
caecum. 
 
Since hamsters dosed with sigK– cells exhibited delayed mortality, the possibility 
of differential toxin production in vivo was ruled out by measuring toxin kinetics in 
mice (Figure 3.22). 106 vegetative cells of either the sigK- mutant or CD630 were 
dosed to mice (4/gp), faeces collected daily and tested for quantity of toxins A and 
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B. No significant differences were observed between wild type CD630 and the 
sigK- mutant. 
 
Figure 3.22. Kinetics of sigK- toxin production in mice. Using the non-fatal colonisation model 
(Holloway model) mice (4/gp) were dosed with clindamycin and then 24 hours later dosed (i.g.) 
with 106 vegetative cells of wild type 630 or an isogenic mutant (sigK-) unable to produce spores. 
Levels of toxins A (A) and B (B) were determined by ELISA from faecal samples at the times 
indicated. The presence of functional toxins A and toxin B was also verified using cytotoxicity 
assays using HT29 (toxin A) and VERO (toxin B) cells (data not shown). Error bars represent 
standard deviations.   
 
Note that in caecum samples, a low spore CFU count was found since the sigK– 
mutant being oligosporogenous was presumably able to produce a very low level 
(approximately 4-logs less spores than 630 per gram of faeces) of functional spores 
(Figure 3.21) (Pereira et al., 2013). These results suggest that (i) spores contribute 
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to the virulence of CDI, and (ii) CotE, and potentially additional spore-associated 
proteins, are involved in colonisation. 
 
3.2.7 Evaluation of GlcNAc and glucosamine in a murine model of CDI 
To further test the importance of CotE in the colonisation of the host by C. difficile, 
GlcNAc or glucosamine hydrochloride was orally administered to mice in drinking 
water (ad libitum) to determine whether they were able to prevent colonisation by 
CD630. By administering GlcNAc in drinking water, competitive inhibition of the 
CotE chitinase domain to the GlcNAc present in mucin was attempted, thereby 
preventing initial binding of the spore and subsequent colonisation. It has been 
previously shown that GlcNAc can be used to competitively inhibit the binding of 
Vibrio cholerae vegetative cells to chitin (Tarsi and Pruzzo, 1999) and of chitin 
binding protein GbpA to mucin (Bhowmick et al., 2008). Glucosamine 
hydrochloride is a supplement often used in the treatment of osteoarthritis (Gregory 
et al., 2008) of which GlcNAc is a derivative of (Tomonaga et al., 2016).   
 
From day -2 until the end of the experiment mice received sterile drinking water 
with solubilised GlcNAc or Glucosamine at concentrations of 20, 50 or 100 mg/ml 
ad libitum. Animals in the naive group received sterile drinking water only. 
Clindamycin (30 mg/kg) was dosed to mice on day -1 and they were challenged 
with CD630 (102 spores) on day 0 (Figure 3.23).  
 
Throughout the experiment the quantity of GlcNAc and glucosamine consumed 
was considerably high. All animals in the GlcNAc 50 mg/ml and 100 mg/ml group 
looked healthy throughout the experiment, but when the caecum was removed it 
was observed to be slightly swollen and of a yellow colour. 
 
At the end of the experiment the caecum was removed and analysed for Toxin A 
and B content and for ethanol resistant CFU (Figure 3.24). 
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Figure 3.23. Regimen for GlcNAc/glucosamine evaluation in a murine model. GlcNAc and 
glucosamine given at concentrations of 100, 50 and 20 mg/ml in drinking water. The caecum was 
analysed for toxins A and B and ethanol resistant CFU.   
Throughout the experiment the amount of water consumed by the mice was 
measured so as to estimate the actual amount consumed. Table 3.2 displays the 
quantities consumed and the equivalent amount for a 60 kg human. 
 
Table 3.2. Quantities of GlcNAc and glucosamine consumed during the study
 
GlcNAc
Placebo
Clindamycin
30 mg/kg o.g
102 CD630 
spores i.g.
Group
Day -2 Day 0 Day 1
End of experiment,
caecum sampling
GlcNAc, Glucosamine or drinking 
water ad libitum
Day -1
Glucosamine
Group
Daily dose
administered 
to mouse (mg)
Daily dosage 
per kg (mg)
Daily 
equivalent for 
60 kg human
(mg)
GlcNAc
20 mg/ml
60 2400 144,000
GlcNAc
50 mg/ml
140 5600 336,000
GlcNAc
100 mg/ml
250 10000 600,000
Glucosamine
20 mg/ml
84 3360 201,600
Glucosamine
50 mg/ml
140 5600 336,000
Glucosamine
100 mg/ml
100 4000 240,000
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Figure 3.24. Effect of GlcNAc and glucosamine administration on CDI. At 24 hours post CD630 
challenge mice were culled, and caecum was removed. Ethanol resistant CFU (A), levels of toxin A 
(B) and toxin B (C) were determined. 
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Interestingly, all concentrations of GlcNAc and of glucosamine showed efficacy at 
preventing CDI. Both toxin levels and CFU counts were diminished when mice 
were administered either of the two monosaccharides. The lack of CFU would 
indicate that prevention of colonisation, rather than mere toxin neutralisation had 
occurred, therefore lending support to the hypothesis that GlcNAc can act as a 
competitive inhibitor to CotE and prevent interaction with mucin and subsequent 
colonisation and infection. The concentrations and quantity consumed by the mice 
was very high and so further experiments will aim to reduce the amount required 
whilst still preventing CDI. 
 
3.3 Discussion 
This chapter provides important insights into the role of the spore in CDI: first, that 
the spore is responsible for initial colonisation by targeting and binding mucus, 
enabling the establishment of infection and, second, that the spore is an active agent 
in the acute stage of infection. Although an interaction of the spore with mucus 
might not be unexpected, this can now be attributed to at least one spore-associated 
protein, CotE, a bifunctional peroxiredoxin/chitinase that is embedded in the 
outermost layers of the spore. What is surprising is that this spore enzyme is 
functionally active and able to bind directly to mucin monomers (the glycoproteins 
GlcNAc and GalNAc) and directly or indirectly facilitates mucin degradation. 
Some chitinases are thought to degrade mucus (Sanders et al., 2007) and chitin 
binding proteins are considered colonisation factors that have been found in several 
other important pathogens including Listeria monocytogenes (Chaudhuri et al., 
2010), Legionella pneumophila (DebRoy et al., 2006), and Escherichia coli (Low 
et al., 2013). In each case, the proteins are secreted and have a direct role in 
virulence, colonisation, and infection. Vibrio cholerae is a well-studied example 
where two proteins, GbpA and ChiA2 (1 of 2 chitinases in V. cholerae), act 
synergistically to bind and degrade both chitin and mucin. GbpA is a chitin-binding 
protein that is able to recognise GlcNAc present in chitin, as well as on the surface 
of epithelial cells, enabling colonisation of host cells by V. cholerae. Meanwhile, 
Chia2 has been demonstrated to deglycosylase mucin and release nutritionally 
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available sugars such as GlcNAc, aiding in the growth and survival of V. cholerae 
vegetative cells (Kirn et al., 2005). 
 
The adhesion of intestinal pathogenic bacteria to the gastrointestinal tract is a 
crucial aspect of host colonisation as it prevents them being mechanically cleared 
(Ribet and Cossart, 2015). In the case of C. difficile, the spore is the transmissible 
entity and it has been shown here that for the successful establishment of infection, 
the spore must also adhere to the host. Interestingly, Theriot et al. (2016) 
demonstrated that, within the small intestine, spores are able to germinate 
regardless of antibiotic perturbation. It is therefore possible that spores are able to 
initiate colonisation in the small bowel in the absence of microbiota disruption and 
that an intact microbiota is required to suppress vegetative C. difficile outgrowth to 
prevent clinical disease. It was recently shown that mucosal antibodies against the 
C-terminal of toxin A also recognise the spore and vegetative cells of C. difficile 
and prevents CDI in hamsters by blocking colonisation (Hong et al., 2017). Here it 
has been shown that the spore binds to the gastrointestinal tract prior to germination 
to initiate CDI via interactions mediated by CotE. In the study shown here, animals 
(both mice and hamsters) infected with spores lacking CotE show a marked 
reduction in colonisation. It is important to consider that several adhesins may be 
responsible for initial spore attachment. In support of this, Phetcharaburanin et al. 
(2014) identified hair-like appendages comprised of the BclA1 protein that make 
“first contact” with the host mucosa. However, this study observed no differences 
between the severity of CDI caused by mutant BclA1 and wild type 630 in hamsters. 
 
Spores therefore appear able to enhance the severity of disease once initial 
colonisation has been established. This is clear from hamster studies showing that 
the time required to develop symptoms in colonised animals was markedly delayed 
in animals dosed with spores devoid of CotE. To explain this, several scenarios can 
be envisaged. One possible explanation could be that by degrading mucus, CotE 
facilitates transit of toxins to the underlying epithelial cells and so mucin 
degradation is an integral step in pathogenesis. Another possibility is that the 
severity of disease is due to the combined action of toxins and spores interacting 
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with the large number of macrophages and neutrophils produced during the acute 
stages of infection leading to the production of inflammatory cytokines (Rupnik et 
al., 2009). In support of this it has been shown, in vitro, that spores are 
inflammatory, and that this response is significantly reduced in the absence of CotE. 
Also demonstrated is that recombinant CotEN induces high levels of expression of 
the inflammatory cytokines IL-6, MIP-2α and TNF-α. The spore acting as a 
virulence factor has been shown in Bacillus anthracis where a spore surface 
superoxide dismutase enhances virulence by as much as 40-fold in a mouse model 
of anthrax (Cybulski et al., 2009). 
 
Over the past decade, a multitude of studies have been conducted to understand the 
severity of epidemic and hypervirulent 027/B1/NAP1 strains, but precise causative 
mechanisms have yet to be found and links between high sporulation rates and 
hypervirulence remain inconclusive (Akerlund et al., 2006; Burns et al., 2011). A 
direct role for the spore in acute infection has implications for the concept of 
hypervirulence, a phenomenon that so far lacks clarity. Most compelling are recent 
in vivo studies showing (i) increased persistence of hypervirulent 027 strains 
(R20291) in the gastrointestinal tract (Phetcharaburanin et al., 2014) and (ii) 
increased levels of intestinal sporulation that correlated with increased severity of 
disease (Kansau et al., 2016). Using isogenic strains, administration of cells of a 
sigK- mutant that exhibits very low levels of spores resulted in an extended period 
of infection, post-colonisation. One straightforward explanation is that increased 
spore numbers together with greater intestinal persistence exacerbate symptoms of 
CDI by CotE mediated mucin degradation and/ or inflammation. 
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   CHAPTER 4 
The Role of Allochthonous Bacillus in the Suppression of 
CDI 
 
4.1 Introduction 
Although CDI is primarily a nosocomial infection mainly affecting the elderly, 
studies have shown an increasing rate of CDI in young people and healthy 
individuals without a history of antibiotic use (Depestel and Aronoff, 2013). 
Clindamycin resistance has historically been one of the largest contributing factors 
in the development of CDI in humans and animals (Gerding, 2004). CDI rates are 
higher in developed countries such as the US and UK, although antibiotics are more 
heavily used in developing countries (Lessa et al., 2012, 2015; Gupta et al., 2014). 
Perhaps, the distribution of hypervirulent strains and variations in diets and hygiene 
contribute to this difference in rates of CDI.  
 
Faecal microbiota transplantation (FMT) has been shown highly effective in the 
treatment of recurrent CDI. A single treatment has reliably been shown to resolve 
85-90% of cases while two treatments, up to 100% (Gough et al., 2011; Costello et 
al., 2015; Drekonja et al., 2015; Khoruts and Sadowsky, 2016). The scientific 
rationale for FMT is based on two assumptions, either that patients with dysbiosis 
have lost their healthy microbiota or that the microbiota is unable to retain its 
normal functionality. Traditional FMT techniques aim to transfer a stable, viable 
and diverse microbial community contained in stool preparations from healthy 
donors. The therapeutically active agent(s) could comprise bacteria, components of 
faecal water (e.g., the virome) or potentially products of the donor’s human cells 
(Ott et al., 2017). 
 
Due to the potential long-term safety concerns of FMT (Smits et al., 2013; Petrof 
and Khoruts, 2014) there has been a shift to the use of defined mixtures of bacteria 
(bacteriotherapy) that have been derived from donor faeces. In a seminal study 
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using mice, cocktails of intestinal bacteria were isolated from the faeces of healthy 
animals that prevented the relapse of CDI in mice (Lawley et al., 2012). 
Interestingly, the intestinal microbiota of treated animals was shown to shift 
towards that of healthy animals with an increased bacterial diversity. The six 
species included obligate and facultative anaerobic species representing three of the 
four predominantly intestinal microbiota phyla (Staphylococcus warneri, 
Enterococcus hirae, Lactobacillus reuteri, Anaerostipes sp. Nov., Bacteroidetes sp. 
Nov, and Enterorhabdus sp.nov.). In the Lawley et al. (2012) study autoclaved 
faeces, faecal filtrates and individual strains failed to suppress infection leading to 
the conclusion that these bacteria displaced the C. difficile population by 
competition. However, FMT has not yet been shown to be effective when used as 
a primary CDI treatment without the use of antibiotics in conjunction. 
 
The study described above together with others using defined or mixed populations 
of faecal bacteria (Orenstein et al., 2016) suggest competitive exclusion as the 
mechanism for suppression of CDI and that the active agents emanate from the 
bacterial fraction. Therefore, it is possible that the activity might arise from one or 
more components derived from the bacteria. For example, antimicrobial 
compounds or metabolites produced by the transplanted bacteria or bacteriophages 
integrated into the bacterial genome (prophages), which are subsequently activated 
and released following transfer to the patient. With FMT, stool water together with 
bacteria is transferred to the patient and this fraction is itself rich in bacterial debris, 
proteins, antimicrobial compounds, metabolic products and oligonucleotides/DNA. 
Using just the faecal filtrate, symptoms of CDI were abolished in five patients 
exhibiting chronic-relapsing infection following nasojejunal transfer of the sterile 
filtrate (Ott et al., 2017). Symptoms were eliminated for six months post-transfer 
confirming that the sterile stool water could abolish relapsing CDI. The active agent 
present in faecal water has remained elusive and no protein candidate was 
identified. Two explanations were proposed, first, fragments of the bacterial cell 
wall or DNA that might stimulate (via pattern recognition receptors) the host 
immune system to facilitate growth of beneficial bacteria. Second, through the 
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transfer of bacteriophage virions or induction of temperate bacteriophages, that 
directly or indirectly, suppress growth of C. difficile. 
 
The human microbiota contains anywhere from 100-1000 bacterial species with 
considerable diversity between individuals (Qin et al., 2010). This population is 
dominated by strict anaerobes, so an important question has been how they transfer 
between individuals. This can now be partly explained by the remarkable finding 
that about 60% of genera found in the human GI tract are spore-forming bacteria 
representing 30% of the total intestinal microbiota (Browne et al., 2016). In this 
study spore-forming bacteria isolated from human faeces were cultured 
anaerobically then identified using analysis of the 16S rRNA. Clearly, spores 
(endospores) have the ability to survive outside of the host indefinitely so are well 
suited for transfer to other humans.  
 
Culture under anoxic conditions would preclude the isolation and identification of 
many aerobic spore formers such as members of the Bacillus genus. Standard 
metagenomics is unable to routinely detect bacteria at concentrations below 105 
bacteria/g (Lagier et al., 2012) but using a culture-based approach coupled with 
MALDI-TOF and 16S rRNA sequencing the presence of the Firmicutes and 
particularly Bacillus species has been illuminated (Lagier et al., 2012). Species of 
Bacillus are not normally considered part of the intestinal flora yet they are readily 
isolated from human samples (Fakhry et al., 2008; Hong et al., 2009; Alou et al., 
2016).  Moreover, if present in the GI tract as spores they will be refractory to DNA 
extraction methods routinely in use, so the presence of aerobic spore formers is 
likely to be underestimated. Although generally considered as soil microorganisms 
a number of Bacillus species are probably allochthonous members of the intestinal 
microbiota that are acquired from food and the environment and are thought to be 
present in human faeces at levels of ~104/g (Hong et al., 2009). In the environment 
vegetative cells of Bacillus species are commonly found associated with 
decomposing plants and the rhizosphere but in the soil they mostly exist in the 
dormant spore form (Nicholson, 2002). When ingested Bacillus spores have been 
shown able to germinate in the small intestine, proliferate and re-sporulate followed 
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by shedding in the faeces (Casula and Cutting, 2002; Tam et al., 2006; Cartman et 
al., 2008; Ghelardi et al., 2015).  Although under defined nutrient conditions some 
Bacilli can grow anaerobically (Nakano and Zuber, 1998) they are mostly 
considered as aerobes. The lower intestinal tract is typically deprived of oxygen but 
sufficient levels are present in the small intestine to permit growth of Bacillus 
species (Marteyn et al., 2011). The Bacillus genus carries a number of species that 
are thought to have beneficial properties and indeed some are used as probiotics 
(Hong et al., 2005). Bacilli are well known for the diversity of compounds they 
secrete, notably, enzymes (amylases, proteases, lipases, cellulases), short chain 
fatty acids that result from fermentation of dietary carbohydrates and antimicrobials 
and all of these can produce beneficial effects (Ilinskaya et al., 2017). Of particular 
relevance are the antimicrobials comprising peptide and lipopeptide antibiotics, 
bacteriocins and bacteriocin-like substances, some of which are non-ribosomally 
produced (Stein, 2005; Abriouel et al., 2011; Zhao et al., 2016; Ilinskaya et al., 
2017). These Bacillus antimicrobials have broad-spectrum activity against Gram-
positives, Gram-negatives as well as fungi (Abriouel et al., 2011; Ayed et al., 2015). 
 
The efficacy shown by these allochthonous bacteria in preventing infection by 
pathogens has recently been reported, where intestinal Bacillus produced fengycin 
was able to abolish colonisation in mice by Staphylococcus aureus by inhibiting 
quorum sensing (Piewngam et al., 2018). Previous studies have demonstrated that 
spores of B. subtilis administered to mice or hamsters reduce symptoms and the 
onset of C. difficile infection (CDI) (Permpoonpattana et al., 2011; Colenutt and 
Cutting, 2014; Hong, Hitri, et al., 2017). Similarly, Bacillus amyloliquefaciens has 
been shown to suppress CDI in a mouse model of infection (Geeraerts et al., 2015). 
Recent studies have focussed on the undoubtedly important role of secondary bile 
acids play in the inhibition of C. difficile spore germination and outgrowth in non-
antibiotic treated, CDI resistant organisms (Buffie et al., 2015; Koenigsknecht et 
al., 2015; Winston and Theriot, 2016). However, C. scindens, a bacterium heavily 
implicated in the possible prevention of CDI via enzymatic synthesis of C. difficile 
inhibitory deoxycholate is unable to confer full protection against CDI (Buffie et 
al., 2015). This has recently been supported by the observation that C. scindens is 
127 
 
often present in the GI tract  of CDI patients (Amrane et al., 2018). These 
observations therefore predict the involvement of other factors, in addition to bile 
salt regulatory mechanisms, to underlie the resistance displayed by health 
individuals against CDI.  
 
A hypothesis was therefore proposed, whereby Bacillus species acquired from the 
environment play a role in helping to control the proliferation of C. difficile and this 
chapter will investigate the mechanism underlying this phenomenon. This 
hypothesis is based on several observations. The high rate of asymptomatically 
colonised C. difficile in infants (reaching 75%), followed by declining levels (to 0% 
at 2 years old) with increasing age is counterintuitive, and suggests that exposure 
to the environment and therefore more C. difficile does not result in increasing 
levels in the GI tract  (Al-Jumaili et al., 1984; Yamamoto-Osaki et al., 1994; Jangi 
and Lamont, 2010; Rousseau et al., 2012). Although this could be explained by the 
development of a mature microbiota, another contributing factor could be increased 
environmental exposure allowing the introduction of Bacillus and other probiotics 
to the GI tract which are able to inhibit C. difficile colonisation. In piglets the same 
trend is observed; C. difficile colonisation is correlated with animal age, 73-100% 
of neonatal piglets were found to be positive with C. difficile but levels decline to 
0% just 2 weeks after birth (Schneeberg et al., 2013; Grześkowiak et al., 2018). 
 
We posit that a soluble substance is present in the small intestine which suppresses 
the growth of C. difficile and is produced by Bacillus. This substance has been 
implicated previously in hamsters whereby soluble factors produced by the 
microbiota suppress the growth and toxin production of C. difficile (Miezeiewski et 
al., 2015). This soluble factor may also help to explain the successful treatment of 
CDI by sterile filtrates from donor stool (Ott et al., 2017).  These studies suggest 
that soluble excretions from indigenous microbiota may contribute to resistance 
against CDI. Due to the complexity of C. difficile resistance there are likely to be 
many contributing factors. Secondary bile acids have been strongly implicated in 
the control of C. difficile germination and outgrowth in the gastrointestinal tract 
(Sorg and Sonenshein, 2008; Koenigsknecht et al., 2015; Theriot et al., 2016; 
128 
 
Winston and Theriot, 2016). The small intestine is purported to be the site for C. 
difficile germination and the large intestine the site of secondary bile acid mediated 
growth inhibition (Koenigsknecht et al., 2015). Recently it has been demonstrated 
that a diet low in microbiota-accessible carbohydrates may contribute to C. difficile 
outgrowth (Hryckowian et al., 2018). In this chapter, data will be shown suggesting 
that allochthonous bacteria are able to secrete soluble antimicrobials which are able 
to inhibit the growth of germinating C. difficile spores within the small intestine 
and the protective effects these bacteria have against CDI in vivo will be 
demonstrated.  
 
4.2 Results 
4.2.1 Isolation of bacteria from the GI tract with activity against C. difficile  
As 50-60% of the bacterial genera from the intestinal microbiota are able to produce 
resilient spores (Browne et al., 2016), both aerobic and anaerobic spore formers 
were isolated and tested for activity against C. difficile. Approximately 1000 
colonies of heat resistant aerobic and anaerobic bacteria in faeces of mice and 
hamsters were isolated prior to screening for activity against C. difficile. Manual 
isolation of colonies was considered to be the most accurate method of assessing 
the intestinal microbiota, as standard metagenomics is generally considered not able 
to detect bacteria at concentrations lower than 105 bacteria/g (Lagier et al., 2012) 
 
Ten days before the start of the experiment, C57BL/6 mice were kept in IVC cages 
with autoclaved water, UV-treated food and sterile bedding. Fresh faecal samples 
were taken before and after treatment with clindamycin. Clindamycin, administered 
by i.g. gavage, was used at a concentration (30 mg/kg) sufficient to induce CDI but 
here, the animals were not challenged with C. difficile. Homogenised faeces were 
heat-treated to kill vegetative cells and serial dilutions made on agar plates, which 
were incubated aerobically or anaerobically. Resultant colonies would arise from 
heat-resistant spores that had germinated and a total of 500 colonies from the 
aerobic or anaerobic plates were colony purified for further analysis. First, the 
number of colonies that inhibited growth of C. difficile strain 630 (CD630) were 
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determined using a microdilution assay that measured activity from a cell-free 
supernatant of the cultured bacterium (Table 4.1).  
 
Table 4.1. Intestinal spore formers pre- and post-clindamycin treatment. 
 
Source 
 
Sporesa 
Pre-clindamycin Post-clindamycin 
No. 
isolated 
No. anti-
CD 
activityb 
CFU/g 
faeces 
No. 
isolated 
No. anti-
CD 
activityb 
CFU/g 
faeces 
Mouse 
faeces 
Aerobic 
spore 
formers 
500 40 1 x 103 500 4 4.1 x 
101 
Anaerobic 
spore 
formers 
500 0 0 500 0 0 
Hamster 
faeces 
Aerobic 
spore 
formers 
100 26 3.25 x 
103 
100 11 1.38 x 
102 
Anaerobic 
spore 
formers 
100 0 0 0 0 0 
a spores isolated by aerobic or anaerobic incubation of heat-treated faeces.  
b activity against CD630 using a well-diffusion assay of sterile cell free supernatants from colony 
cultures. 
 
Surprisingly, no anaerobic isolates either before or after clindamycin treatment 
were found to be able to inhibit CD630. Similarly, no Lactobacillus (100 colonies 
picked from MRS selective agar) had activity (data not shown). On the other hand, 
1 x 103/g faeces of the aerobic, spore-forming, isolates (n = 40) carried anti-C. 
difficile activity in the extracellular material but after clindamycin treatment the 
number of isolates carrying anti-C. difficile activity had reduced to 4.1 x 101/g 
faeces (n = 4) (Table 4.1). Interestingly, Bacillus species could not be detected in 
mouse faecal samples using 16S metagenomic sequencing (data not shown). This 
could be in part due to the presence of Bacillus spores rather than vegetative cells 
or the total number of Bacillus being below the detection limit for metagenomic 
analysis (Lagier et al., 2012). 
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Figure 4.1 demonstrates the significant differences observed between number of 
colonies with activity before compared to after clindamycin treatment. Prior to 
antibiotic treatment, mice had over 1 x 103 colonies with activity against C. difficile 
per gram of faecal sample, but this number was significantly diminished after mice 
were treated with clindamycin. 
 
 
Figure 4.1. Anti-C. difficile colonies in faeces of mice before and after antibiotics. Data taken 
from Table 4.1 with one independent repeat. Error bars represent standard deviations.   
 
 
A similar study using hamsters was done and a similar phenomenon observed with 
3.25 x 103/g faeces of aerobic spore formers carrying activity against C. difficile 
and this being reduced to 1.38 x 102/g faeces post-clindamycin treatment (Table 
4.1). Figure 4.2 highlights the discrepancy between the number of colonies with 
activity against C. difficile prior to clindamycin treatment, compared with after 
antibiotic therapy.  
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Figure 4.2. Anti-C. difficile colonies in faeces of hamsters before and after antibiotics. Data 
taken from Table 4.1 with one independent repeat. Error bars represent standard deviations.   
 
 
Subsequently, the aerobic isolates that carried anti-C. difficile activity from mouse 
faecal samples were characterised. Using gyrA sequencing, which is more 
informative than 16S rRNA sequencing (Chun and Bae, 2000), it was demonstrated 
that only three Bacillus species were present, B. amyloliquefaciens (n = 22), B. 
subtilis (n = 10) and B. licheniformis (n = 12) (Table 4.2 and Figure 4.3A). Using 
an assay for biosurfactant activity, it was demonstrated that the B. 
amyloliquefaciens (n = 22) and B. subtilis (n = 10) isolates all carried biosurfactant 
activity in their cell-free supernatants (Table 4.2 and Figure 4.3B). It was also 
observed that they all formed mucoid colonies and were sensitive to clindamycin. 
However, the B. licheniformis isolates (n = 12) were all resistant to clindamycin, 
did not carry biosurfactant activity nor produce mucoid colonies.  
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Table 4.2. Phenotype of aerobic spore formers with activity against C. difficile isolated from 
mouse faecesa 
 
a from Table 4.1 
b ClinR = clindamycin resistant, ClinS, clindamycin sensitive, BS+, biosurfactant activity, BS-, no 
biosurfactant activity. Resistance to clindamycin was determined using a microdilution assay with 
resistance defined as an MIC of > 4 mg/L (EFSA, 2012). 
 
 
Figure 4.3. Anti-C. difficile and biosurfactant activity of isolated colonies.  The cell-free 
supernatants from cultures of all B. amyloliquefaciens (B.a.), B. subtilis (B.s.) and B. licheniformis 
(B.l.) strains that were isolated from mouse faeces (Table 4.1). Endpoint titres (average) against 
CD630 were determined using a microdilution assay (A) and biosurfactant activity (average) was 
determined using an oil-dispersion assay (B). Error bars represent standard deviations.   
Bacillus species Phenotypeb No. Pre-
Clindamycin
No. Post-
Clindamycin
B. amyloliquefaciens ClinR BS+ 0 0
ClinR BS- 0 0
ClinS BS+ 19 3
ClinS BS- 0 0
B. subtilis ClinR BS+ 0 0
ClinR BS- 0 0
ClinS BS+ 10 0
ClinS BS- 0 0
B. licheniformis ClinR BS+ 0 0
ClinR BS- 11 1
ClinS BS+ 0 0
ClinS BS- 0 0
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Finally, SDS-PAGE analysis of the cell free supernatants produced revealed that B. 
amyloliquefaciens and B. subtilis carried a low molecular weight species able to 
inhibit C. difficile when overlaid on the SDS-eluted acrylamide gel (Figure 4.4).  
 
  
Figure 4.4. Molecular weight of anti-C. difficile activity of Bacillus species. Samples of 
supernatants were fractionated by 20% SDS-PAGE. Strips were overlaid with 10 ml of soft BHIS 
agar (0.7% w/v) containing 1 ml of a logarithmic culture of CD630. A prominent band of inhibition 
was present in B. amyloliquefaciens (B.a) and B. subtilis (B.s) supernatants corresponding to about 
1 kDa (arrow), but not with B. licheniformis (B.l). 
 
The resultant band of inhibition demonstrated by B. amyloliquefaciens and B. 
subtilis suggests that the compound responsible is approximately 1 kDa in 
molecular weight. The absence of a band by B. licheniformis may either suggest 
that the active compound is unstable and has therefore degraded or is present in 
very low quantities. 
 
In order to show that the intestinal cohort of aerobic spore formers represents an 
allochthonous population, groups of mice were housed in either conventional cages 
or IVCs using three animals per cage. IVCs carry HEPA-filtration and prevent 
exposure of animals to airborne bacteria. Animals received sterile food and water 
together with regular changes of sterile bedding. Every ten days faeces were 
examined for the presence of aerobic bacteria including total and heat-resistant 
B.lB.sB.a
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(representing bacterial spores) CFU. As shown in Figure 4.5A, over time, the 
number of aerobic bacteria identified in faecal samples remained constant at about 
105 - 106 CFU/g. The level of spores (103 – 104/g) in faeces closely matched the 
predicted concentration in human faeces (Tam et al., 2006) (Figure 4.5B).  
 
Remarkably, for animals housed in IVCs, spore counts showed a marked temporal 
reduction and after 40 days no spores could be detected (n.b., 102 CFU is at the 
limit of detection). This decline in aerobic spore counts was not observed in mice 
housed in conventional cages implying that the aerobic population of spore formers 
were allochthonous and had been acquired from the environment. Based on this 
data, C57BL/6 mice caged in IVCs for 60 days, or in conventional cages were 
challenged with 103 spores of CD630 without prior antibiotic treatment to gauge 
whether the decrease in aerobic spore formers would diminish colonisation 
resistance and render mice susceptible to CDI (data not shown). However no signs 
of infection were observed in faecal or caecal samples (toxins or CFU) indicating 
that other factors are also most likely involved in preventing CDI in healthy mice, 
such as microbiota linked bile acid regulation (Winston and Theriot, 2016). Another 
possibility is the remaining presence of Bacillus species, but either as vegetative 
cells in the small intestine or at a level below the limits of detection. 
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Figure 4.5. Intestinal Bacilli represent an allochthonous population. Mice (n = 6) were housed 
in either conventional cages (CC) or IVCs with three animals per cage. Faeces was sampled every 
ten days and the total counts (A) or heat-resistant, spore counts (B), determined following aerobic 
incubation. The experiment was performed twice. Error bars represent standard deviations.   
 
4.2.2 Dynamics of C. difficile germination and growth in the murine 
gastrointestinal tract 
It has recently been demonstrated that upon ingestion, C. difficile spores first 
initially adhere to the mucin within the small intestine via chitinase activity present 
on the spore surface (Hong, Ferreira, et al., 2017). To colonise the GI tract these 
spores must first germinate within the small intestine. Studies have shown that 
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germination and outgrowth of C. difficile is dependent on specific primary bile 
acids, and after antibiotic perturbation of the intestinal microbiota there is an 
alteration of the bile acid profile within the small intestine which is conducive to 
both germination and growth (Sorg and Sonenshein, 2009; Giel et al., 2010). 
However more recent studies have demonstrated C. difficile spores’ ability to 
germinate in the GI tract regardless of antibiotic treatment (Koenigsknecht et al., 
2015; Theriot et al., 2016). An early study looking at the population dynamics of 
ingested C. difficile spores in hamsters also noted the occurrence of germination in 
non-antibiotic treated animals (Wilson et al., 1985). So, to confirm that germination 
occurs both in clindamycin and non-clindamycin treated mice ex vivo and in vivo 
germination experiments were conducted.  
 
Figure 4.6 shows an ex vivo germination assay performed by incubating Histodenz 
purified CD630 spores with small intestinal contents from clindamycin treated and 
non-treated mice. Samples were taken at 0, 1- and 5-hours post addition of CD630 
spores to the intestinal extracts. Germination of spores was measured by heat 
resistant CFU counts on BHISS agar plates.  
 
The data demonstrates a similar trend as reported by Koenigsknecht et al. (2015) 
and Theriot et al. (2016), with small intestine from both clindamycin treated and 
untreated mice displaying a similar germination rate. At the 5-hour time point, 
100% of the added spores had germinated in both clindamycin treated and untreated 
small intestine samples. At 1-hour post addition of spores, although approximately 
1 x 103 heat resistant spores remained, the germination was significant with a 3-log 
drop in CFU. Interestingly, it can be observed that in the small intestine of non-
antibiotic treated mice there is a significant reduction in viable, vegetative CFU at 
both 1- and 5-hours post addition of spores. This loss of viability is absent in 
clindamycin treated small intestinal contents, suggesting that a soluble compound 
within the small intestine of untreated mice is toxic to C. difficile vegetative cells. 
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Figure 4.6. C. difficile spores germinate in small intestine ex vivo regardless of antibiotic 
treatment. Ex vivo germination of CD630 spores (106 CFU/ml) in small intestinal contents (SI) of 
clindamycin and non-clindamycin treated mice measured by comparing heat resistant CFU at 1 hour 
and 5 hours incubation to the 0-hour time point. A comparison between total and heat counts (A) 
and the relative heat resistant CFU/ml, calculated in relation to the heat count at 0 hour are shown 
(B). The experiment was performed three times. Errors bars represent standard deviation.  
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To support the conclusions from the ex vivo germination experiment (Figure 4.6) 
and to validate that the same phenomenon occurs within the gastrointestinal tract in 
vivo, a germination experiment was designed using C57BL/6 mice (Figure 4.7), 
modified from Wilson et al. (1985).  
 
The results from this experiment demonstrate that ingested spores rapidly germinate 
within the small bowel of mice with and without antibiotic treatment (Figure 4.7). 
At 2 hours post challenge, the proportion of spores within the total count in the 
stomach of clindamycin treated and untreated mice remains high, 66% and 68% 
respectively. This indicates that CD630 has a relatively low rate of germination in 
the stomach of treated/untreated mice, with only 34% and 32% of spores 
undergoing germination by 2 hours post challenge. However, in the small intestine 
of clindamycin treated mice only 0.77% of the total count is comprised of spores, 
indicating a germination rate of 99%. The numbers are similar in the case of 
untreated mice, with 0.5% of spores comprising the total count and a germination 
rate of almost 100%. Like the small intestine, the large intestine has a very small 
proportion of spores comprising the total count, which can be explained by the fact 
that the spores have already germinated in the small intestine and it is principally 
the newly germinated vegetative cells which have passed down the GI tract into the 
large intestine. This has been demonstrated previously by Koenigsknecht et al. 
(2015) who added C. difficile spores to small intestinal ex vivo extracts and 
determined within 6 hours the majority of C. difficile spores germinate regardless 
of antibiotic administration.  
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Figure 4.7. C. difficile spores germinate in small intestine in vivo regardless of antibiotic 
treatment. In vivo germination of CD630 spores at 2 hours post challenge from stomach (ST), small 
intestine (SI) and large intestine (LI) contents. Mice were dosed with 107 spores, culled at selected 
time points and had intestinal contents removed and plated for CFU counts. The proportion of heat 
resistant spores (60oC, 20 min.) as a % of the total count is displayed (A), as well as the recovered 
total, and heat resistant CFU (B). The experiment was performed twice. Error bars represent standard 
deviations.   
 
So, the question would be why, if germination occurs without antibiotic use, does 
infection not occur? Studies have demonstrated that secondary bile acids play a key 
role in preventing outgrowth (Shen, 2015; Theriot et al., 2016; Winston and 
Theriot, 2016) but we posit that allochthonous Bacillus also have a role to play in 
the colonisation resistance displayed by healthy organisms against CDI. We 
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hypothesise that Bacillus secrete inhibitory compounds in the GI tract of mice 
which are able to inhibit the outgrowth of vegetative C. difficile and so help to 
prevent the onset of infection. Antibiotic therapy alters the profile of the microbiota, 
decimating the population of Bacillus (Figure 4.1 and 4.2), thereby ceasing the 
production of anti-C. difficile antimicrobials and the corresponding drop in 
colonisation resistance that can lead to the development of CDI. 
 
In order to confirm whether the production of soluble microbials by Bacillus may 
protect against CDI in vivo, first the purification, isolation and identification of the 
active substance had to be performed in vitro. This was done using a human isolate 
of B. amyloliquefaciens named SG277, which had previously been demonstrated to 
have high inhibitory activity against CD630 (see Chapter 5). The process of 
characterisation, purification, isolation and identification of this activity will be 
described in greater detail in Chapter 5. Eventually, active compounds were isolated 
using the multi-step purification method detailed in Figure 4.8.  
 
 
Figure 4.8. Purification procedure for active compounds within SG277 filtrate. SG277 was 
grown from a single colony in BHIB (37oC, 16 hours) and the culture centrifuged, sterile filtered 
(0.45 µm) and the supernatant ammonium sulphate precipitated at a final concentration of 20% (w/v, 
4oC, O/N), and resuspended at a final concentration of 30x in PBS. The resulting precipitate was 
dialysed followed by resuspension in PBS (+ 0.1% w/v SDS) and fractionated using size-exclusion 
chromatography. Active fractions were recombined, washed using a 10 kDa MWCO and loaded on 
a uBondapack Phenyl column and separated by RP-HPLC. Activity was tested against CD630 at 
every stage using a microdilution assay. Activity for the RP-HPLC separated fractions were 
measured by combining the total separation. 
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Using 20% ammonium sulphate (AmSO4), the SG277 precipitate was found to 
carry activity against C. difficile as well as biosurfactant activity. The apparent low 
molecular weight by SDS-PAGE (Figure 4.4) did not agree with the AmSO4 
precipitation since 20% AmSO4 should only precipitate high molecular weight or 
possibly hydrophobic molecules. Gel filtration of the 20% AmSO4 precipitate using 
a Superdex 200 column and the subsequent high molecular weight elution (see 
Figure 5.9) also confirmed that the active components are of higher molecular 
weight, suggesting perhaps the formation of a complex.  
 
To characterise the active components further, size-exclusion chromatography 
(SEC) and a microdilution assay were utilised to identify active fractions that were 
then analysed further by reversed phase HPLC (RP-HPLC). To isolate active 
species for later confirmation by mass spec (MS) MALDI-TOF analysis the 
preparative SEC fraction was separated on a phenyl column using a MeOH (+ 0.1% 
(v/v) acetic acid) gradient; from 65% to 95%. This column separates according to 
hydrophobicity, as MeOH concentration increases, the greater the hydrophobicity 
of the species that is eluted. MeOH is a denaturing agent and interferes with 
hydrophobic interactions thereby potentially breaking up complexes into their 
constituent monomers. Fifteen distinct fractions were obtained by RP-HPLC 
(Figure 4.9), tested for activity against CD630 and analysed by mass spectrometry.  
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Figure 4.9. RP-HPLC of preparative SG277 SEC fraction. RP-HPLC analysis of SG277 
supernatant, grown in BHIB reveals the presence of low molecular weight antibiotic chlorotetaine 
and three distinct families of lipopeptides - iturins, fengycins and surfactins. Red triangle denotes 
the injection time. Peak identification number (1-3) labelled underneath the individual peaks. 
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Different isoforms of the lipopeptides, iturin A, fengycin, surfactin and the low 
molecular weight antibiotic, chlorotetaine were identified (Figure 4.9 and Table 
4.4). In addition, evidence of three additional lipopeptides, mojavensin A (Ma et 
al., 2012), mycosubtilin and kurstakin was observed (Béchet et al., 2012) (data not 
shown). Compounds demonstrating anti-CD630 activity are shown in Table 4.3. 
Fractions comprising the same molecular identity were combined and tested. 
 
Table 4.3. Activity of SG277 RP-HPLC fractions against CD630 (from Figure 4.9) 
Compound  Anti-CD activity (dilution factor) 
Chlorotetaine 1/10 
Iturin 1/10 
Fengycin 1/20 
Surfactin 1/320 
 
 
Using the microdilution assay several fractions were found to carry anti-CD630 
activity albeit with reduced activity, active fractions being comprised of 
chlorotetaine, iturin A, fengycin and surfactin. As can be seen Table 4.3, the activity 
demonstrated by surfactin seems to suggest that it is the principal agent of this 
complex. Although the activity is well below the activity shown by the SG277 
preparative SEC fraction, this can perhaps be explained by loss of activity via 
purification and the separation of the complex resulting in monomers with less 
activity individually than as part of an agglomeration. It could suggest that these 
surfactants are forming mixed micelles of high molecular weight, explaining the 
low molecular weight when run on an SDS-PAGE gel as they break apart (Figure 
4.4), but the high molecular weight indicated by their precipitation by 20% AmSO4 
(Figure 4.8) and their high molecular weight elution using SEC. This aspect of the 
activity will be further elaborated upon experimentally in Chapter 5.  
 
RP-HPLC analysis of SG277 grown in BHIB medium (Figure 4.8) revealed the 
presence of the antibiotic chlorotetaine and three distinct groups of lipopeptides - 
iturins (C12 to C17), fengycins (C15 to C19) and surfactins (C12 to C17). The 
molecular composition of all individual fractions was confirmed by MALDI-TOF-
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MS (data not shown) and the identities from each subset of molecules were analysed 
by MALDI-TOF (Table 4.4).  
a correlating to the identities found within the surfactin, fengycin, iturin and chlorotetaine 
groupings shown in Figure 4.9. MALDI analysis performed in collaboration with Dr Mikhail 
Soloviev, Royal Holloway University. 
 
 
Bacillus endospores often integrate themselves into the human microbiota by 
exposure to the environment and consumption of vegetables (Tam et al., 2006). 
Table 4.4. MALDI-TOF analysis of active SG277 RP-HPLC peaks (from Figure 4.9) a 
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These endospores can subsequently germinate into metabolically active, vegetative 
cells (Casula and Cutting, 2002) within the small intestine and temporarily colonise 
the GI tract (Duc et al., 2004). The subsistence of Bacillus within the small intestine 
may be due to the nutrient rich environment, and the higher oxygen levels as 
compared to further down the GI tract (Albenberg et al., 2014). The small intestine 
is also the site of C. difficile germination (Wilson et al., 1985; Koenigsknecht et al., 
2015) (Figure 4.6 and 4.7) and so it would seem likely that inhibition of growth 
begins there. To determine whether the small intestine of non-clindamycin treated 
mice contain soluble compounds able to inhibit growth of C. difficile, an assay was 
developed to test the effect that soluble compounds have on the viability of newly 
germinated CD630 spores in clindamycin treated and non-clindamycin treated 
animals (Figure 4.10).  
 
Figure 4.10. Effect of small intestinal extracts on survival of germinating C. difficile spores. 
Intestinal contents were extracted in 90% (v/v) MeOH, vacuum evaporated, resuspended in saline 
and diluted in 1:1 BHIS (2% sodium taurocholate). CD630 spores were added to a concentration of 
1 x 106/ml, and aliquots taken for enumeration on BHISS agar at each time point. Heat counts (60oC, 
20 min.) were performed at each time point to ensure germination had taken place (data not shown). 
SG277 supernatant was used as a positive control for the assay. The experiment was performed 
twice. Error bars represent standard deviations.   
 
Only SG277 supernatant, and the small intestinal contents from non-clindamycin 
treated mice showed an inhibitory effect upon C. difficile vegetative cells. Together 
these results demonstrate that ingested spores rapidly germinate within the small 
bowel of mice with and without antibiotic treatment but are killed only in non-
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clindamycin treated intestinal samples. This may be explained by increased levels 
of bile salts in untreated sample, such as muricholate and its derivatives which have 
been shown to have an inhibitory effect upon C. difficile growth (Francis, Allen and 
Sorg, 2013) and to decrease in the ileum upon antibiotic administration (Theriot et 
al., 2016). However, was it also possible that Bacillus secreting anti-C. difficile 
iturin/surfactin/fengycin also contribute to this ‘killing’ effect? 
 
To determine whether Bacillus may be contributing to the data observed in Figure 
4.10, and therefore colonisation resistance against C. difficile an extraction 
procedure was performed to see if the lipopeptides could be identified within the 
gastrointestinal tract of mice and whether they exhibit any activity. The extraction 
procedure involved passing the intestinal content extraction through a Sep-Pak C18 
column at a concentration of 20% MeOH to remove the most hydrophilic of 
molecules, reducing background and further purifying the sample so as to be able 
to separate it via RP-HPLC (Figure 4.11). 
 
A single injection into the uBondapack Phenyl column consisted of extract from 
0.5 g of intestinal content. Additional sample, again from 0.5 g originally was 
resuspended in 50 μl of saline and tested for activity against CD630 in a 
microdilution assay to give the ‘total extract activity’, shown in Figure 4.11. All 
individual peaks were analysed by MALDI-TOF, and in the untreated sample only, 
several peaks of iturin, fengycin and surfactin were identified; no lipopeptides could 
be detected in the intestinal extract from clindamycin treated mice. Regions 
corresponding to the lipopeptide locations were combined, evaporated, resuspended 
in 50 μl saline and tested for activity against CD630 in a microdilution assay. 
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Figure 4.11. RP-HPLC of small intestine from untreated vs clindamycin treated mice. The blue 
trace represents small intestinal extract from untreated mice, and the grey dotted trace small 
intestinal extract from clindamycin treated mice. The presence of lipopeptides iturin, fengycin and 
surfactin were detected using MALDI-TOF analysis only in untreated mice and the locations and 
isoforms are highlighted. A variety of secondary bile acids have been separated using the same 
conditions (data not shown), and the area in which they elute is highlighted in grey. Fractions were 
combined within the regions designated by the 3 blue lines at the top of the diagram, named 1, 2 and 
3, evaporated, resuspended in saline and tested for activity against CD630 in a microdilution assay. 
Total extract prior to separation was also tested. 
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Interestingly, the activity within region 1 is identical for both clindamycin and non-
clindamycin treated intestinal content. This would represent the most hydrophilic 
and polar constituents of the extract. However, activity between the samples differs 
for both region 2 and 3, with the clindamycin sample having an endpoint titre of 
1/10 for both and the non-clindamycin treated sample having an endpoint titre of 
1/20. Region 2 likely includes secondary bile salts, and as can be seen in the 
chromatogram there are a set of peaks designated by the grey line in the non-
clindamycin treated sample which may confirm the presence of bile salts, and 
perhaps explain the difference in activity. Four secondary bile salts, all shown to be 
inhibitory to C. difficile were found to elute in this area; ursodeoxycholate, 
hyodeoxycholate, lithodeoxycholate and deoxycholate (data not shown). Region 3 
however, contains only fengycin and surfactin in the non-clindamycin treated 
sample and the activity was twice that of the treated sample, an end point titre of 
1/20 and 1/10 respectively. The total activity prior to separation for non-
clindamycin treated sample is also twice that of treated sample, 1/80 to 1/40 
respectively. This data suggests a correlation between the presence of lipopeptides 
in the small intestine and an observed ex vivo inhibitory effect upon C. difficile; the 
difference in activity between clindamycin treated and untreated mice seemingly 
being in part due to the presence of Bacillus lipopeptides in the latter, although 
interference by additional factors (e.g. secondary bile salts) cannot be completely 
ruled out. 
 
4.2.3 Inhibition of CDI in vivo 
To determine whether in vitro activity to C. difficile could translate to inhibition in 
vivo, two groups of mice were dosed (intragastric, i.g.) with suspensions of bacteria 
isolated from the pre-clindamycin faecal samples (Table 4.1). Group 1 were dosed 
with a mixture of three Bacillus species (B. amyloliquefaciens, B. subtilis and B. 
licheniformis) that showed activity against C. difficile while Group 2 were dosed 
with three Bacillus isolates that showed no in vitro activity against C. difficile. 
Animals were first dosed (i.g.) with clindamycin and then, before and after 
challenge, they were dosed (i.g.) with the different bacterial mixtures (Figure 4.12). 
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Figure 4.12. Dosing regimen for testing inhibition of CDI in C57BL/6 mice. Mice were dosed 
first with clindamycin (i.g.; 30 mg/kg) and then given five doses of the bacterial suspensions. After 
the second dose mice were challenged with 102 spores of C. difficile strain 630. Caecum was 
collected at 24 hours post challenge for toxin and CFU analysis. 
 
All animals in the ‘positive cocktail’ group showed no evidence of CDI as 
demonstrated by the absence of toxin A (Figure 4.13A) and C. difficile CFU (Figure 
4.13B) in caecum samples. By contrast, animals dosed with Bacilli showing no in 
vitro activity against C. difficile exhibited clear signs of C. difficile colonisation 
(high levels of toxin A and C. difficile CFU), equivalent to naïve mice.  
 
 
Figure 4.13. Mouse-derived Bacillus species prevent colonisation of C. difficile. Groups of mice 
(n = 4) were dosed (intra-gastric) with suspensions of Bacillus isolated from the mouse GI tract 
(Table 4.1). Group 1 mice comprised three isolates that had inhibitory activity against C. difficile 
while Group 2 contained three isolates that had no activity. For each group the oral dose comprised 
a total of 3 x 109 bacteria consisting of 1 x 109 bacteria from each isolate tested. A third group 
consisted of naïve animals dosed only with PBS. 24 hours post challenge all animals were sacrificed 
and levels of toxin A (A) and C. difficile CFU (B) was determined in caecum samples. 
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Mouse and hamster models were used to test whether a B. amyloliquefaciens strain 
on its own, SG277, could provide protection against CDI. A number of different 
administrations were considered, first; use of the sterile, cell-free supernatant, 
second, a suspension of spores, and finally a suspension of a SG277 culture washed 
and either suspended in PBS or suspended in the supernatant. For the latter 
approach, overnight cultures of SG277 were used that were found to contain a 
mixture of vegetative cells and spores (70-100% spores, data not shown). For 
evaluation in mice a model of CDI was used where two attributes are used to define 
colonisation, the presence of toxins and C. difficile (CFU) in the caecum (Hong, 
Ferreira, et al., 2017; Hong, Hitri, et al., 2017). Animals were dosed with the four 
different SG277 preparations using the regimen shown in Figure 4.12. As well as a 
naïve group, a group dosed with B. amyloliquefaciens SG378 cells (suspended in 
their supernatant) that did not show any in vitro inhibition to C. difficile was also 
included. The level of C. difficile caecum CFU and the toxins A and B (Figure 4.14) 
showed that five doses of SG277 supernatant or a cell suspension suspended in 
either PBS or supernatant prevented colonisation of CD630 as shown by the 
absence of bacterial CFU and toxins A and B in the caecum.  
 
Use of the sterile supernatant achieved almost complete arrest of colonisation with 
only one mouse having low levels of C. difficile CFU and toxins in the caecum. 
Surprisingly, SG277 spores showed no effect on C. difficile colonisation and were 
similar to SG378 and the naïve group. Overnight culture of SG277 showed 
equivalent efficacy in preventing colonisation and toxin production regardless of 
whether the pellet was resuspended in PBS or supernatant prior to dosing. 
 
 
 
 
 
 
 
 
151 
 
 
 
Figure 4.14. Prevention of C. difficile colonisation in mice. Groups of mice (n = 10) were dosed (i.g.) five 
times with different prophylactic treatments using a schedule as shown in Figure 4.12. 24 hours after challenge 
of clindamycin-treated mice with 102 spores of CD630, caecum samples were taken for analysis of C. difficile 
CFU (A) and toxins A (B) and B (C). Treatments were: 277-SUP, SG277 overnight culture suspended in 
supernatant; 277-PBS, SG277 overnight culture suspended in PBS, SUP, sterile cell-free supernatant of SG277 
grown overnight; Spores, purified spores of SG277; 378-SUP, overnight culture of SG378 suspended in their 
sterile cell-free supernatant; naïve, animals received PBS buffer. 
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Hamsters are considered a ‘gold-standard’ for evaluation of CDI (Sambol et al., 
2001). Hamsters were used to evaluate the ability of the same SG277 treatments 
described above to prevent CDI in mice. The dosing strategy involved multiple 
doses of each treatment (Figure 4.15) using groups of six hamsters per treatment.  
 
 
Figure 4.15. Dosing regimen for testing inhibition of CDI in Golden Syrian hamsters. Hamsters 
were dosed first with clindamycin (i.g.; 30mg/kg) and then were given six doses before CD630 
challenge and then three-times/day post-challenge for 12 days. Animals were monitored for 
symptoms of disease progression and culled upon reaching the clinical endpoint. Caeca were 
removed and analysed for EtOH resistant CD630 CFU and toxins A and B. 
 
SG277 cells suspended in supernatant provided 100% protection to a lethal 
challenge with CD630 (Figure 4.16). SG277 cells suspended in PBS produced 
somewhat lower levels of protection (5/6 hamsters protected) and the sterile 
supernatant conferred only 30% protection and within the spores group only one 
animal was protected. Naïve animals and animals dosed with SG378 cells showed 
no protection. 
 
Together with the mouse data this demonstrates that a suspension of SG277 cells 
(comprising vegetative cells and spores) suspended in their supernatant or in buffer 
prevents C. difficile colonisation. Two further points can be made; first, that spores 
have limited efficacy for which it could be assumed that insufficient numbers of 
spores can germinate in the GI tract to secrete the active compounds. Second, 
despite the in vitro data the cell-free supernatant was not as effective as when 
combined with cells. This could be due to the active compounds remaining partially 
attached to the cell envelope with the cells acting as a delivery system, and it is 
possible that cells transiently proliferate in the GI tract, further boosting the levels 
of the active compounds. In data not shown it has been found that SG277 
administered to mice as a single dose persists (as determined by faecal shedding) 
for up to 10 days post-dosing. 
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Figure 4.16. Prevention of C. difficile colonisation in Golden Syrian hamsters. Groups of 
hamsters (n = 6) were dosed (i.g.) with different prophylactic treatments before and after challenge 
with 102 spores of CD630 (Figure 4.15). Treatments were: 277-SUP, SG277 overnight culture 
suspended in supernatant; 277-PBS, SG277 overnight culture suspended in PBS, SUP, sterile cell-
free supernatant of SG277 grown overnight; Spores, purified spores of SG277; 378-SUP, overnight 
culture of SG378 suspended in their sterile cell-free supernatant; naïve, animals received PBS buffer. 
CD630 challenge was made 3 days after clindamycin treatment (i.g.) after which animals were 
monitored for symptoms. Animals showing symptoms were sacrificed and Kaplan-Meier survival 
curves are shown (A). Colonisation was determined by analysis of CD630 CFU (B) and toxins (C) 
in caecum samples. One hamster from the SG378 was excluded form the experiment for technical 
reasons. 
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To further examine the efficacy of SG277 in the prevention of CDI, an experiment 
was performed using lyophilised SG277 O/N culture and purified SG277 
preparative SEC fraction (Figure 4.8). The lyophilisation of treatment products is a 
convenient method for storage and transportation allowing for easier treatment of 
CDI. Meanwhile, treatment with the SEC fraction would build on the protection 
data gathered for the SG277 supernatant and narrow down the mode of action in 
the prevention of CDI to the active compounds produced by B. amyloliquefaciens. 
Using the regimen displayed in Figure 4.12, mice were administered the various 
SG277 preparations, sacrificed at 24 hours and caeca samples were tested for CFU 
and toxins (Figure 4.17). 
 
Administration of ~5 x 109 CFU of freeze-dried cells/spores of B. 
amyloliquefaciens strain SG277 was efficient at suppressing CDI in a murine 
model. No toxin A or toxin B was detected in the caeca of mice infected by CD630 
24 hours post challenge using the Holloway model of C. difficile colonisation. 
Bacteria remain viable after the lyophilisation process and they retain their 
antimicrobial activity (data not shown). The administration of SG277 preparative 
SEC fraction (as described in Section 4.2.2 and Figure 4.8) significantly decreased 
toxins levels in caeca when compared to the naïve group. In 3/8 samples toxins 
were not detected, and in the case of spore counts 2/8 mice showed no evidence of 
colonisation. Interestingly, SEC was not as efficacious in the prevention of CDI as 
the SG277 supernatant although the theoretical concentration and activity of active 
compounds is much higher in the SEC sample (1/1280 vs 1/160). This could 
possibly be explained by a difference of buffering capacity between the two 
solutions, supernatant being in the high protein solution BHIB while the SEC 
fraction was dissolved in water. Further optimisation of the dosing regime, and the 
type of delivery vehicle is required for SG277 preparative SEC fraction.  
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Figure 4.17. Prevention of C. difficile colonisation by preparative SG277 SEC fraction and 
lyophilised material. Groups of mice (n = 8) were dosed (i.g.) five times with different prophylactic 
treatments using a schedule as shown in Figure 4.12. 24 hours after challenge of clindamycin-treated 
mice with 102 spores of CD630, caecum samples were taken for analysis of C. difficile CFU (A) and 
toxins A (B) and B (C). Treatments were: 277-SUP, SG277 overnight culture suspended in 
supernatant; 277-PBS, SG277 overnight culture suspended in PBS, SUP, sterile cell-free supernatant 
of SG277 grown overnight; Spores, purified spores of SG277; 378-SUP, overnight culture of SG378 
suspended in their sterile cell-free supernatant; naïve, animals received PBS buffer. Treatments 
were: 277-PBS, SG277 overnight culture suspended in PBS, 277-FD, SG277 overnight culture 
freeze-dried/lyophilised and suspended in PBS, SUP, sterile cell-free supernatant of SG277 grown 
overnight; SEC, preparative SEC fraction- Superdex 200 purified SG277 supernatant (see Section 
4.2.2 ), naïve, animals received PBS buffer. 
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4.3 Discussion 
Targeted restoration of the gut microbiota has proven efficacious for treatment of 
CDI but the mechanism of action has remained elusive and might include 
rebalancing the gut microbiota, competitive exclusion and the contribution of 
predatory bacteriophages (Lawley et al., 2012; Orenstein et al., 2016). It is shown 
here that these methods appear to have overlooked the contribution of aerobic 
spore-formers for control of CDI. There are several reasons for this. First, methods 
have employed sequence or metagenomic-based methods to identify candidates for 
bacteriotherapy, which have been shown unable to detect bacteria at concentrations 
below 105 bacteria/g (Lagier et al., 2012). Second, a focus on anaerobic bacteria 
and the assumption that minority bacterial populations are unlikely to play a 
predominant role in the control of intestinal infections. The integral role played by 
anaerobes has been further supported by recent work which looked at the 7α-
dehydroxylation activity certain groups of anaerobic bacteria display, for example 
C. scindens (Buffie et al., 2015). The 7α-dehydroxylation activity demonstrated by 
subsets of the intestinal microbiota provides a strong mechanism in which the 
removal of the 7α-dehydroxyl group of primary bile acids results in the formation 
of C. difficile toxic secondary bile acids, thereby providing colonisation resistance 
against CDI in healthy people (Giel et al., 2010). The administration of antibiotics 
perturbs this mechanism and results in the decrease of these secondary bile acids 
and a subsequent decrease in colonisation resistance against CDI.  
 
By contrast, the approach described here has focussed on traditional 
microbiological methods for identification of bacteria with functional activity, 
coupled with a focus on aerobic spore-forming bacteria. Using C. difficile as a 
model gastrointestinal pathogen, the cohort of aerobic spore-formers from this work 
are Bacillus species and of course these would ordinarily be mostly undetectable 
using standard metagenomic or sequence-based approaches (Lagier et al., 2012). 
These bacteria constitute an allochthonous population that implies our exposure to 
aerobic spore formers plays an important role in controlling CDI. It is possible that 
this same cohort of aerobic spore-formers might also play a role in controlling other 
intestinal infections in both humans and animals and this is an area worthy of future 
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exploration. Rates of CDI are highest in industrialised countries, most notably the 
USA followed by the UK (Bauer et al., 2011; Lessa et al., 2015) and it could be 
argued then that the increase in processed food and decreased exposure to 
environmental bacteria might be an important factor in why rates are so high in 
these countries. The hygiene hypothesis attempts to link changes in lifestyle in 
industrialised countries that have produced a decrease in infectious disease with a 
concurrent rise in allergic and autoimmune disease (Strachan, 1989; Kelly et al., 
2007; López-Serrano et al., 2010). It could therefore be speculated that, broadly, 
the same phenomenon may be a contributing factor underlying the high rates of 
CDI observed in the USA and UK (Lessa et al., 2012, 2015; Gupta et al., 2014). 
Decreased exposure to environmental microbes through for example, diet and 
increased hygiene standards, might be expected to lower our exposure to Bacilli 
and may, in part, account for the increased rates of CDI. As noted by others the root 
cause is likely to be multifactorial (Bloomfield and Riley, 2016) but the 
contribution of exposure to environmental microbes and particularly aerobic 
microbes has, hitherto, been unnoticed. Although the lack of thorough or proper 
diagnosis may partly explain the low incidence rates of CDI in developing 
countries, it is intriguing that these are the same countries that have a record of 
abuse and overuse of antibiotics (Ayukekbong et al., 2017). It is also interesting 
that CDI is now beginning to emerge in many developing countries in parallel with 
improved living standards, hygiene and nutrition (Collins et al., 2013; Burke and 
Lamont, 2014). It could therefore be suspected that exposure to environmental 
bacteria plays a contributing role in controlling CDI and perhaps also in other 
gastrointestinal diseases.  
 
The ability of Bacillus species, including B. amyloliquefaciens and B. subtilis, to 
produce antimicrobials is well known and the non-ribosomally produced, cyclic 
anionic, lipopeptides (iturins and surfactins and fengycins) are considered 
particularly powerful biosurfactants (Duitman et al., 1999; Deleu et al., 2008; Xu 
et al., 2014; Mnif and Ghribi, 2015; Zhi et al., 2017).  A number of these are used 
commercially as anti-fungal agents for the control of plant disease (Klich et al., 
1994; Yoshida et al., 2001; Kim et al., 2004; Romero et al., 2007). It is shown here 
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that the functional antibiotic produced by B. amyloliquefaciens and B. subtilis is a 
water-soluble complex that comprises different isoforms of iturin A, surfactin, 
mycosubtilin, chlorotetaine, fengycin A and B and potentially others.  This 
antibiotic is therefore an antimicrobial lipopeptide (AMLP) and is particularly 
unusual because it comprises a mixture of different anionic biosurfactants. It has 
been shown that when combined the apparent molecular weight of the active 
fraction is higher than that of the individual monomers indicating that micelles are 
formed, a characteristic of many biosurfactants (Cui et al., 2008). AMLP micelles 
have been shown to aggregate into nanostructures, are more stable and resistant to 
degradation, have enhanced solubility and carry a higher antimicrobial activity than 
the monomeric form (Makovitzki et al., 2008; Horn et al., 2012, 2013). These 
characteristics will be further explored in the subsequent chapter. It could be 
surmised then, that this antibiotic is most likely a mixture of different AMLPs that 
in some B. amyloliquefaciens strains is produced in sufficient concentrations to 
form micelles.  
 
In Figure 4.10 and 4.11, a link between the presence of lipopeptides in the small 
intestine and the ex vivo exhibition of activity against C. difficile is demonstrated. 
This implies a mechanism for CDI resistance in healthy mice, the presence of 
lipopeptides aides in the suppression of C. difficile growth following spore 
germination. The activity demonstrated by the small intestinal extract from 
untreated mice differs from previous findings: Koenigsknecht et al. (2015) and 
Theriot, Bowman and Young (2016) both showed that following C. difficile spore 
germination, growth was supported in the small intestine of untreated mice. There 
could be several reasons for this divergence in the data; both of the mentioned 
publications diluted the intestinal extract 1:1 in PBS (w/v), centrifuged and then 
added spores and proceeded to use a single 6 hour time point to measure the change 
in CFU. In this study’s method however, a more rigorous extraction procedure 
(90% MeOH) was used and CFU was measured over a shorter time frame (1, 2 and 
3 hours). The use of an organic solvent in our extraction method may therefore be 
more effective at removing surface associated hydrophobic compounds, including 
some bile salts and lipopeptides. The passage of C. difficile through the small 
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intestine is 1-2 hours (Figure 4.7) and our data suggests that in this time frame there 
are compounds which would inhibit vegetative cell outgrowth, but it is possible that 
if left for a longer period of time (6 hours) that recovery and subsequent growth 
would occur.  
 
It has been previously reported that surfactins can act synergistically with iturins 
(Razafindralambo et al., 2002) and mycosubtilin (Jauregi et al., 2013) and 
considering the elution of the complex occurs in the same high molecular weight 
fractions after Superdex 200 SEC separation, it is likely that mixed micelles are 
being formed. The presence of surfactins, fengycin and iturin in the small intestine 
of healthy mice was confirmed and their ability to form mixed micelles may provide 
a link between their inhibitory action and that of secondary bile acids. Bile acids 
function in the GI tract by forming mixed micelles which increase the uptake of 
cholesterol and fatty acid. Although to date there have been no studies describing 
mixed micelles forming between bile acids and bacterial lipopeptides, bile acids 
have been shown to form mixed micelles with other anionic surfactants (Poša and 
Ćirin, 2012; Faustino et al., 2014; Jójárt et al., 2014). This may suggest a 
mechanism by which bacterially produced lipopeptides combine with inhibitory 
secondary bile acids in mixed micellar complexes within the GI tract of healthy 
hosts to provide colonisation resistance against CDI via direct antimicrobial action 
against the vegetative cells. The interaction of iturin A with surfactin in mixed 
micelles has been previously shown to enhance the lytic activity against erythrocyte 
membranes (Thimon et al., 1992). Furthermore, the increased presence of agents 
capable of forming micelles in the GI tract is likely to increase the chance of micelle 
formation; it being a concentration dependent phenomena, and it has been 
established that the micelle in solution is better than the corresponding monomers 
at membrane binding, while also showing preferential selectivity towards bacterial, 
rather than mammalian membranes (Lin and Grossfield, 2014, 2015; Bereau, 2015). 
By forming micelles, monomers increase their relative solubility thereby allowing 
for an increased concentration of compound per unit volume.   
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This chapter presents data showing that either a cocktail of Bacillus strains or a B. 
amyloliquefaciens strain alone, SG277, can be used as a probiotic in vivo to control 
CDI. Interestingly, using the active filtrate or the purified SEC fraction also confers 
protection against CDI, although not to the same degree. Using probiotics based on 
their antibacterial activity against CDI is fairly novel, and to our knowledge only 
shown before by Geeraerts et al. (2015). CDI was induced in all naïve groups 
successfully and was measured by toxin ELISA and EtOH resistant CFU counting 
in caecum samples. SG277 was administered 4 hours prior to challenge for mice, 
and 48 hours prior for hamsters to enable the bacteria to colonise the gut and start 
producing lipopeptides. When SG277 was administered at 5 x 109 cells/dose 
according to the regimen shown in Figures 4.12 and 4.15, full protection was seen 
in a mouse model with no toxins or CFU observed. The absence of C. difficile 
spores suggests that SG277 works by inhibiting C. difficile directly, and therefore 
toxin production. In hamsters, 83% survived when dosed with SG277 resuspended 
in PBS, and 100% when dosed with SG277 resuspended in supernatant. This may 
reflect the additional antimicrobial activity provided by the supernatant. Although 
some toxins and CFU are observed in non-moribund hamsters (3 out of 12), the 
levels are relatively low (symptoms were minor) and may be transitory, as due to 
hamster’s sensitivity to C. difficile toxins a sustained, high level would certainly 
lead to death. Perhaps if the experiment had been elongated longer than the 12 days 
they would have succumbed to infection.  
 
It has been proposed that only multistrain probiotics will be efficacious in the 
prevention of CDI (Hell et al., 2013), but our data suggests a single strain of B. 
amyloliquefaciens is sufficient for near complete protection. The secretion of a 
lipopeptide complex with high antibacterial activity against C. difficile is seemingly 
the mechanism behind the protection. The effect of these compounds on the 
microbiota is yet to be investigated but could be an interesting avenue for future 
research. The effectiveness of SG277 as a probiotic suggests that it can survive 
clindamycin administration and colonise the gut, despite its sensitivity to the 
antibiotic. This could be due to the high proportion of spores within the dose, the 
number of doses and the diminishing levels of clindamycin within the host post 
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administration. This has been shown before with other bacterial species, including 
Lactobacillus casei, which has been shown to reduce the incident rate of AAD and 
CDI when taken in conjunction with antibiotic therapy (Hickson et al., 2007; Wong 
et al., 2014). In conclusion, it has been shown that the administration of SG277 as 
a probiotic is effective, however further work, perhaps investigating the potential 
of the strain to be used as a treatment for CDI, or for CDI relapse is required.  
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CHAPTER 5 
Purification, Identification and Characterisation of 
Bacillus Antimicrobial Activity 
 
5.1 Introduction 
The intestinal microbiota is integral to the health of the gut, largely due to the 
protection provided by individual species against pathogens. Disruption of this 
complex, diverse ecosystem can leave the host susceptible to a wide range of 
gastrointestinal infections. The administration of antibiotics perturbs the intestinal 
flora and approximately 25% of recipients develop AAD (Bartlett, 1992) of which 
C. difficile accounts for 15 – 25% of these. It is the dysbiosis of the healthy gut 
microbiota by antibiotics that triggers CDI. The standard treatment for CDI is a 
cessation of antibiotic use, and if that is not effective metronidazole or vancomycin 
are employed. However, the use of antibiotics to treat an illness initially caused by 
antibiotics is contradictory and somewhat ineffective, with relapse rates as high as 
30% (Cole and Stahl, 2015). There is therefore an urgent need to develop 
alternative, effective measures for controlling CDI; measures that do not further 
disrupt the microbiota. Probiotics meet these requirements, by repopulating the gut 
with microorganisms capable of protecting the host from pathogens, either by 
activation of the immune system, competition for space/nutrients or by the secretion 
of antimicrobial compounds. Lactobacillus rhamnosus GG and Saccharomyces 
boulardii have both been shown to be partially effective in treating AAD (Siitonen 
et al., 1990; Armuzzi et al., 2001; Kotowska et al., 2005; Can et al., 2006). 
However, both have had mixed results in the treatment of CDAD and the data thus 
far is not sufficient to merit any specific recommendations of using these bacteria 
as treatments. 
 
Bacillus is a genus of Gram-positive, spore-forming bacteria which are often used 
in probiotic products. Bacillus probiotics have been found to be effective in the 
prevention of AAD, but the core underlying mechanisms have yet to be identified 
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(Hempel et al., 2012). Many Bacillus species are able to produce abundant amounts 
of diverse biologically active compounds (Ongena and Jacques, 2008; Ilinskaya et 
al., 2017). Bacillus is known to produce a wide range of antimicrobial substances, 
including cell wall lytic enzymes, exoenzymes, bacteriocins, RNA-degrading 
enzymes and lipopeptides (Korenblum et al., 2005; Stein, 2005; Abriouel et al., 
2011). These compounds can either have a broad spectrum of activity, or specific 
activity against closely related species (Jack et al., 1995). Due to the emerging 
antibiotic resistance of pathogens, discovery, identification, purification, 
characterisation and development of alternative antimicrobial compounds is 
necessary. 
 
Bacillus, specifically B. subtilis, B. cereus, B. licheniformis, and B. 
amyloliquefaciens are major producers of non-ribosomally generated amphipathic 
lipopeptide antibiotics. Bacillus lipopeptides are synthesised by large, multi-
enzyme, non-ribosomal peptide synthetases (NRPs), resulting in exceptional 
uniformity and heterogeneity of amino acid sequences, length/branching of the fatty 
acid chain and peptide cyclisation amongst the lipopeptides (Ongena and Jacques, 
2008). The lipopeptides so far identified fall into one of three main groups; iturins, 
fengycins or surfactins (Yang et al., 2015). Iturins are cyclic heptapeptides with 
tails comprised of C14-C17 β-amino fatty acids. Fengycins are cyclic decapeptides 
formed by lactonization, with β-hydroxy fatty acid chains of 14-17 carbons in 
length. Fengycin has antifungal activity against filamentous fungi (Meena and 
Kanwar, 2015). Surfactins are cyclic, heptapeptide lactone rings comprising C13-
C16 β-hydroxy fatty acid chains. Lipopeptides are formed as families of closely 
related isoforms, with differences in the length and fatty acid side chain branching 
defining isoforms. Due to the amphipathic nature of lipopeptides, lipid bilayer 
membranes can be disrupted through the formation of pore and ion channels, 
thereby providing a reduced likelihood of resistance emerging when compared to 
antibiotics (Inès and Dhouha, 2015). Lipopeptides tend to have low toxicity and 
higher stability in terms of pH, temperature, enzymes and salinity, making them 
attractive options as antimicrobial agents (Banat et al., 2000). The function and 
biological activity of lipopeptides is dependent on the amino-acid peptide sequence, 
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length/branching of the fatty acid chain and cyclisation of the peptide (Zhao et al., 
2018). Lipopeptides display a wide range of useful properties, including but not 
limited to anti-viral, anti-bacterial, anti-fungal, anti-inflammatory and anti-cancer 
activities. These properties make them commercially attractive in the agricultural, 
food and pharmaceutical industries. The majority of Bacillus species can produce 
at least one type of lipopeptide, with some producing two or three types (Chen et 
al., 2017; Toral et al., 2018).  
 
In the preceding chapter, data was presented indicating that allochthonous Bacillus 
species can secrete soluble antimicrobials that i) inhibit the growth of germinating 
C. difficile spores within the small intestine and ii) have inhibitory activity against 
C. difficile in vivo. This chapter will report on the steps taken to identify these 
molecules, evaluate and postulate on their mechanism of action. 
 
5.2 Results 
5.2.1 Screening of Bacillus isolates and identification of activity  
Our laboratory has a large number of Bacillus isolates from various sources. 
Bacillus isolated from humans faeces has previously been characterised by our 
laboratory (Hong et al., 2009). Using an agar well-diffusion assay (Figure 5.1), 
isolates were screened for extracellular activity against C. difficile strain CD630 
present in filtered (0.45 m) supernatants. A total of 166 strains from the Bacillus 
genera were screened for activity against C. difficile CD630 using the agar well-
diffusion assay.  Of 166 strains, 80 belonged to B. subtilis, 20 to B. megaterium, 6 
to B. licheniformis 40 to B. pumilus and 20 to B. amyloliquefaciens. Of the strains 
screened, only those of B. subtilis (27/80), B. licheniformis (3/6) and B. 
amyloliquefaciens (17/20) showed activity against C. difficile. B. amyloliquefaciens 
strains showed the highest level of activity, with B. subtilis and B. licheniformis 
demonstrating comparatively lower levels of activity. Examples of activity against 
C. difficile strain 630 (CD630) obtained in representative Bacillus strains is shown 
in Table 5.1. 
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Table 5.1. Anti-CD630 activity of human Bacillus isolates using a well-diffusion assay a 
Strainb Species Diameter of zone of 
inhibition (mm) 
PY79 subtilis 0 
SG140 subtilis 10 ± 1.11 
SG83 subtilis 10 ± 0.89 
10A1 amyloliquefaciens 0 
SG57 amyloliquefaciens 22 ± 2.00 
SG137 amyloliquefaciens 22 ± 1.00 
SG185 amyloliquefaciens 23 ± 0.58 
SG277 amyloliquefaciens 27 ± 1.73 
SG297 amyloliquefaciens 27 ± 2.65 
a ± Standard deviation 
b PY79 is a B. subtilis control strain and 10A1 is a B. amyloliquefaciens strain obtained 
from the Bacillus Genetic Stock Centre. Results are means of three individual assays. 
 
A microdilution assay was developed to quantify levels of extracellular inhibitory 
activity against C. difficile CD630 (Table 5.2). 
 
Table 5.2. Anti-CD630 activity using a microdilution assay 
Strain Species Endpoint titrea 
expt 1 expt 2 expt 3 
PY79 subtilis 0 0 0 
SG140 subtilis 1/20 1/20 1/10 
SG83 subtilis 1/20 1/20 1/20 
10A1 amyloliquefaciens 0 0 0 
SG57 amyloliquefaciens 1/40 1/40 1/40 
SG137 amyloliquefaciens 1/40 1/40 1/40 
SG185 amyloliquefaciens 1/80 1/40 1/40 
SG277 amyloliquefaciens 1/160 1/160 1/80 
SG297 amyloliquefaciens 1/160 1/160 1/160 
a Highest dilution factor showing inhibition.  
 
As was the case with the agar well-diffusion assay, B. amyloliquefaciens showed 
the highest levels of activity. In the case of SG277 and SG297, activity was 
consistently 4 to 8-fold higher than B. subtilis strains SG140 and SG183. Using the 
agar well-diffusion assay activity was tested for against a selection of C. difficile 
strains (Table 5.3). 
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Table 5.3. Activity of SG277 and SG297 against a selection of C. difficile ribotypes by the 
welldiffusion assaya b 
Test C. difficile strain 
CD630 
RT012 
CD196 
RT027 
R20291 
RT027 
VPI 10463 
RT087 
SH1 
RT078 
SG277 26 ± 0 26 ± 1.4 28.5 ± 2.1 27.5 ± 3.5 26.5 ±4.9 
SG297 26 ± 1.4 24.5 ± 0.7 23 ± 2.8 25 ± 0 25.5 ± 0.7 
PY79 0 0 0 0 0 
10A1 0 0 0 0 0 
a Inhibition of CD strains was made using the well diffusion assay and defined as diameter 
of zone of inhibition (mm). Results are means of three individual assays. RT, ribotype. 
b ± Standard deviation 
 
The data demonstrated that the extracellular activity of SG277 and SG297 was 
effective against a variety of C. difficile strains and ribotypes, including the 
hypervirulent 027 ribotype and ribotype 078, and the diameters produced by the 
extracellular activity were roughly equivalent to one another. Furthermore, an 
experiment was conducted to assess the inhibition of C. difficile cell growth by 
measuring the optical density after overnight growth of C. difficile strains in BHIS. 
C. difficile cultures were grown for 10 hours at 37oC in BHIS and 18 ml was 
removed to a falcon tube followed by an addition of 2 ml of SG277 filtrate. The 
cultures were incubated for 18 hours at 37oC after which the OD600 was read to 
assess the inhibitory activity against the strains (Table 5.4). SG277 showed strong 
inhibitory effects against all tested C. difficile strains. The level of inhibition 
suggests that SG277 activity is bacteriolytic, as the OD of the culture returned to 
baseline and the culture almost completely cleared suggesting lysis of the C. 
difficile vegetative cells. 
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Table 5.4. Activity of SG277 against various C. difficile strains using a co-culture assaya 
 
C. difficile 
strain 
 
Ribotype 
OD600  
% inhibition  
Untreatedb 
 
+ SG277 
CD630 RT012 0.756 0.059 92 
SH1 RT078 0.845 0.086 90 
SH101 RT115 0.772 0.081 89.5 
SH102 RT176 0.981 0.072 93 
R20291 RT027 0.857 0.091 89 
CD196 RT027 0.798 0.056 93 
SH104 RT023 0.534 0.056 89.5 
VPI 10463 RT087 0.687 0.054 92 
CD10 non-tox 0.824 0.102 88 
SH242 RT111 0.672 0.089 87 
SH200 RT056 0.914 0.076 92 
SH203 RT038 0.882 0.064 93 
SH218 RT001 0.732 0.081 89 
SH210 RT002 0.655 0.055 92 
SH213 RT014 0.758 0.064 92 
SH215 RT54 1.025 0.056 95 
SH220 RT336 0.783 0.049 94 
SH222 RT401 0.952 0.082 91 
SH231 RT56 0.791 0.073 91 
SH236 RT005 0.883 0.091 90 
SH239 RT103 0.966 0.086 91 
SH103 RT075 0.761 0.106 86 
SH3 RT017 0.692 0.055 92 
a SG277 filtrate was incubated overnight as a control and showed no growth 
b Untreated control had 2 ml of BHIB added to 18 ml of culture prior to being incubated for 18 hours 
at 37oC. 
 
A notable feature of B. amyloliquefaciens is the formation of mucoid colonies 
which were more pronounced on some media. It was shown that SG277 and SG297 
could produce proficient biofilms in LB, DSM as well as S7 medium (a minimal 
medium; (Saggese et al., 2018)). Biofilms were always more pronounced when 
cells were grown at 30oC rather than at 37oC. When SG277 or SG297 were grown 
in S7 medium with no shaking a dark brown pigment was produced. Figure 5.1 
shows scanning EM (SEM) images of SG277 and SG297 biofilms developed in S7 
medium. Spores could be seen in the biofilms together with vegetative cells. 
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Figure 5.1. SG277 and SG297 biofilms developed in S7 medium imaged using SEM. Red arrows 
highlight spores in the biofilm. Image courtesy of Dr Ezio Ricca, Federico II University, Naples. 
Magnification at 10,000x. 
 
5.2.2 Characterisation of anti-C. difficile activity  
Table 5.4 suggests that the extracellular activity exhibited by Bacillus strains 
against C. difficile is bacteriolytic, as the decreasing OD suggested that the bacteria 
had lysed. Co-culture experiments were therefore conducted where SG277 and 
SG297 filtrates were added to exponentially growing cultures of CD630, VPI-
10463, R20291 or SH1 (Figure 5.2). 
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Figure 5.2. Co-culture assays using SG277 and SG297 filtrates against various C. difficile 
strains. Samples of sterile extra-cellular filtrates from either SG277 or SG297 were added (1:10, 
v/v) to exponential growing cultures of four different C. difficile strains (time of addition indicated 
by arrow). Cultures with or without addition of samples were grown at 37oC and OD600 readings 
taken every hour. ● indicates cultures without addition of filtrate and Δ indicates cultures with 
filtrate added. Strains used were VPI-10463 (RT087), CD630 (RT012), R20291 (RT027) and SH1 
(RT078).  
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Upon addition of the filtrates the OD immediately dropped to baseline levels. Both  
SG277 and SG297 filtrates significantly reduced the optical density of all C. 
difficile strains confirming that they exhibited bacteriolytic activity resulting in 
almost complete lysis in < 1 hour.  
 
To further characterise the activity exhibited by SG277, a simple stability assay was 
performed for the supernatant and lyophilised supernatant. Prior to storage (time 
point 0), fresh and lyophilised supernatants were tested for activity against CD630 
in a microdilution assay. The endpoint titre for both was 1/160, and so all samples 
tested during the assay had their percentage of retained activity calculated 
according to this value. Table 5.5 shows the activity of fresh and lyophilised 
supernatants, stored under various temperature conditions over 8 weeks. Samples 
were removed weekly from their storage conditions and all tested at the end of the 
8 weeks with the exception of the -20oC samples (which were tested on a weekly 
basis). At the end of the experiment a sample were thawed, lyophilised samples 
resuspended in 1 ml dH2O and samples either heated (65
oC, 15 min.) or left 
untreated for activity testing. Samples were heated prior to activity testing to 
measure whether prolonged storage had an effect on the heat resistance of the 
compound/s. The percentage of activity retained over time is displayed in Figure 
5.3. The data showed that i) heating the samples (65oC, 15 min.) prior to the 
microdilution assay had no effect on activity, ii) storage of fresh or lyophilised 
supernatants at -20oC had no effect on activity, and iii) lyophilised samples 
exhibited better stability at 4oC and RT than fresh samples. 
 
The activity of SG277 and SG297 filtrates was further characterised (filter-
sterilised, 0.45 µm) by a variety of treatments using a microdilution assay to 
measure inhibitory activity against CD630 (Table 5.6). The filtrates showed high 
levels of heat resistance, retaining activity at 90oC for 30 min. and only losing some 
activity at 100oC (1/40) and upon autoclaving. SG277 and SG297 filtrates showed 
resistance to all enzymes and solvents tested, as well as to simulated gastric fluid. 
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Table 5.5. Stability of SG277 lyophilised and fresh supernatant. 
 
 
 
Figure 5.3. Retention of activity of SG277 lyophilised and fresh supernatants at different 
temperatures over time. 
 
A slight loss of activity was observed after acetone treatment, with the endpoint 
titre halving to 1/40. The resistance to proteases, lipases and amylases suggests that 
the active molecule was not protein, lipid or carbohydrate based. Resistance to 
simulated gastric fluid indicated that the activity might remain stable if dosed orally 
in vivo. All concentrations of glutaraldehyde had no effect on the activity of the 
SG277 or SG297 filtrates, indicating that there were no amine groups for 
glutaraldehyde to crosslink with. 
 
Supernatant Storage Week
0 1 2 3 4 5 6 7 8
Fresh -20 C 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160
-20 C heated 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160
4 C 1:160 1:160 1:80 1:80 1:80 1:80 1:80 1:40 1:40
4 C heated 1:160 1:160 1:80 1:80 1:80 1:80 1:80 1:40 1:40
RT 1:160 1:40 1:40 1:20 1:10 0 0 0 0
RT heated 1:160 1:40 1:40 1:20 1:10 0 0 0 0
Lyophilised -20 C 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160
-20 C heated 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:160
4 C 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:80 1:80
4 C heated 1:160 1:160 1:160 1:160 1:160 1:160 1:160 1:80 1:80
RT 1:160 1:80 1:80 1:80 1:40 1:40 1:40 1:40 1:20
RT heated 1:160 1:80 1:80 1:80 1:40 1:40 1:40 1:40 1:20
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Table 5.6. Characterisation of extracellular activitya 
Treatment SG277 filtrate SG297 filtrate 
No treatment 1/80 1/80 
Heatb 60oC 1/80 1/80 
70oC 1/80 1/80 
80oC 1/80 1/80 
90oC 1/40 1/80 
100oC 1/40 1/40 
Autoclavingc 0 0 
SGFd pH2 1/80 1/80 
pH3 1/80 1/80 
pH4 1/80 1/80 
Enzymese Lysozyme 1/80 1/80 
Lipase 1/80 1/80 
Amylase 1/80 1/80 
Pronase 1/80 1/80 
Trypsin 1/80 1/80 
Proteinase K 1/80 1/80 
Solventsf Toluene 1/80 1/80 
Chloroform 1/80 1/80 
Acetone 1/40 1/80 
0.1% (w/v) SDSg 1/80 1/80 
0.1% (v/v) glutaraldehydeh 1/80 1/80 
0.25% (v/v) glutaraldehydeh 1/80 1/80 
0.5% (v/v) glutaraldehydeh 1/80 1/80 
1% (v/v) glutaraldehydeh 1/80 1/80 
a The highest dilution factor that showed inhibitory activity is shown. Treatment only controls (no 
filtrate) was used for all tests. The no treatment control was diluted 1:1 in dH2O (v/v) prior to activity 
testing, and all samples diluted by treatments were further diluted if necessary, with dH2O so that 
supernatants were at a final concentration of 1:1 (v/v). 
b Supernatants were incubated in an oven at the selected temperature for 30 min. and allowed to cool 
to RT before assay. 
c 121oC, 20 psi, 20 min. 
d For simulated gastric fluid three solutions at pH, 2, 3 and 4 were made using HCl to adjust pH. 
Supernatants were incubated with an equal volume of SGF and incubated for 1 hour at 37oC before 
assay. 
e Supernatants were incubated with the following enzymes at 1 mg/ml final concentration for 1 hour 
at 37oC before assay, lysozyme, lipase, amylase. For the proteases, pronase, trypsin and proteinase 
K were used. 
f Supernatants were vortexed for 1 min. 1:1 with 100% solvent (v/v) and incubated for 1 hour. 
g  Incubated at RT for 3 hours. 
h Incubated at 37°C for 2 hours. Glutaraldehyde was neutralised by glycine at a molar ratio of 1:10. 
Although the data showed that significant activity was associated with the 
extracellular material, whether activity was associated with the cell surface was not 
yet addressed. For this, SG277 was grown in BHIB for 16 hours at 37oC and the 
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cell and supernatant fractions were separated. The cell fraction (comprised of both 
spores and cells) was washed with PBS 3x and mixed with CD630 cells in soft agar 
(0.7%), poured onto petri dishes and then grown overnight anaerobically (Figure 
5.4).  
 
Figure 5.4. Lytic activity is associated with the cell/spore surface. Activity was shown by 
complete lysis of the bacterial lawn. SG277 cell suspensions were mixed with soft agar and 
incubated overnight as a control and as aerobes showed no growth (not shown). 
  
Plates carrying SG277 extracellular supernatant + CD630 showed complete lysis, 
as did the SG277 cell fraction + CD630 (Figure 5.4). Heat treatment (80oC, 30 min.) 
of both the washed cell fraction and the supernatant had no effect upon the activity, 
with complete lysis still occurring. Heat treatment would kill SG277 vegetative 
cells indicating that activity must be associated, in situ, with the cell/spore surface, 
rather than with potential growth and secretion of the active inhibitory compound/s. 
Under anoxic conditions growth of SG277 cannot occur confirming that inhibitory 
activity must be present on the surface of the cells.  
CD630 lysed lawnCD630 lawn
CD630 Plate 
Lysis
Untreated -
+ SG277 supernatant +
+ SG277 supernatant (80oC) +
+ SG277 washed cells/spores +
+ SG277 washed cells/spores (80oC) +
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5.2.3 Purification of the active molecules  
The final purification method used for identifying the active molecules has been 
described in Chapter 4 and shown in Figure 4.8. However, there were various other 
avenues which were explored in regard to the nature of the compounds responsible 
for the activity, and they are outlined further here. Figure 5.5 shows the various 
ways in which attempts were made to determine the properties of the inhibitory 
activity against C. difficile. Unless specified otherwise, all purification steps were 
performed using extra-cellular (filter-sterile, 0.45 µm) material obtained from 16-
hour overnight cultures of SG277 grown in BHIB medium (37oC). All functional 
testing was performed against CD630 in a microdilution assay. 
 
 
Figure 5.5. Purification of the active components responsible for anti-C. difficile activity. See 
methods for more details. 
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Initially, purification of SG277 filtrate was attempted using Vivaspin centrifugal 
molecular weight cut offs (MWCOs), to give an approximation of the molecular 
weight. Analysis of the SG277 filtrate using a sequence of MWCOs (100 kDa, 30 
kDa and 10 kDa) and testing for activity against CD630 is shown in Table 5.7.  
 
Table 5.7. Size fractionation of SG277 activity 
Cut-off (kDa)
a
 Activity titre 
Untreated 1/80 
<10 0 
10-30 0 
30-100 1/40 
>100 1/40 
a sterile filtered (0.45 m) culture supernatant passed through 
Vivaspin 6 centrifugal concentrators. Activity against CD630 
measured using a microdilution assay. 
 
 
Activity against CD630 was found in two fractions:  30-100 kDa and >100 kDa. 
This suggests that a relatively high molecular weight compound was responsible. 
The presence of the activity above and below 100 kDa suggested the formation of 
a complex, which might be physically labile and able to dissociate and pass into the 
flow through while retaining some activity.  
 
It was found that activity could be precipitated using 20% AmSO4 as well as with 
polyethylene glycol (PEG) and following centrifugation through CsCl gradients 
three distinct bands were present, of which one, band 2 (B2), carried functional 
activity against C. difficile (Figure 5.6). 
 
SG277 filtered supernatant was precipitated using PEG and resuspended at a 100x 
concentration in SM buffer. Activity of the supernatant used was 1/80, total PEG 
ppt. was 1/320 and B2 had 1/320 activity, demonstrating retention of all activity 
from the PEG ppt. in B2.   
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Figure 5.6. CsCl centrifugation of PEG precipitated SG277 filtrate. PEG precipitation was used 
to precipitate material from the SG277 sterile filtrate. Following ultra-centrifugation through CsCl 
gradients three bands were present with only band B2 having activity against CD630 using the 
microdilution assay. 
 
Transmission EM analysis (TEM) of B2 revealed distinct aggregates present in the 
active fractions following CsCl gradient centrifugation (Figure 5.7). Interestingly, 
this analysis revealed granular clusters of approximately 20-30 nm in diameter. 
Also apparent from the TEM images was some indication of ordered assembly. 
These assemblies were abundant and if responsible for the activity seen against C. 
difficile then the observed size would be broadly consistent with the data from Table 
5.7.  
 
 
Figure 5.7. TEM analysis of CsCl band B2. Image courtesy of Dr Wilfried Meijer, CSIC. 
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AmSO4 precipitation of the SG277 filtrate was made at final concentrations of 20% 
(w/v) and 70% (w/v), followed by incubation O/N at 4oC and resuspension of the 
precipitate in PBS at a concentration of 30x (for 30 ml of initial culture the 
precipitate would be dissolved in 1 ml of PBS). Precipitates were run on 12% SDS-
PAGE and Coomassie stained (Figure 5.8A). A soft agar overlay assay was used to 
look for the region of activity (Figure 5.8B). 
 
 
Figure 5.8. SDS-PAGE and soft-agar overlay analysis of AmSO4 precipitates. SG277 
extracellular material was AmSO4 precipitated at concentrations of 20%, 70% or 20% followed by 
70% (2X). Precipitates were run on 12% SDS-PAGE and Coomassie stained (A). A soft agar overlay 
assay was performed by excising all gel lanes and overlaying with soft BHIS agar and a logarithmic 
culture of CD630 (B). Arrow indicates presence of activity. 
 
Figure 5.8A shows the presence of a white band close to the dye front, of 
approximately 1 kDa in molecular weight. This band is only present at a 
concentration of 20% AmSO4 and is mirrored by the activity observed in Figure 
5.8B, where the corresponding zone of inhibition is only seen with 20% AmSO4. 
Following this observation, a 2-step AmSO4 precipitation procedure was followed, 
first precipitating with 20% AmSO4, followed by a 2
nd precipitation at 70%; this 
abolished the activity seen initially at 20%. Precipitation at 20% AmSO4  but not at 
20%  70%   2X 20%          70%         2X
Anti-CD +       - - +    - -
A B
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70% could be explained by several characteristics of the active molecules; it may 
occur due to the high hydrophobicity of the compounds resulting in oligomerisation 
and therefore precipitation at low concentrations, but at high concentrations the salt 
may coat the structure and repel interactions thereby preventing precipitation. 
Another potential explanation might be the differing pHs of the two solutions, with 
the pH at 20% AmSO4 proving to be less favourable for solubilisation of the 
compound. 
 
For identification of the active compounds using MALDI-TOF analysis, further 
purification would be necessary. As the first step in the purification process, 
AmSO4 precipitation rather than PEG precipitation was selected due to a far greater 
yield of activity retained by AmSO4 ppt. post PEG precipitation, a 100x 
concentrated solution (v/v) had an endpoint titre of 1/320, while AmSO4 ppt. at a 
concentration of 30x had an endpoint titre of approximately 1/2560. 
 
In order to further purify the active species, the AmSO4 ppt. was separated using a 
Superdex 200 column (10,000 Da - 600,000 Da) in PBS + 0.1% SDS (w/v). This 
allowed for a preparative separation of high MW species. SDS was added to 
denature/linearise unwanted proteins, and an isocratic buffer containing 0.1% SDS 
(w/v) resulted in a purer separation (Figure 5.9A) when compared to buffer without 
SDS (Figure 5.9B). Figure 5.9A shows that SEC purification successfully removes 
protein content, and that activity does not correlate with the position of protein 
elution indicating that the active species are not proteinaceous.  
 
Separation was performed without the presence of SDS so as to calculate the 
molecular weight using four internal standards; IgG (150 kDa), BSA (66.5 kDa), 
lysozyme (14.3 kDa) and insulin (5.8 kDa) (Figure 5.9C). SG277 active 
components had a retention time of 26 min. and solving the equation of the straight 
line for y gave a value of 4.81414 and 104.81414 = 65,184 Da.  
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Figure 5.9. Analysis of SG277 AmSO4 ppt. by preparative SEC. AmSO4-precipitated material 
from SG277 cell-free supernatant was fractionated using SEC in the presence (A) or absence (B) of 
0.1% SDS. Fractions were analysed for protein concentration (NanoDrop, A280nm) and inhibitory 
activity to C. difficile 630. The position of size standards is shown. The log (mwt.) of the four 
standards were plotted as a function of the retention time. A trend line was used to calculate the 
straight-line equation and was solved for y (SG277 retention volume: 26 min. as indicated by red 
arrow) to determine the molecular weight of the complex (65,184 Da) (C). 
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Following SEC separation active fractions were combined, washed and 
concentrated using a 10 kDa MWCO to a final volume of 1 ml. Activity testing of 
the preparative SEC fraction indicated that the endpoint titre for activity was 
approximately 1/1280. The preparative SEC fraction was further examined using 
TEM (Figure 5.10). 
 
Figure 5.10. TEM analysis of SG277 preparative SEC fraction. Marker = 100nm. Image 
courtesy of Dr Wilfried Meijer, CSIC. 
 
As was the case in Figure 5.7, there was an abundance of granular like clusters of 
approximately 20-30 nm in diameter. 
 
The accumulated data indicated that the active species responsible were 
lipopeptides. Bacillus lipopeptides are low molecular weight cyclic, amphipathic 
antibiotics able to agglomerate and form large molecular weight micelles in 
aqueous solution. This would explain the discrepancy seen in the molecular weight; 
in Figure 5.8 where activity is observed to be approximately 1 kDa, yet the SEC 
separation (Figure 5.9) suggests a compound of higher molecular weight (65,184 
Da). A large molecular weight complex is supported by Table 5.7, where activity 
is retained above a 30 kDa MWCO. It seems that in aqueous solution lipopeptides 
were forming micelles of large molecular weight while in denaturing conditions 
(SDS-PAGE) these micelles are broken down into their constituent, low molecular 
weight monomers. Lipopeptides have high biosurfactant activity, and in Figure 
4.3A an association is seen between the level of anti-C. difficile and biosurfactant 
181 
 
activity using an oil dispersion assay. Bacillus are known to produce large 
quantities of lipopeptides (Yang et al., 2015; Ilinskaya et al., 2017) with 
antimicrobial activity (Meena and Kanwar, 2015) and so to determine whether 
micelles were responsible for the observed activity a modified method from Jauregi 
et al. (2013) was used. This method relies upon methanol for the disruption of the 
micellar aggregation of the surfactant molecules. A diagrammatic representation of 
the procedure is shown in Figure 5.11. 
 
  
   
Figure 5.11. High molecular weight activity is due to micelle formation of lipopeptide 
surfactants. SG277 SEC fraction was centrifuged through a 30 kDa MWCO filter to ensure activity 
measured was above 30 kDa (A). The retentate was collected and MeOH added to a final 
concentration of 50% (v/v) thereby disrupting the micelles (B) followed by centrifugation through 
a 5 kDa MWCO. The resulting filtrate was aliquoted into two equal volumes, vacuum evaporated 
and pellets resuspended either in dH2O (C) or 50% MeOH (v/v) (D) and centrifuged through 30 and 
5 kDa MWCO respectively. All fractions were normalised by volume and tested for activity against 
CD630 using a microdilution assay. 
Figure 5.11 confirms the presence of lipopeptide micelles through the formation of 
high molecular weight structures in a polar solvent (dH2O) and dissolution of the 
complex into low molecular weight monomers in an organic solvent (MeOH). The 
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dissolution of micelles by MeOH can be reversed by removing the solvent and 
replacement with a polar solvent. 
 
Further purification of the preparative SEC was performed using RP-HPLC and 
SEC-HPLC on SG277 AmSO4 precipitate. RP-HPLC separation was performed on 
a phenyl column using a MeOH (+0.1% (v/v) AcOOH) gradient; from 65% to 95%. 
The resulting chromatogram (Figure 4.9), peak collections, activity testing (Table 
4.3) and MALDI-TOF identification (Table 4.4) was described in Section 4.2.2. 
MS analysis revealed different isoforms of the lipopeptides, iturin A, fengycin, 
surfactin and mycosubtilin. In addition, two additional lipopeptides, mojavensin A 
(Ma et al., 2012) and kurstakin (Béchet et al., 2012) were detected. Using the 
microdilution assay chlorotetaine, iturin, fengycin and surfactin were found to carry 
anti-CD630 activity albeit at reduced levels compared to the preparative SEC 
fraction. Furthermore, RP-HPLC fractionation was used to analyse the preparative 
SEC fractions from SG297 (B. amyloliquefaciens) and two B. subtilis strains, 
SG140 and SG83 (Figure 5.12). 
 
RP-HPLC of the SG297 preparative SEC fraction demonstrated evidence for the 
presence of iturins, fengycins and surfactins, although the iturin and fengycin 
profiles differed slightly from that of SG277. B. subtilis strains SG83 and SG140 
preparative SEC fraction contained fengycins and surfactins but no iturins. 
Abundance of fengycin/surfactin between SG83 and SG140 differed markedly but 
activity of the original filtrate is of an equivalent level (1/20; Table 5.2). The 
difference in quantity of fengycin/surfactin between SG297 and SG140 is also 
noticeable, although the difference in activity (1/160 vs 1/20) seems somewhat 
disproportionate according to the size of the peaks. Although iturins display very 
little individual activity (1/10; Table 4.3), they may play another role within the 
micellar complex hence exaggerating the activity exhibited by strains producing 
this lipopeptide in addition to surfactin and fengycin.  
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Figure 5.12. RP-HPLC separation of B. amyloliquefaciens and B. subtilis preparative SEC 
fraction. RP-HPLC separation of B. amyloliquefaciens strains SG277 and SG297 (A) and B. subtilis 
strains SG83 and SG140 (B). 
 
 
To examine further the constituent species of the preparative SEC active fraction, 
separation was performed using SEC-HPLC on a TSK Gel G2500PW XL column 
(Figure 5.13). SEC-HPLC is more analytical than the preparative SEC performed 
using Superdex 200 resin described earlier (Figure 5.9) and separates molecules 
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between the range of 200-3,000 Da. The column was run under denaturing 
conditions, using a mobile phase of 65% ACN (+ 0.1% acetic acid). 
 
 
 
Figure 5.13. SEC-HPLC fractionation of SG277 preparative SEC. Analytical SEC-HPLC under 
denaturing conditions using HMW active SG277 SEC fraction. Non-polar mobile phase (65% 
acetonitrile + 0.1% acetic acid) breaks down the supramolecular lipopeptide aggregates to release 
LMW iturins, fengycins and surfactins. The LMW chlorotetaine elutes last. MALDI-TOF 
identification of material within peaks noted in the chromatogram. More in depth data of observed 
masses shown in Table 4.4. 
 
SEC-HPLC analysis of high molecular weight species purified from SG277 growth 
medium using preparative SEC (Superdex 200) confirms their composition as a 
mixture of fengycins, surfactins, iturins and chlorotetaine (for MALDI-TOF data 
see Table 4.4). No additional high molecular weight components were identified 
(Figure 5.13). 
 
 It should be noted that absorbance at 220 nm, and the resultant peak sizes is not 
strictly quantitative if comparing different molecules. This is due to differential 
absorption of UV by biomolecules. Four peaks were observed during SEC-HPLC, 
collected and tested for activity against CD630 (Table 5.8). 
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Table 5.8. Anti-CD activity of SG277 SEC-HPLC fractions 
Purification 
step 
Anti-CD activity 
(endpoint titre) 
Extracellular 
Filtrate 
1/160 
AMSO4 (30x) 1/2560 
Preparative SEC 
fractiona 
1/1280 
S1a 1/20 
S2a 1/320 
S3a 1/10 
S4a 1/10 
a Normalised by volume according to volume of AmSO4 used. 
 
The amount of activity of differing fractions separated by SEC-HPLC was 
equivalent to those separated by RP-HPLC, as would be expected. Surfactin 
displays by far the most activity (1/320), with fengycin, iturin and chlorotetaine 
providing significantly smaller amounts. Interestingly, the level of activity 
demonstrated by surfactin is of a much lower level than that of the preparative SEC 
fraction (1/1280) and considering that these various components elute in the same 
fractions during SEC, and appear to share the same, high molecular weight it is 
possible that they were forming mixed micelles.  
 
A further experiment was performed to examine the mechanism of activity against 
CD630 in a co-culture assay (Figure 5.14). At an OD600 of 0.3-0.4, samples from 
various stages of SG277 purification, anti-C. difficile activity normalised (to an 
approximate end point titre of 1/100) were added to growing C. difficile cultures at 
a dilution factor of 1:10 and for every hour thereafter OD600 readings were recorded 
and CFU counts (plated on BHISS) enumerated. All samples showed equally rapid 
lytic activity against the log phase CD630 culture; within an hour the OD had 
dropped to the baseline and there were no detectable CFU.  
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Figure 5.14. Co-culture assay using purified SG277 material against CD630. Samples of SG277 
at various stages of purification; supernatant (0.45 µm filtered), dialysed 20% AmSO4 ppt. in PBS, 
preparative SEC fraction and RP-HPLC purified surfactin were all diluted so activity against CD630 
in a microdilution assay would be approximately 1/100. Samples were added to log phase CD630 
cultures at a dilution of 1:10 (v/v) and OD600 readings were taken and CFU counts were enumerated 
hourly. The arrow indicates addition of sample.    
 
5.2.4 Investigating the nature of the micellar structure 
It has been reported that surfactins can act synergistically with iturins 
(Razafindralambo et al., 2002) and mycosubtilin (Jauregi et al., 2013). The 
interaction of iturin A with surfactin in mixed micellar structures has been shown 
to enhance the lytic activity against erythrocyte membranes (Thimon et al., 1992). 
Figure 5.12 provided some evidence for iturin’s mediatory role in the enhancement 
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of anti-C. difficile activity, with strains producing iturins in addition to 
fengycin/surfactin seemingly exhibiting disproportionately high levels of activity 
in comparison to strains lacking this single lipopeptide. Other studies have shown 
the complementary effect different amphipathic compounds can have on each other, 
and the resultant increase in antibacterial activity when they combine to form mixed 
micelles (Sheikh et al., 2013). When surfactants mix within an aqueous solution, 
several physicochemical changes take place due to interactions between 
amphiphiles often resulting in enhanced interfacial and micellar properties. One 
example of a property which can be affected by the mixing of surfactants is the 
critical micellar concentration (CMC) (Sheikh et al., 2013), the altering of which 
can affect the level of solubility and therefore the concentration of surfactants per 
unit volume and this can enhance their biosurfactant properties. Gram-positive 
bacteria lack an outer lipopolysaccharide layer but carry a thicker peptidoglycan 
and phospholipid membrane bilayer. Surfactin’s detergent-like activity acts to 
create a permeable environment for the lipid bilayer, therefore disrupting and 
solubilising the bacterial membrane (Heerklotz and Seelig, 2001). For antibacterial 
activity, a significant concentration of surfactin is required (between 12 and 50 
g/ml) and so the CMC and solubility are integral to the active process. The 
resulting synergism from the formation of mixed micelles can lower the CMC, 
decrease the polarity of mixed micelles thereby enhancing interactions between the 
micelles and the bacterial membrane resulting in greater antibacterial activity. 
Sheikh et al. (2013) notes that their observed antibacterial activity only occurs 
above the CMC value, demonstrating the necessity of micelle formation for 
antibacterial activity.  
 
It was therefore decided to investigate whether the combination of lipopeptides has 
a cumulative effect upon the activity against C. difficile (Figure 5.15). SG277 RP-
HPLC purified material was collected according to identity (chlorotetaine, iturin, 
fengycin and surfactin), evaporated and tested against CD630 individually or in 
combination in a microdilution assay. Commercially produced (Sigma) 
lipopeptides were also tested alone and in combination against CD630.  
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Interestingly, the amount of activity increased as the molecules were combined. 
Importantly, this was greater that the mathematical sum of the individual activities 
for each of the four compounds. This suggests that a synergistic effect between the 
compounds was taking place, and for an optimal level of activity the compounds 
needs to be in solution together. Using commercial compounds (Sigma), none 
demonstrated any activity, on their own or when combined.  
 
To further discern the nature of these mixed micelles two techniques were 
employed. The first of which was Cryo-TEM analysis (Figure 5.16) which has 
been used to visualise micelles in solution (Vinson et al., 1991; Won et al., 2002). 
Surfactin has been previously imaged with Cryo-TEM displaying micelles of 
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Figure 5.15. Cumulative activity of RP-HPLC purified SG277 material. SG277 SEC-HPLC 
separated material, individual or combined was tested for activity against CD630. Sum of 
individual peaks refers to mathematical addition of the activities of individual compounds, while 
combined positive peaks were pooled and then tested. All samples were normalised according to 
volume and represent the quantity found within the equivalent volume of SG277 preparative SEC 
fraction used for column injections. The average activity for three replicates is displayed above 
the relevant bars (standard deviation). Commercial compounds from Sigma were assessed for 
activity. 
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approximately 5-9 nm at pH 7 (Isa et al., 2007). The size and shape of surfactin 
micelles however were heterogeneous, with some appearing cylindrical with 
lengths up to 160 nm. 
 
Figure 5.16. Cryo-TEM analysis of SG277 SEC material. Image courtesy of Professor Alain 
Brisson, University of Bordeaux.  
 
Cryo-TEM analysis of the SG277 preparative SEC material showed disc-like 
objects tightly packed and <10 nm in size. Occasionally large size discs were 
apparent with an approximate diameter of 160 nm. These objects resembled 
micelles of <10 nm and ~160 nm in size. Individual RP-HPLC fractions were also 
imaged, corresponding to iturin, fengycin and surfactin but instead of showing 
micelles, displayed rod-like filaments (data not shown). 
 
The second technique employed was dynamic light scattering (DLS) analysis. All 
analysis was performed using material in 150 mM sodium phosphate buffer (pH 
7.2). The preparative SEC material was analysed and the presence of micelles with 
a hydrodynamic diameter of 6.8 nm was confirmed (Figure 5.17A). The micelles 
remained remarkably stable over 17 hours at RT during which no change in size 
was detected (Figure 5.17B). In Figure 5.17B, the intensity of the main 6.8 μm peak 
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increases slightly over time and the peaks indicated aggregates larger than 100 nm 
that disappeared completely after 17 hours, due to either re-assembly into smaller 
micelles or sedimentation over time. A freeze-dried SEC fraction was reconstituted 
in phosphate buffer and the size distribution measured by DLS was equivalent to 
the original sample, suggesting that the micelles could withstand lyophilisation and 
resuspension (Figure 5.18A).  
 
Figure 5.17. DLS analysis of SG277 preparative SEC material. Self-assembly of lipopeptides. 
Hydrodynamic size distribution of preparative SEC material prepared in 150 mM sodium phosphate 
buffer at pH=7.2 shows high molecular weight monodisperse complexes with an average diameter 
of 6.8 ± 0.009 nm (A). Size distributions of the SEC fraction at different times after dilution in 150 
mM sodium phosphate buffer at pH = 7.2 (B). Data points are the average of three measurements 
with error bars representing SEM. DLS performed in collaboration with Dr Enrico Ferrari, 
University of Lincoln and Dr Mikhail Soloviev, Royal Holloway University.  
 
In an attempt to identify the minimum molecular subset responsible for the self-
assembly of the micellar complex, the high molecular weight preparative SEC 
fraction was further fractionated under fully denaturing conditions using either RP-
HPLC (Figure 4.9) or SEC-HPLC (Figure 5.13). All the individual lipopeptides 
collected from the HPLC experiments were tested individually and mixed to 
reconstitute the original composition. When complete sets of collected fractions 
were recombined and analysed, the size distributions measured by DLS showed the 
same data as observed in the original SEC and freeze-dried reconstituted sample, 
suggesting that micelle formation is driven by spontaneous self-assembly of the low 
molecular weight lipopeptides (Figure 5.18A). However, HPLC reconstituted 
samples showed the presence of aggregates, suggesting that the exact conditions 
and molar ratios in which individual components agglomerate is most likely 
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important in the optimal construction of micelles with a narrow size distribution 
and equivalent yield to those formed in native conditions. Individually reconstituted 
HPLC fractions displayed high polydispersity due to aggregation and so rigorous 
analysis and fitting of the hydrodynamic diameter was not possible. However, DLS 
analysis provided the cumulants fit intercept (CFI) for all fractions and 
combinations (Figure 5.18B). CFI crudely quantifies the presence of scattering 
particles over the background noise, with a maximum value of 1 indicting extensive 
scattering from particles in suspension and values below 0.2 typically indicating no 
scattering. The cumulant fit analysis also provided the polydispersity index (PDI), 
which indicates how broad the size distribution is. PDI is greatly affected by the 
presence of multiple peaks, with values between 0.5 and 1 indicating extensive 
aggregation, and values below 0.5 indicating monodispersed distributions.  
  
Figure 5.18. DLS analysis of HPLC purified SG277 material. Self-assembly of lipopeptides from 
original and freeze-dried preparative SEC fraction and from reconstituted combined HPLC 
preparations, containing all lipopeptides. The size distributions of samples reconstituted from HPLC 
fractions yields higher polydispersity and indicates limited aggregation (A). The polydispersity 
index (PDI) versus the cumulants fit intercept (CFI) of individual RP-HPLC fractions or 
combinations of them (B). Squares represent mixtures not separated by HPLC, circles correspond 
to RP-HPLC fractions and combinations thereof. All red symbols indicate the presence of all 
lipopeptides, blue symbols correspond to individual RP-HPLC fractions and orange symbols are 
defined mixtures comprised of different peaks S= surfactin, F= fengycin, I= Iturin, X= chlorotetaine; 
(SFI=S3+F3+I3; SFIX=S3+F3+I3+X; SF=S3+F3; IF=I3+F3; SI=S3+I3). Individual peak fractions 
used can be viewed in Figure 4.9. Filled shapes indicate preparations where a peak of 6.8 nm was 
visible by DLS, whereas open symbols represent preparations where no such nm peak was detected 
by DLS. Data points are the average of three measurements with error bars representing SEM. DLS 
performed in collaboration with Dr Enrico Ferrari, University of Lincoln and Dr Mikhail Soloviev, 
Royal Holloway University. 
 
The scatter plot of PDI versus CFI revealed that iturins, fengycins and chlorotetaine 
on their own yield highly polydisperse aggregates. Individual surfactin fractions 
A B
Preparative SEC
Freeze-dried SEC
SEC-HPLC combined
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eluted from RP-HPLC and combinations of surfactins with the other lipopeptide 
fractions do assemble into micelles to some extent (Figure 5.18B). However, no 
combinations yielded monodisperse and stable micelles as seen in the original 
preparative SEC fraction and with freeze-dried SEC, except for the combination of 
all the RP-HPLC fractions (complete), where size distribution was comparable to 
that of the preparative SEC material. RP-HPLC fraction F3 yielded size and PDI 
values similar to that of the combined RP-HPLC fractions (complete) and S2, which 
is not entirely unexpected as this fraction contains both fengycin and surfactins as 
confirmed by MALDI-TOF-MS and RP-HPLC analyses (Table 4.4 and Figure 4.9). 
It is therefore reasonable to conclude that surfactins are responsible for providing a 
micellar morphology to the mixture but the formation of the stable and 
monodisperse micelles observed in the original sample depends on the precise 
combination of multiple lipopeptides in a mixed micellar complex (Figure 5.19).    
 
Figure 5.19. Micellar constituents. The individual, principal components of the micellar complex 
responsible for activity against C. difficile are shown, in addition to a hypothetical diagram of their 
association with each other. Iturin (A), fengycin (B), chlorotetaine (C), surfactin (D) and a 
hypothetical composite micelle formed by surfactins (red), fengycins (green) and iturins (yellow) 
(E). The micelle contains low molecular weight components (e.g. Chlorotetaine; purple), and may 
act as a delivery vehicle, increasing the bioavailability of all of the components. All images from 
KEGG; iturin- (KEGG: C12266. ChEBI:31737, PubChem: 14411) CAS: 52229-90-0, fengycin- 
(KEGG: C12042. ChEBI: 29583, PubChem: 14197. 3DMET: B05603, MW=1463.7122) CAS: 
102577-03-7, surfactin-(KEGG: C12043. ChEBI:29681&71978, PubChem: 14198. 3DMET: 
B04413, MW=1036.3446) CAS: 24730-31-2. 
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5.3 Discussion 
This chapter provides evidence for a complex of lipopeptides produced by strains 
of B. amlyloliquefaciens, B. subtilis and B. licheniformis. This complex exerts 
significant bacteriolytic activity upon the nosocomial pathogen, C. difficile. The 
principal lipopeptides responsible for this activity are iturin, fengycin and surfactin; 
surfactin seemingly being the predominant constituent evidenced by its 
proportionally high presence (Figure 5.13), high activity (Table 5.8) and 
responsibility in providing a stable, monodisperse micellar morphology in 
combination with the other lipopeptides (Figure 5.18B). These individual 
lipopeptides self- assemble to form mixed micelles thereby magnifying the activity 
exhibited against C. difficile. This effect has been noted previously, in the case of 
surfactin and mycosubtilin (Jauregi et al., 2013) and surfactin and iturin A 
(Razafindralambo et al., 2002; Thimon et al., 1992). The observed synergy 
presented by the mixing of micelles is likely due to the complimentary effect that 
different amphipathic compounds have upon each other; physiochemical changes 
due to interactions between amphiphiles and the subsequent enhancement of 
interfacial and micellar properties resulting in an increase in antibacterial activity 
(Sheikh et al., 2013). Physiochemical alterations of micelles can be inferred by the 
DLS analysis data presented in Figure 5.18B, where upon the mixing of differing 
lipopeptides, an increase in mono-dispersity and a decrease in aggregation suggest 
modifications to the solubility of the constituents. These physiochemical changes 
translate into increased antibacterial activity against C. difficile (Figure 5.15), 
where the mixing of the individual lipopeptides resulted in activity which was 
greater than the mathematical sum of the individual activities for each of the four 
compounds.  
 
Interestingly, activity was associated with the outer surface of the bacterial cell 
and/or spore (Figure 5.4). This material is most probably associated with the 
polysaccharide matrix of the outer surface of the cell envelope, a characteristic of 
the mucoid B. amyloliquefaciens. B. subtilis strains which demonstrated activity 
against C. difficile also tended to share this mucoid characteristic in their colony 
morphology. Surfactin has been implicated in the motility and swarming of B. 
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subtilis by increasing surface wettability (Angelini et al., 2009; Ghelardi et al., 
2012), and so it would follow that surfactins associated with the surface of the cell 
would provide benefit to the host bacterium by providing high and localised 
concentrations of the surface-active agent in the immediate vicinity of the cell. This 
surface association has intriguing implications when applied to protection against 
CDI in vivo. In Chapter 4 increased protection against CDI was observed when 
animals were dosed with SG277 cells and compared to the administration of the 
filtrate alone. This may be explained by the phenomenon of cell/spore surface 
associated activity; it is possible that the filtrate is retained within the GI tract for a 
lesser amount of time than spores or vegetative cells, which may form biofilms 
(Vogt et al., 2018) or otherwise associate with the gut mucosa. This could result in 
comparatively higher persistence of antibacterial lipopeptides within the GI tract 
and therefore enhanced elimination of C. difficile. The provision of cells/spores 
with lipopeptides associated with the surface may therefore provide a longer lasting, 
and more consistent supply of antibacterial lipopeptides within the GI tract, 
resulting in greater elimination of C. difficile and enhanced protection against CDI. 
In addition, germination of spores, and outgrowth of cells may provide additional 
lipopeptides but in the case of the mouse study this is unlikely considering the short 
time span of the experiment and the rapidity at which C. difficile initiates infection 
within the host post-challenge.  
 
Cryo-TEM analysis in Figure 5.16 presents micelles of the approximate diameter 
as determined by DLS analysis. Of further interest is the presentation of the micelles 
during TEM analysis of the CsCl band and of the SEC fraction (Figure 5.7 and 
5.10). At the time of TEM analysis the identity of the active components had not 
been confirmed, and so TEM analysis was performed without full knowledge of the 
expected size of the compound/s. However, rather than the presence of circular 
micelles, extended granular clusters 20-30 nm in diameter were observed. These 
granular clusters most likely represent the formation of ‘wormlike’ micelles (Helvig 
et al., 2015). Wormlike micelles are formed by the agglomeration of amphiphiles 
into flexible, elongated, self-assembled structures (Dreiss, 2007). Furthermore, the 
formation of wormlike micelles has been documented for surfactins (Arutchelvi et 
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al., 2014). Although surfactants and their structure have been well studied over the 
past century, the function and implications of the biophysical phenomenon of 
wormlike micelles is not well understood (Dreiss, 2007).  
 
The activity shows remarkable stability against various chemical and enzymatic 
insults, in addition to resistance to high temperatures and acidic pH. This high 
stability is most likely due to the hydrophilic cyclical structure of the lipopeptides 
and the added stability in solution conferred by micellisation (Lin and Grossfield, 
2015). The lipopeptides showed good stability against simulated gastric fluid, 
providing an explanation for the effectiveness demonstrated in vivo against CDI. 
100% of the activity against C. difficile is retained for 1 week at 4oC, and 50% for 
~6 weeks. These properties provide an advantage over conventional antimicrobial 
peptides (AMPs), which are effective, broad-spectrum, thermally stable agents but 
are labile under high temperatures for extended periods of time (80oC for 15 min.) 
and extremes of pH (Lin and Grossfield, 2015). 
 
The activity displayed by these lipopeptides is bacteriolytic (Figure 5.2). This 
would imply the mechanism of action is similar to that of a detergent, where lysis 
of the cell occurs through a combination of surface layer protein solubilisation, pore 
forming and membrane lytic mechanisms (Bechinger and Lohner, 2006). Gram-
positive bacteria are generally more susceptible to this action than are Gram-
negative bacteria (Baker et al., 1941). Surfactin has been shown to have detergent-
like, membrane destabilising action upon lipid membranes, and this has been 
attributed to its preference for micelle formation over membrane insertion 
(Heerklotz and Seelig, 2001). The activity exerted upon C. difficile occurs rapidly, 
with almost complete lysis occurring in less than 1-hour post addition of SG277 or 
SG297 filtrate to growing C. difficile cultures. Extracellular material produced from 
B. amyloliquefaciens has previously been shown to have activity against C. difficile 
using a cross-streak method (Boottanun et al., 2017) but the work presented here is 
the first to define the nature of the inhibitory activity.  
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CHAPTER 6 
Discussion 
 
6.1 Spore mediated colonisation of C. difficile   
As is the case with many bacterial diseases, CDI involves host colonisation and 
subsequent toxin production. Colonisation is comprised of several distinct phases, 
starting with the ingestion and acquisition of C. difficile spores, germination, 
outgrowth and proliferation. Studies focussing on the colonisation of C. difficile 
have mostly examined the role of the vegetative cell, since it has been pre-supposed 
that the role of the spore is confined to transmission and dissemination of this 
obligate anaerobe. However, it has been shown that the spore may contribute to 
colonisation and infection and the spore coat protein, CotE, has been identified as 
an agent of mucus binding and colonisation. 
 
The spore of C. difficile is a dormant entity that enables indefinite survival outside 
of the host. It is therefore vital for transmission and dissemination and accounts for 
the prevalence of this organism in humans and animals. It is assumed that C. 
difficile is acquired immediately prior to infection although there is evidence that 
humans can be asymptomatic carriers with low numbers of spores resident and 
latent in the GI tract (Deakin et al., 2012). C. difficile strains defective in spore 
formation (spo0A mutants), fail to transmit disease, confirming the functional role 
of the spore in dissemination (Deakin et al., 2012). 
 
Prior to this work, there was preliminary evidence that the spore may play a role in 
colonisation and infection. The C. difficile spore exosporium carries three large 
collagen-like proteins that form hair-like filaments. One of these proteins, BclA1 
has been shown to play a direct role in colonisation. In hamsters, bclA1 mutant 
spores had a 2-log higher ID50 (50% infectious dose) than isogenic wild-type spores 
demonstrating that BclA1 plays a role in the initial colonisation of the host, prior to 
germination of the spore (Phetcharaburanin et al., 2014). C. difficile has recently 
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been shown to form biofilms in vivo (Semenyuk et al., 2014, 2015; 
Soavelomandroso et al., 2017). Spores and vegetative cells were found in equal 
numbers in localised biofilms throughout the caecum and colon. The biofilm was 
shown to be enriched with polysaccharides, and to reside on the uppermost layer of 
mucus. In the case of R20291 the biofilm was both above the mucus layer and 
embedded within it. The presence of spores within the biofilm may therefore extend 
their role beyond that of only dissemination.   
 
Inflammation is an important symptom of CDI and results from the action of both 
cytotoxins (Shen, 2012). However, there is evidence that factors (currently 
unknown) other than toxins contribute to pathogenesis (Buckley et al., 2013). While 
C. difficile spores can survive within phagocytes for extended periods of time 
(Paredes-Sabja et al., 2012), there is also evidence for invasion into epithelial cells 
(Goulding et al., 2009). The ability to invade enterocytes is both intriguing and 
important since it could potentially contribute to the inflammatory response. This 
assumption is supported by hamster models performed using a sigK- mutant strain 
of C. difficile, in which administration of sigK- vegetative cells results in a marked 
reduction in virulence (Figure 3.21). The infected animals carried equivalent levels 
of toxins in the caeca as animals infected with spores, yet endpoints were reached 
much later for the sigK- mutant (168 hours) than for wild-type C. difficile (72 hours). 
This suggests that the spore, as well as the vegetative cell may a role in 
inflammation and therefore in the infection process.  
 
Chapter 3 presents data in support of the spore’s role in colonisation and infection. 
This process is mediated by the bifunctional protein, CotE, through its C-terminal 
chitinase. The CotE chitinase domain was shown to be required for the adhesion of 
spores to mucus in vitro (HT29-MTX cells) and ex vivo (pig mucus explants) and 
that antibodies specific to the C-terminus were able to reduce adhesion. Using an 
ELISA assay, it was shown that the recombinant C-terminal chitinase of CotE 
(rCotEC) bound to mucin, in addition to mucin’s monomer constituents GlcNAc 
and GalNAc (Brockhausen et al., 1985). This mechanism underlying colonisation 
has been previously found to facilitate infection by Vibrio cholerae (Kirn et al., 
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2005). The chitin binding protein GbpA was found to be required for efficient 
intestinal colonisation by binding to GlcNAc present on the surface of intestinal 
epithelial cells. A gbpA mutant showed a 50% reduction in attachment to HT29 
cells and a tenfold increase in the LD50 compared to wild type. To further test the 
importance of CotE in the colonisation of the host by C. difficile, GlcNAc or 
glucosamine hydrochloride was orally administered to mice (in drinking water) and 
was found to prevent colonisation by CD630. By administering GlcNAc in drinking 
water we aimed to competitively inhibit the binding of the chitinase domain to the 
GlcNAc present in mucin thereby preventing colonisation. The prevention of 
infection observed suggests that this is what occurred, and so underscores the 
importance of CotE mediated adhesion to mucin via interaction with GlcNAc in 
colonisation by C. difficile. A possible confounding variable in this experiment is 
the effect of GlcNAc on the microbiota. The ingestion of dietary trehalose and 
microbiota accessible carbohydrates (MACs) has been shown to have an enhancing, 
and inhibiting effect on CDI respectively (Collins et al., 2018; Hryckowian et al., 
2018). The consumption by mice of MACs, either as a complex mixture or with 
inulin being the sole source, has demonstrated significant effects on the microbiota 
membership of the GI tract and its metabolic output. The outgrowth of MAC-
utilising taxa results in the production of short chain fatty acids (SCFAs) and a 
subsequent decrease in fitness of C. difficile. It is therefore possible that the 
administration of GlcNAc had a similar effect and so further in vivo studies utilising 
concomitant metagenomic analysis of intestinal contents over time are required. 
 
It was also demonstrated that wild type C. difficile spores were able to degrade 
mucin in vitro and that spores devoid of the CotE chitinase domain were unable to 
do so. Mucin degradation has also been displayed by Vibrio cholerae, where the 
secreted chitinase ChiA2 is used by the organism to hydrolyse intestinal mucin to 
release GlcNAc which is subsequently used for growth and survival within the GI 
tract (Mondal et al., 2014). Interestingly, chitinases alone have been shown to have 
low mucolytic effects, and it is the additional presence of proteases and nucleases 
which amplify the degradation exhibited by chitinases (Sanders et al., 2007). This 
perhaps suggests that the mucin degradation demonstrated by the CotE chitinase 
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may, in part, be due to assistance from either vestigial proteases/nucleases from the 
spore purification process or from enzymes resident on the spore surface layers. It 
could be imagined that the limited degradation of the mucin polysaccharide 
moieties by CotE renders mucin increasingly sensitive to protease degradation. 
Therefore, a direct role for CotE in mucus degradation remains to be established.  
 
Previous data gathered by our laboratory demonstrated that CotE chitinase activity 
is at its highest during spore germination (Permpoonpattana et al., 2011). Spore 
germination occurs within minutes and CotE is likely to be active in the spore coat 
integuments following release of the cell from the spore coat. It is therefore possible 
that the degradation of mucin by CotE provides nutrients for the newly germinated 
C. difficile cell. It has been previously shown that C. difficile is capable of 
metabolising mannose, fucose, galactose, GalNAc and GlcNAc for growth; all of 
which are components of mucin glycan side chains (Engevik et al., 2015). To 
further test CotE’s role in the degradation of mucin, wild type and CotE- spores 
could be assayed for degradation against various glycosylation profiles, purified 
from mouse models, pigs and human cell lines. The supernatants following 
treatment assays would then be analysed using 1H NMR to identify the metabolites 
produced from the pattern of their chemical shift signatures (Crost et al., 2013, 
2018). 
 
Studies in humans, have showed that compared to healthy subjects, CDI patients 
demonstrated decreased levels of MUC2, the major component of mucus (Engevik 
et al., 2015). The hypothesis that the demonstrated ability of CotE to degrade 
mucin, and therefore mucus, may facilitate progression of toxins towards the 
epithelium could be tested by using in vitro organ culture (IVOC). This system is 
based on human intestinal biopsies and can be used to monitor for the appearance 
of “dark holes” devoid of MUC2 staining in infected tissue samples symbolising 
mucin proteolysis (Etienne-Mesmin et al., 2019). This could be performed with 
wild type and CotE- spores and used to determine the effect of decreased mucus 
levels on toxin progression, with exogenous toxin added during the IVOC 
experiment, the mucus layer removed, and the biopsy epithelium quantified for 
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spores and toxins using ELISA or immunofluorescent staining (Etienne-Mesmin et 
al., 2019). 
 
Mice infected with CotE mutant spores, showed a marked reduction in colonisation 
relative to those infected with wild type spores, as demonstrated by the ID50 data. 
In a hamster model of infection, CotE clearly influenced the virulent phase of 
infection since the time from first presentation of symptoms to severe symptoms of 
CDI was significantly delayed in animals dosed with spores devoid of CotE. This 
phenotype was in marked contrast to that of a BclA1 mutant which showed no 
difference in the severity of CDI compared to wild type spores (Phetcharaburanin 
et al., 2014), suggesting that BclA1 is involved in the primary stages of colonisation 
rather than the virulent phase. Interestingly, the level of caecal toxins and CFU of 
deceased hamsters were essentially equivalent whether animals were infected with 
wild type or CotE mutant spores. This suggests that CotE plays an important role 
in CDI by targeting the spore to the mucosa enabling subsequent steps in the 
infection process. It should be noted that the deletion of bclA1 resulted in 
significant, morphological defects in the C. difficile spore coat (Phetcharaburanin 
et al., 2014). This may suggest a role for BclA1 as a structural protein within the 
spore coat and exosporium, as is the case for the B. anthracis protein, BclB, which 
is vital for the integrity of the exosporium (Thompson and Stewart, 2008). It is 
therefore entirely possible that deletion of BclA1 results in a loss in the abundance 
of spore coat proteins, such as CotE, on the outer surface of the spore, thereby 
reducing the spore’s ability to bind to mucus and colonise a host.  
 
Chitinases and peroxiredoxins have both been linked to inflammatory responses 
(Lee et al., 2011; Knoops et al., 2016). It is possible peroxiredoxins, as antioxidants 
and reducers of superoxide dismutase could play a role in spore survival within 
phagocytes, as has been shown in the case of Listeria monocytogenes (Kim et al., 
2007). Chitinases have been linked to the uptake of bacteria by host cells 
(Chaudhuri et al., 2010), thereby providing a possible reason as to why 
peroxiredoxin and chitinase are positioned within the same gene. Additionally, 
considering the inflammatory responses elicited by the rCotEN protein in our 
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studies, and the extremely high levels of spores that are produced concurrent with 
toxin secretion, spores could contribute to, and amplify, the inflammatory responses 
that are typical of acute CDI. In summary, our data combined with that of others 
suggest that CotE plays a direct role in C. difficile colonisation and virulence. That 
this attribute is associated with the dormant spore is both unique and unexpected.  
 
To better determine if CotE contributes to the inflammation observed during CDI, 
a triple mutant devoid of both CotE and toxins A and B could be used. This could 
be created by introducing an insertional mutation of cotE into a tcdA- tcdB- clostron 
mutant using a plasmid-based system shown to work for construction of triple 
mutants (Kuehne et al., 2014). A triple mutant would allow for comparisons 
between a tcdA- tcdB- and a tcdA- tcdB- cotE- mutant thereby isolating the in vivo 
inflammatory properties of CotE. This experiment could be performed in a mouse 
model at multiple time points, with symptoms being recorded. Colonic tissue could 
be isolated, examined histopathologically and spleens and mesenteric lymph nodes 
examined for induction of inflammatory cytokines using RT-PCR (Nguyen Van et 
al., 2006). 
 
The ability of CotE to bind oligosaccharides might provide a mechanism by which 
CotE contributes to biofilm assembly and colonisation. To test this hypothesis, a 
wild type and a cotE- mutant could be cultured anaerobically on polycarbonate 
discs, a technique shown to produce robust C. difficile biofilms (Semenyuk et al., 
2014). SEM could be used to assess the extent of the extracellular matrix and to 
check for the presence of vegetative cells and spores. ELISA assays using 
antibodies against spores, CotE and toxins A and B could be used to assess 
differences. To gain further insights into the receptors involved in the interaction 
with mucus, and to test the hypothesis that CotE is able to interact with biofilms, 
assays could be performed to test the binding of wild type and cotE- mutant spores 
to a range of mucins with different glycosignatures (Gunning et al., 2016). 
 
This work has been focussed on the chitinase domain of CotE, so studies could also 
explore the potential role of the N-terminal peroxiredoxin. As mentioned earlier, 
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peroxiredoxin has been implicated in intra-phagocyte survival through the 
detoxification of reactive oxygen species (ROS) which contribute to killing of 
intracellular microorganisms (e.g., H2O2 and potentially nitric oxide) (Harder et al., 
2006; Kim et al., 2007). Interestingly, spores of Bacillus subtilis which share 
similarity with those of C. difficile are completely phagocytosed after several hours 
(Ceragioli et al., 2009). Experiments to measure the degree to which CotE 
contributes to phagocyte survival could be performed. Uptake and internalisation 
of wild type and CotE- mutant spores could be monitored by fluorescence 
microscopy using Alexa Fluor 488 and biotin labelled spores (Paredes-Sabja and 
Sarker, 2012a; Paredes-Sabja et al., 2012). Survival within phagocytes could be 
determined using direct counting of viable CFU within lysed cells. Studies could 
also be performed in vivo following histopathology of colonic samples from mice 
infected either with wild type of CotE- mutant spores. TEM could be used to 
examine infected gut material with a focus on phagocytic cells, and specific focus 
could be directed to detecting the presence of C. difficile in neutrophils and non-
phagocytic cells in which C. difficile has been shown to invade (Goulding et al., 
2009). 
  
Peroxiredoxins react with hydrogen peroxide using an active site peroxidatic 
cysteine which consequently becomes oxidised to a sulfenic acid. Peroxiredoxins 
can be classified into different groups via mechanistic differences (Rhee, 2016). A 
2-Cys peroxiredoxin possess a ‘resolving’ cysteine which displaces the hydroxyl 
from the peroxidatic cysteine to form a disulphide bond which is usually reduced 
by a thioredoxin (Trx)/thioredoxin reductase (TrxR) system of proteins (Park et al., 
2014). 1-Cys peroxiredoxins lack the resolving cysteine and so the sulfenic acid is 
often reduced by small molecules such as glutathione or ascorbate (Rhee, 2016). 
CotE was originally assigned as a 1-Cys peroxiredoxin (Permpoonpattana et al., 
2011), however the presence of other cysteines in its peroxiredoxin domain and the 
more recent recognition that the resolving cysteine can have varying locations in 
different 2-Cys peroxiredoxins warrants further investigation (Perkins et al., 2015). 
Experiments could be performed where the CotE peroxiredoxin domain is 
incubated in the presence of H2O2 and the capacity of Trx/TrxR/NADPH and small 
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molecule reductants to support peroxidase activity could be tested. UV/Vis 
spectrophotometry could also be used to monitor the reactions (Lu et al., 2006). 
The presence of cis-regulation of activity by the partner domain should also be 
investigated, for example, by assaying the chitinase activity in the presence of H2O2. 
 
Up until this point effort has almost exclusively been focused on the vegetative cell 
as the primary factor of colonisation and so the work presented here is new to the 
field. Measures to control CDI are mostly focused on the toxins and therefore, 
understanding that the spore interacts with the mucosa may open new avenues for 
research into disease prevention. Further work to understand how the spore interacts 
with the mucosa may provide strategies to prevent spore attachment and gut 
colonisation by C. difficile. The suggested studies in this chapter will help to further 
unravel how C. difficile spores colonise the host, and long-term this may provide 
novel approaches for rational drug design and more robust measures to control this 
human and animal pathogen.  
 
6.2 On the role of allochthonous Bacillus in CDI 
There is growing appreciation at the integral role played by gastrointestinal 
microbiota in preventing the colonisation and subsequent infection by pathogens 
(Guarner and Malagelada, 2003; Kamada et al., 2013). The use of probiotics are 
frequently claimed to improve human health, and the implicated mechanisms 
behind this beneficial effect are mostly attributed to indirect effects, such as 
immune system modulation, intestinal epithelium enhancement and competition 
with pathogens for space and for nutrients (Macpherson and Harris, 2004; 
Gourbeyre et al., 2011; Bermudez-Brito et al., 2012). Evidence for direct effects 
exerted upon pathogenic bacteria by probiotics are less commonly found in the 
literature. It has been shown that bacteriocin-producing E. coli prevents 
colonisation of related pathogenic species in the inflamed gut of mice (Sassone-
Corsi et al., 2016). Evidence for non-bacteriocin probiotic interference of 
pathogens in humans is scarce, but a recent study by Piewngam et al. (2018) 
demonstrated that Bacillus produced cyclic lipopeptides that abolished colonisation 
by the pathogen S. aureus in humans by inhibiting quorum sensing. 
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Bacillus are a genus of soil bacteria, able to form highly resistant endospores which 
often integrate themselves into the human microbiota by exposure to the 
environment and consumption of vegetables (Tam et al., 2006). These endospores 
can subsequently germinate into metabolically active, vegetative cells (Casula and 
Cutting, 2002) within the small intestine and temporarily colonise the GI tract (Duc 
et al., 2004). The reported numbers of Bacillus spores in faeces are on average ~105 
CFU/gram (Tam et al., 2006). Several probiotic formulations include species of 
Bacillus (Hong et al., 2005) but the mechanism of action remains poorly defined.  
 
In this work Bacillus was isolated from the faeces of mice and it was demonstrated 
that several strains from three species, B. amyloliquefaciens, B. subtilis and B. 
licheniformis had extracellular activity against C. difficile. It was shown that this 
‘active’ population decreased, both in the quantity per gram and as a proportion of 
the total isolated spore formers, in response to clindamycin treatment. Furthermore, 
Bacillus was shown to be an allochthonous population within the GI tract; the 
population must be replenished from environmental Bacillus. The activity against 
C. difficile coincided with the demonstrated biosurfactant activity of the strains, as 
assayed using an oil dispersion assay. Previously, it has been shown that the solvent 
extracted biosurfactant from B. amyloliquefaciens and P. aeruginosa had activity 
against a range of pathogens, including S. aureus, E. coli and C. albicans (Ndlovu 
et al., 2017). 
 
These findings provided a link to the hygiene hypothesis. The hygiene hypothesis 
attempts to link changes in lifestyle in industrialised countries that have produced 
a decrease in infectious disease with a concurrent rise in allergic and autoimmune 
disease (Strachan, 1989; Kelly et al., 2007; López-Serrano et al., 2010). It could 
therefore be speculated that the same phenomenon may be a contributing factor 
underlying the high rates of CDI observed in the USA and UK (Lessa et al., 2012, 
2015; Gupta et al., 2014). Decreased exposure to environmental microbes through 
for example, diet and increased hygiene standards, might be expected to lower our 
exposure to Bacilli and may, in part, account for high rates of CDI.  As noted others 
the 'root cause' is likely to be multifactorial (Bloomfield and Riley, 2016) but the 
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contribution of exposure to environmental microbes and particularly aerobic 
microbes has, until now, been unnoticed. To lend credence to this hypothesis, 
efforts were bifurcated into two simultaneous investigations; to discover the role of 
Bacillus within the GI tract in the suppression of C. difficile (Chapter 4) and the 
mechanism underlying the extracellular activity against C. difficile (Chapter 5).  
 
Chapter 5 reports on the efforts made to identify the active molecule/s produced by 
Bacillus that inhibited C. difficile. For purposes of purification the high activity B. 
amlyloliquefaciens strain SG277 was used. Evidence was provided for a complex 
of lipopeptides produced by strains of B. amlyloliquefaciens, B. subtilis and B. 
licheniformis using RP-HPLC and MALDI-TOF analysis. The principal 
lipopeptides responsible for this activity were shown to be iturin, fengycin and 
surfactin and the ensuing complex displayed significant bacteriolytic activity upon 
C. difficile. Surfactin, the predominant constituent, demonstrated the highest 
activity and was responsible for providing a stable, monodisperse micellar 
morphology in combination with the other lipopeptides. These individual 
lipopeptides self-assemble to form mixed micelles thereby magnifying the activity 
exhibited against C. difficile. This combinatorial effect has been noted previously, 
in the case of surfactin and mycosubtilin (Jauregi et al., 2013) and surfactin and 
iturin A (Razafindralambo et al., 2002; Thimon et al., 1992). The observed synergy 
presented by the mixing of micelles is likely due to the complimentary effect 
different amphipathic compounds have upon each other; physiochemical changes 
due to interactions between amphiphiles and the subsequent enhancement of 
interfacial and micellar properties resulting in an increase in antibacterial activity 
(Sheikh et al., 2013). Physiochemical changes in the micelles can be inferred from 
the DLS analysis (Figure 5.17), and these changes translated into increased 
antibacterial activity against C. difficile (Figure 5.15), with combined micelles 
demonstrating higher activity than individual compounds.  
 
In Chapter 4 previous findings were confirmed, in which C. difficile spores were 
shown to germinate in the small intestine regardless of antibiotic administration 
(Wilson et al., 1985; Koenigsknecht et al., 2015; Winston and Theriot, 2016). 
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Considering that antibiotics are a prerequisite to the development of CDI, the 
subsequent step was to then discover the fate of these newly germinated vegetative 
cells and so ex vivo experiment was designed to measure the ‘killing’ ability of 
small intestinal extract from either naïve, or clindamycin treated mice. We 
hypothesised that the increased presence of Bacillus in the small intestine of naïve 
mice would result in a higher quantity of C. difficile inhibitory lipopeptides and 
consequently an ex vivo killing effect. This experiment measured over time the 
effect of the extract upon taurocholate induced germinated CD630 spores and it was 
observed that only the intestinal samples from naïve mice reduced the count of C. 
difficile. RP-HPLC and MALDI-TOF analysis of the intestinal extract identified 
iturin, fengycin and surfactin in the naïve mice only, and it was shown that activity 
against C. difficile within the region corresponding to these lipopeptides was 
comparatively higher than the equivalent region in the small intestinal extract from 
clindamycin treated mice. Finally, the administration of SG277 was shown to 
confer full protection against CDI in a mouse and hamster model of disease 
therefore demonstrating the efficacy of this protective mechanism. The dosing of 
SG277 supernatant, or SEC purified material also conferred protection (to a lower 
degree), indicating that an increased concentration of these lipopeptides within the 
GI tract results in suppression of CDI.  
 
Current literature provides strong evidence for the key role bile salts play as a 
regulatory mechanism fundamental to the life cycle of C. difficile. Current opinion 
places the site of germination for C. difficile spores as within the small intestine, 
and the site for C. difficile inhibition in a healthy host is the caecum/large intestine 
where anaerobic bacteria enzymatically synthesise inhibitory secondary bile acids 
to suppress the development of CDI (Theriot et al., 2014; Koenigsknecht et al., 
2015; Shen, 2015; Winston and Theriot, 2016). However, C. scindens, a bacterium 
heavily implicated in the possible prevention of CDI via enzymatic synthesis of C. 
difficile inhibitory deoxycholate is unable to confer full protection against CDI 
(Buffie et al., 2015). This has recently been supported by the observation that C. 
scindens is often present in the GI tract of CDI patients (Amrane et al., 2018). These 
observations therefore allow room for other factors, in addition to bile salt 
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regulatory mechanisms, to underly the resistance displayed by healthy individuals 
against CDI. An intriguing possibility could be based on the ability of bile acids to 
form mixed micelles with other anionic surfactants (Poša and Ćirin, 2012; Faustino 
et al., 2014; Jójárt et al., 2014). This may suggest a mechanism by which bacterially 
produced lipopeptides combine with inhibitory secondary bile acids in mixed 
micellar complexes within the GI tract of healthy hosts to provide colonisation 
resistance against CDI via direct antimicrobial action against the vegetative cells. 
Recent work by Dubois et al. (2019) found that sub-lethal concentrations of 
deoxycholate, perhaps encountered by C. difficile following termination of 
antibiotic treatment induces the formation of biofilms. The authors therefore 
hypothesised that production of deoxycholate by the intestinal bacterial community 
induces biofilm formation while suppressing spore and toxin production. This was 
demonstrated experimentally using in vitro biofilm assays, where growing C. 
difficile and C. scindens together resulted in increased biofilm formation by the 
former in response to higher levels of deoxycholate. This perhaps provides an 
explanation for the partial protection observed against CDI in adoptive transfer 
experiments involving C. scindens; if the deoxycholate levels are insufficient then 
protection will not be complete due to the formation of biofilms. It follows then, 
that the presence of additional antibacterial agents, lipopeptides produced by 
Bacillus, able to form mixed micelles with deoxycholate would increase the relative 
concentration of inhibitors in the GI tract thereby eliminating C. difficile outright 
and increasing resistance to CDI. The capability of deoxycholate to synergise with 
antimicrobials produced by residents of the GI tract and thereby enhance the 
activity of these compounds has recently been demonstrated by Kang et al. (2019). 
This hypothetical ‘synergy’ may hold intriguing implications for both the 
administration of Bacillus to those at risk of CDI and the underlying mechanism by 
which a healthy microbiota staves off C. difficile outgrowth. 
 
In conclusion, this work has expanded on our understanding of C. difficile 
pathogenesis with two important findings. First, that the spore of C. difficile is not 
a silent participant in the infection process but instead plays an active role in 
infection. Second, that environmental factors play an important role in our 
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susceptibility to infection. With regard to the role of the spore it is clear that the 
spore should be considered in treatment strategies, whether this be drug or vaccine 
and perhaps partly explains why vaccine strategies focused on targeting the toxins 
have, to date, failed. Regarding the link to the environment we can propose that the 
rise over the last 30 years of infection rates may be linked to a change in lifestyle. 
This is important because it suggests that the Western lifestyle may reduce our 
exposure to environmental factors enabling not only C. difficile to emerge but also 
the possibility that other diseases may, in the future arise. It is interesting that two 
recent studies also link C. difficile infection to lifestyle, the first being a link with a 
fibre-less diet (Hryckowian et al., 2018) and a second to increased consumption of 
dietary glucose (Kumar et al., 2019) (Figure 6.1). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6.1. Schematic representation of the three risk factors driving CDI. 
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Appendix A 
 
 
 
Figure 1. Adhesion of spores to mucus monolayers. Image analysis (20x magnification) of day 
14 cell monolayers probed with anti-C. difficile spore antibodies (green). Scale bar = 200 mm.  
Spores of C. difficile were added to seeded cells (MOI = 100) and incubated for 2 hours. After 
washing with DPBS to remove non-adherent bacteria, cells were fixed with 4% paraformaldehyde 
(Alfa-Aesar) in PBS for 15 min. at RT using 250 µl/well. Cells were then washed twice with DPBS 
and permeabilised with 0.5% triton-X-100 in PBS for 10 min. at RT, 200 µl/well. After two washes 
with DPBS they were incubated with 1:100 dilution of mouse antiserum against C. difficile spores 
in 1% (w/v) BSA in PBS for 1 houe at 37ºC, 5% CO2 using 200 µl/well. Cells were washed 3-times 
with DPBS and then incubated with a 1:1000 dilution of anti-mouse IgG-FITC antibody (Sigma) in 
1% BSA in PBS for 1 hour at 37ºC, 5% CO2 using 200 µl/well. Cells were washed 3-times with 
DPBS and incubated with a 1:1000 dilution of DAPI (1 µg/ml) (Sigma-Aldrich, UK) using 200 
µl/well for 5 min. in the dark followed by three washes with DPBS. Coverslips were mounted using 
Vectashield mounting medium (Vectorlabs, UK) and sealed using clear nail varnish. Slides were 
visualised using an EVOS FL digital microscope (Life technologies). Assay was performed by 
fellow student, Saba Anwar. 
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